

# Selection 6 – Ex-US Cash Distribution to Mundipharma KK (aka Mundipharma Japan), July 2017 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100168810	Company Code	208	Fiscal Year	2017
Doc. Date	17.07.2017	Posting Date	16.07.2017	Period	07
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	CWS	Overall No.	0100168810208 17		
Doc. Currency	USD				
Doc. Hdr Text	CTW208 07102017-07162017				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
84	40	100010	Cash Concentration		GEN			50.000.000,00	UNITED STATES TREASURY BILLS UNITED S
220	40	100400	Temp. Invest. Chase		GEN			49.895.729,17	UNITED STATES TREASURY BILLS UNITED S
37	40	100010	Cash Concentration		GEN			12.459.721,50	MCKESSON
60	40	100010	Cash Concentration		GEN			10.824.007,66	AMERISOURCE BERG
38	40	100010	Cash Concentration		GEN			9.750.598,98	CARDINAL HEALTH
221	40	201150	Payroll Suspense		GEN			6.624.097,51	TAX SERVICE 702
203	40	302045	Dist #45 PH LP		GEN			3.783.780,00	PURDUE HOLDINGS L P 1 STAMFORD F
3	40	100010	Cash Concentration		GEN			2.350.819,32	MCKESSON
219	40	100040	Chase Control ZBA		GEN			2.097.212,49	ZBA DEBIT TRANSFER
243	40	302045	Dist #45 PH LP		GEN			1.969.729,00	PURDUE HOLDINGS L P 1 STAMFORD F
4	40	100010	Cash Concentration		GEN			1.574.901,21	AMERISOURCE BERG
5	40	100010	Cash Concentration		GEN			1.362.737,59	CARDINAL HEALTH

**Transfer #1:** \$1.969M transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100168810	Company Code	208	Fiscal Year	2017
Doc. Date	17.07.2017	Posting Date	16.07.2017	Period	07
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	CWS	Overall No.	0100168810208 17		
Doc. Currency	USD				
Doc. Hdr Text	CTW208 07102017-07162017				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
204	50	100400	Temp. Invest. Chase		GEN			50.000.000,00	UNITED STATES TREASURY BILLS UNITED S
100	50	100010	Cash Concentration		GEN			49.895.729,17	UNITED STATES TREASURY BILLS UNITED S
160	50	100110	Lockbox Clearing		GEN			12.459.721,50	MCKESSON
181	50	100110	Lockbox Clearing		GEN			10.824.007,66	AMERISOURCE BERG
161	50	100110	Lockbox Clearing		GEN			9.750.598,98	CARDINAL HEALTH
101	50	100010	Cash Concentration		GEN			6.624.097,51	TAX SERVICE 702
83	50	100010	Cash Concentration		GEN			3.783.780,00	PURDUE HOLDINGS L P 1 STAMFORD F
128	50	100110	Lockbox Clearing		GEN			2.350.819,32	MCKESSON
99	50	100010	Cash Concentration		GEN			2.097.212,49	ZBA DEBIT TRANSFER
125	50	100010	Cash Concentration		GEN			1.969.729,00	PURDUE HOLDINGS L P 1 STAMFORD F
129	50	100110	Lockbox Clearing		GEN			1.574.901,21	AMERISOURCE BERG
130	50	100110	Lockbox Clearing		GEN			1.362.737,59	CARDINAL HEALTH

## Selection 6 – Ex-US Cash Distribution to Mundipharma KK (aka Mundipharma Japan), July 2017 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100168849	Company Code	208	Fiscal Year	2017
Doc. Date	31.07.2017	Posting Date	23.07.2017	Period	07
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	CWS	Overall No.	0100168849208 17		
Doc. Currency	USD				
Doc. Hdr Text	CTW208 07172017-07232017				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
33	50	100010	Cash Concentration		GEN			17.640.000,00-	██████████ PURDUE HOLDINGS L P 1 STAMFORD F
89	50	100010	Cash Concentration		GEN			15.000.000,00-	██████████ GOLDMAN SACHS FUNDS GROUP FFC: PURDUE PHAR
143	50	100010	Insurance Clearing		GEN			14.133.013,47	██████████ MCVISION

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100168849	Company Code	208	Fiscal Year	2017
Doc. Date	07/31/2017	Posting Date	07/23/2017	Period	07
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	CWS	Overall No.	0100168849208 17		
Doc. Currency	USD				
Doc. Hdr Text	CTW208 07172017-07232017				

**Transfer #6:** \$17.64M transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
135	40	100040	Chase Control ZBA		GEN			402,514.52	ZBA DEBIT TRANSFER
136	40	660080	Bank Service Charges	2100208	GEN			21,054.05	ACCT SERVICE FEE
137	40	205025	Accr.Comdata VMC		GEN			29,034.96	COMDATA NETWORK
138	40	100550	Net Travel Clearing		GEN			28,507.48	load # ██████████
139	40	100540	Insurance Clearing		GEN			199,006.00	██████████ PURDUE PHARMA LP CIGNA MEDICAL INSUUS
140	40	302045	Dist #45 PH LP		GEN			17,640,000.00	██████████ PURDUE HOLDINGS L P 1 STAMFORD F



## Selection 6 – Ex-US Cash Distribution to Mundipharma KK (aka Mundipharma Japan), July 2017 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000899 Company Code 416 Fiscal Year 2017  
 Doc. Date 31.07.2017 Posting Date 23.07.2017 Period 07  
 Calculate Tax ☐  
 Ref.Doc. CWS  
 Doc. Currency USD  
 Doc. Hdr Text CTW416 07172017-07232017

**Transfer #6:** \$17.64M transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			17.640.000,00	██████████ PURDUE PHARMA L P 1 STAMFORD FOR
2	50	100010	Cash Concentration		GEN			5.833,51-	ACCT SERVICE FEE
3	50	100010	Cash Concentration		GEN			17.640.000,00	CAPITAL CONTRIBUTION CREDIT REF ATS OF 17/07/14
4	40	100010	Cash Concentration		GEN			285.714,00	██████████
5	50	107204	Invest - PPLP		GEN			17.640.000,00	██████████ PURDUE PHARMA L P 1 STAMFORD FOR
6	40	660080	Bank Service Charges	2100416	GEN			5.833,51	ACCT SERVICE FEE
7	40	107408	Invest. RSJ Com LLC		GEN			17.640.000,00	CAPITAL CONTRIBUTION CREDIT REF ATS OF 17/07/14
8	50	100530	Misc. Cash Clearing		GEN			285.714,00-	██████████

**Transfer #7:** \$17.64M transfer from Purdue Holdings L.P. to RSJ Company L.P.

## Selection 6 – Ex-US Cash Distribution to Mundipharma KK (aka Mundipharma Japan), July 2017 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number100000895

Company Code416

Fiscal Year2017

Doc. Date17.07.2017

Posting Date16.07.2017

Period07

Calculate Tax☐

Ref.Doc.CWS

Doc. CurrencyUSD

Doc. Hdr TextCTW416 07102017-07162017

Transfer #2B \$4,875 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.

Transfer #1: \$1.969M transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			3.783.780,00	PURDUE PHARMA L P 1 STAMFORD FOR
2	40	100010	Cash Concentration		GEN			1.969.729,00	PURDUE PHARMA L P 1 STAMFORD FOR
3	50	100010	Cash Concentration		GEN			4.875,00-	CORP PAY
4	50	100010	Cash Concentration		GEN			4.854,00-	CORP PAY
5	50	100010	Cash Concentration		GEN			1.960.000,00-	PLP ASSOCIATES HOLDINGS L P ONE
6	50	107204	Invest - PPLP		GEN			3.783.780,00-	PURDUE PHARMA L P 1 STAMFORD FOR
7	50	107204	Invest - PPLP		GEN			1.969.729,00-	PURDUE PHARMA L P 1 STAMFORD FOR
8	40	302042	Dist #42 PP Inc		GEN			4.875,00	CORP PAY
9	40	302042	Dist #42 PP Inc		GEN			4.854,00	CORP PAY
10	40	302044	Dist #44 PLPAH LP		GEN			1.960.000,00	PLP ASSOCIATES HOLDINGS L P ONE

Transfer #2C: \$4,854 transfer from Purdue Pharma L.P. to PLP Associates Holdings Inc.

Transfer #2A: \$1.96M transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.

## Selection 6 – Ex-US Cash Distribution to Mundipharma KK (aka Mundipharma Japan), July 2017 (cont'd)

<b>Doc.Type : SA ( G/L account document ) Normal document</b> Doc. Number 100001133 Company Code 401 Fiscal Year 2017 Doc. Date 07/17/2017 Posting Date 07/16/2017 Period 07 Calculate Tax <input type="checkbox"/> Ref.Doc. CWS Doc. Currency USD Doc. Hdr Text CTW401 07102017-07162017									
Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			1,960,000.00	PURDUE HOLDINGS L P 1 STAMFORD F
2	50	100010	Cash Concentration		GEN			1,960,000.00	BR HOLDINGS ASSOCIATES L.P. 1 ST
3	50	107416	Invest - PH LP		GEN			1,960,000.00	PURDUE HOLDINGS L P 1 STAMFORD F
4	40	302032	Capital #32 Dist BR		GEN			1,960,000.00	BR HOLDINGS ASSOCIATES L.P. 1 ST
<b>Doc.Type : SA ( G/L account document ) Normal document</b> Doc. Number 100001475 Company Code 301 Fiscal Year 2017 Doc. Date 07/17/2017 Posting Date 07/16/2017 Period 07 Calculate Tax <input type="checkbox"/> Ref.Doc. CWS Doc. Currency USD Doc. Hdr Text CTW301 07102017-07162017									
Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			4,875.00	CORP PAY
2	50	107416	Invest - PH LP		GEN			4,875.00	CORP PAY
<b>Doc.Type : SA ( G/L account document ) Normal document</b> Doc. Number 100001039 Company Code 402 Fiscal Year 2017 Doc. Date 07/17/2017 Posting Date 07/16/2017 Period 07 Calculate Tax <input type="checkbox"/> Ref.Doc. CWS Doc. Currency USD Doc. Hdr Text CTW402 07102017-07162017									
Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			4,854.00	CORP PAY
2	50	107416	Invest - PH LP		GEN			4,854.00	CORP PAY

**Transfer #2A:** \$1.96M transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.

**Transfer #3:** \$1.96M transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

**Transfer #2B:** \$4,875 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.

**Transfer #2C:** \$4,854 transfer from Purdue Pharma L.P. to PLP Associates Holdings Inc.

## Selection 6 – Ex-US Cash Distribution to Mundipharma KK (aka Mundipharma Japan), July 2017 (cont'd)

<b>Doc.Type : SA ( G/L account document ) Normal document</b> Doc. Number 100000903 Company Code 413 Fiscal Year 2017 Doc. Date 17.07.2017 Posting Date 16.07.2017 Period 07 Calculate Tax <input type="checkbox"/> Ref.Doc. CWS Doc. Currency USD Doc. Hdr Text CTW413 07102017-07162017									
<b>Transfer #3: \$1.96M transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.</b>									
Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			1.960.000,00	██████████ PLP ASSOCIATES HOLDINGS L P ONE
2	50	107401	Invest. PLP Asc.Hold		GEN			1.960.000,00	██████████ PLP ASSOCIATES HOLDINGS L P ONE

<b>Doc.Type : KZ ( Vendor payment ) Normal document</b> Doc. Number 1500000322 Company Code 413 Fiscal Year 2017 Doc. Date 14.07.2017 Posting Date 14.07.2017 Period 07 Calculate Tax <input type="checkbox"/> Ref.Doc. WIRE TRANSFER Doc. Currency USD									
<b>Transfer #4A: \$980,000 transfer from BR Holdings Associates L.P. to Beacon Company.</b>									
Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			980.000,00	
2	25	1029154	BEACON CO		GEN			980.000,00	

<b>Doc.Type : KZ ( Vendor payment ) Normal document</b> Doc. Number 1500000321 Company Code 413 Fiscal Year 2017 Doc. Date 14.07.2017 Posting Date 14.07.2017 Period 07 Calculate Tax <input type="checkbox"/> Ref.Doc. WIRE TRANSFER Doc. Currency USD									
<b>Transfer #4B: \$980,000 transfer from BR Holdings Associates L.P. to Rosebay Medical Company L.P.</b>									
Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			980.000,00	
2	25	1016497	ROSEBAY MEDICAL COMP		GEN			980.000,00	

## Selection 6 – Ex-US Cash Distribution to Mundipharma KK (aka Mundipharma Japan), July 2017 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000531 Company Code 408 Fiscal Year 2017  
 Doc. Date 31.07.2017 Posting Date 23.07.2017 Period 07  
 Calculate Tax ☐  
 Ref.Doc. CWS  
 Doc. Currency USD  
 Doc. Hdr Text CTW408 07172017-07232017

**Transfer #5A:** \$980,000  
 transfer from Beacon Company  
 to RSJ Company L.P.

**Transfer #5B:** \$980,000  
 transfer from Rosebay Medical  
 Company L.P. to RSJ Company  
 L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			17.640.000,00	CAPITAL CONTRIBUTION DEBIT REF NONREF
2	40	100010	Cash Concentration		GEN			980.000,00	BEACON CO REVINOVA TREUHAND AG F
3	40	100010	Cash Concentration		GEN			980.000,00	ROSEBAY MEDICAL CO L P 14000 QUA
4	50	301045	Capital #45 PH LP		GEN			17.640.000,00	CAPITAL CONTRIBUTION DEBIT REF NONREF
5	50	301026	Capital #26Contrib.		GEN			980.000,00	BEACON CO REVINOVA TREUHAND AG F
6	50	301027	Capital #27Contrib.		GEN			980.000,00	ROSEBAY MEDICAL CO L P 14000 QUA

Doc.Type : KZ ( Vendor payment ) Normal document


Doc. Number 1500000037 Company Code 408 Fiscal Year 2017  
 Doc. Date 20.07.2017 Posting Date 21.07.2017 Period 07  
 Calculate Tax ☐  
 Ref.Doc. WIRE TRANSFER  
 Doc. Currency USD

**Transfer #7:** \$17.6M transfer  
 from Purdue Holdings L.P. to RSJ  
 Company L.P.

**Transfer #8:** \$19.6M transfer  
 from RSJ Company L.P. to  
 Mundipharma KK (Mundipharma  
 Japan)

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			19.600.000,00	
2	25	1018052	MUNDIPHARMA KK		GEN			19.600.000,00	

## Selection 6 – Ex-US Cash Distribution to Mundipharma KK (aka Mundipharma Japan), July 2017 (cont'd)



**Transfer #7:** \$17.64M transfer from Purdue Holdings L.P. to RSJ Company L.P.

**Transfer #5B:** \$980,000 transfer from Rosebay Medical Company L.P. to RSJ Company L.P.

**Transfer #5A:** \$980,000 transfer from Beacon Company to RSJ Company L.P.



## Selection 6 – Ex-US Cash Distribution to Mundipharma KK (aka Mundipharma Japan), July 2017 (cont'd)

**Transfer #1:** Authorization for \$1.969M transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

**Transfer #3:** Authorization for \$1.96M transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

**Transfer #6:** Authorization for \$17.64M transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

**Transfer #7:** Authorization for \$17.64M transfer from Purdue Holdings L.P. to RSJ Company L.P.

1. Purdue Pharma L.P. ("PPLP") Written Consent of General Partner authorizing PPLP to distribute \$1,969,729 to PHLP;
  2. PHLP Written Consent of General Partner authorizing PHLP to distribute \$4,875 to Purdue Pharma Inc., \$4,854 to PLP Associates Holdings Inc. and \$1,960,000 to PLP Associates Holdings L.P.;
  3. PLP Associates Holdings L.P. Written Consent of General Partner authorizing PLP Associates Holdings L.P. to distribute \$1,960,000 to BR Holdings Associates L.P. ("BR Holdings");
  4. BR Holdings Written Consent of General Partner authorizing BR Holdings to distribute \$980,000 to Beacon Company and \$980,000 to Rosebay Medical Company L.P. (each of Beacon Company and Rosebay Medical Company L.P. will in turn contribute these amounts to RSJ Company);
  5. PPLP Written Consent of General Partner authorizing PPLP to distribute \$17,640,000 to PHLP;
  6. PHLP Written Consent of General Partner authorizing PHLP to contribute \$17,640,000 to RSJ Company;
  7. RSJ Company Written Consent of General Partner authorizing RSJ Company to contribute \$19,600,000 to Mundipharma Japan (as noted above the remaining \$400,000 will be contributed to Mundipharma Japan by the shareholders of MKK).
- On the basis of the foregoing please proceed as follows:
1. Distribute the funds up into Beacon Company and into Rosebay Medical Company L.P.;
  2. When RSJ Company receives the \$980,000 from Beacon Company and the \$980,000 from Rosebay Medical Company L.P., please arrange for the wire transfer from RSJ Company in the amount of \$19,600,000 to the account of Mundipharma Japan as follows:
- |                  |                                     |
|------------------|-------------------------------------|
| Account Name:    | Mundipharma K.K.                    |
| Bank Name:       | Sumitomo Mitsui Banking Corporation |
| Branch Name:     | Hibiya Branch                       |
| Type of Account: | Saving (USD)                        |
| SWIFT Code:      | SMBCJPJT                            |
| Account Number:  | [REDACTED]                          |

Separately I've written to [REDACTED] and [REDACTED] to advise them to expect to receive their respective \$980,000 and to immediately transfer those funds to RSJ Company upon receipt.

Thanks for keeping me updated on the progress of the funding and advising when the final value date transfer is from RSJ Company to Mundipharma Japan. Please note that we have been asked to fund these payments as soon as possible.

Kind regards,

Ian

This email message and any attachments are for the sole use of the intended recipient(s). Any unauthorized review, use, disclosure, copying or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message and any attachments.

**Transfers #2A, #2B, and #2C:** Authorization for transfer from Purdue Holdings L.P. of \$1.96M, \$4,875, and \$4,854 to PLP Associates Holdings L.P., Purdue Pharma Inc., and PLP Associates Holdings Inc., respectively.

**Transfers #4 and #5:** Authorization for transfers of \$980,000 from BR Holdings Associates L.P. to each of Beacon Company and Rosebay Medical Company L.P., and subsequent transfers of \$980,000 from each of Beacon Company and Rosebay Medical Company L.P. to RSJ Company L.P.

**Transfer #8:** Authorization and wire instructions for \$19.6M transfer from RSJ Company L.P. to Mundipharma KK.

## Selection 6 – Ex-US Cash Distribution to Mundipharma KK (aka Mundipharma Japan), July 2017 (cont'd)

PURDUE PHARMA L.P.		Status Completed	J.P.Morgan	
<b>Transaction Information</b>				
Account Number/Name [REDACTED] BR HOLDINGS ASSOCIATES LP		Branch Location/Bank Name/Bank ID JPMORGAN CHASE NEW YORK/JPMORGAN CHASE BANK, N.A./021000021		Transaction made from Template BR-Beacon Co
Method Book Transfer		Payment Amount USD 980,000.00		Value Date 07/14/2017
Bank to Bank Transfer No				
<b>Routing/Reference Information</b>				
<b>Beneficiary</b> JPMC US Account [REDACTED] Beacon Co UNITED STATES - US				
<b>Transaction Details</b>				
Distribution		<b>Bank To Bank</b>		
		Charges Remitter	Priority No	
Date Created 07/14/2017 10:05 AM EDT	Transaction ID [REDACTED]	Bank Reference [REDACTED]	Settlement Reference JPM Ref: [REDACTED]	

**Transfer #4A:** Confirmation of \$980,000 transfer from BR Holdings Associates L.P. to Beacon Company.

## Selection 6 – Ex-US Cash Distribution to Mundipharma KK (aka Mundipharma Japan), July 2017 (cont'd)

PURDUE PHARMA L.P.		Status Completed	J.P.Morgan	
<b>Transaction Information</b>				
Account Number/Name [REDACTED] BR HOLDINGS ASSOCIATES LP	Branch Location/Bank Name/Bank ID JPMORGAN CHASE NEW YORK/JPMORGAN CHASE BANK, N.A./021000021	Transaction made from Template BR-Rosebay		
Method Book Transfer	Payment Amount USD 980,000.00	Value Date 07/14/2017		
Bank to Bank Transfer No				
<b>Routing/Reference Information</b>				
<b>Beneficiary</b> JPMC US Account [REDACTED] Rosebay Medical Co LP UNITED STATES - US				
<b>Transaction Details</b> Distribution		<b>Bank To Bank</b>		
		Charges Remitter	Priority No	
Date Created 07/14/2017 10:05 AM EDT	Transaction ID [REDACTED]	Bank Reference [REDACTED]	Settlement Reference JPM Ref: [REDACTED]	

**Transfer #4B:** Confirmation of \$980,000 transfer from BR Holdings Associates L.P. to Rosebay Medical Company L.P.

## Selection 6 – Ex-US Cash Distribution to Mundipharma KK (aka Mundipharma Japan), July 2017 (cont'd)



JPMorgan Chase Bank, N.A.  
Northeast Market  
P O Box 659754  
San Antonio, TX 78265 - 9754

July 01, 2017 through July 31, 2017

Account Number: [REDACTED]

### Customer Service Information

If you have any questions about your statement, please contact your Customer Service Professional.

00066422 WBS 802 211 21317 NNNNNNNNNN 1 000000000 80 0000

PURDUE HOLDINGS L P  
1 STAMFORD FORUM  
STAMFORD CT 06901-3516

### Deposits and Credits

Ledger Date	Description	Amount
07/05	Book Transfer Credit B/O: Purdue Pharma L P Stamford CT 06901-3516 Ref: Distribution Tm: [REDACTED] YOUR REF: ATS OF 17/07/05	\$19,935,752.50
07/07	Deposit [REDACTED]	103,997.59
07/12	Book Transfer Credit B/O: Purdue Pharma L P Stamford CT 06901-3516 Ref: Distribution Tm: [REDACTED] YOUR REF: ATS OF 17/07/11	3,783,780.00
07/14	Book Transfer Credit B/O: Purdue Pharma L P Stamford CT 06901-3516 Ref: Distribution Tm: [REDACTED] YOUR REF: ATS OF 17/07/14	1,969,729.00

**Transfer #1:** \$1.969M transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

### Deposits and Credits (continued)

Ledger Date	Description	Amount
07/17	Book Transfer Credit B/O: Purdue Pharma L P Stamford CT 06901-3516 Ref: Distribution Tm: [REDACTED] YOUR REF: ATS OF 17/07/14	17,640,000.00

**Transfer #6:** \$17.64M transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

## Selection 6 – Ex-US Cash Distribution to Mundipharma KK (aka Mundipharma Japan), July 2017 (cont'd)



JPMorgan Chase Bank, N.A.  
Northeast Market  
P O Box 659754  
San Antonio, TX 78265 - 9754

July 01, 2017 through July 31, 2017

Account Number: [REDACTED]

### Customer Service Information

If you have any questions about your statement, please contact your Customer Service Professional.

00066422 WBS 802 211 21317 NNNNNNNNNN 1 000000000 80 0000

PURDUE HOLDINGS L P

1 STAMFORD FORUM  
STAMFORD CT 06901-3516

### Withdrawals and Debits

Ledger Date	Description	Amount
07/05	Fedwire Debit Via: Bk Amer Nyc/026009593 A/C: Bank of America N.A. US Fx US Ref: Fx Transact Ref: [REDACTED] Imad: [REDACTED] Trn: YOUR REF: NONREF	\$19,935,752.50
07/12	Fedwire Debit Via: Bk Amer Nyc/026009593 A/C: Bank of America N.A. US Fx US Ref: Fx Transact Ref: [REDACTED] Imad: [REDACTED] Trn: YOUR REF: NONREF	3,783,780.00
07/14	Book Transfer Debit A/C: Plp Associates Holdings L P Stamford CT 06901-3431 Ref: Distribution Trn: [REDACTED] YOUR REF: NONREF	1,960,000.00
07/14	Orig CO Name:Holdings Orig ID: [REDACTED] Desc Date:170717 CO Entry Descr:Corp Pay Sec:CCD Trace#: [REDACTED] Eed:170714 Ind ID: [REDACTED] Ind Name:Holdings Trn: [REDACTED]	4,875.00
07/14	Orig CO Name:Holdings Orig ID: [REDACTED] Desc Date:170717 CO Entry Descr:Corp Pay Sec:CCD Trace#: [REDACTED] Eed:170714 Ind ID: [REDACTED] Ind Name:Holdings Trn: [REDACTED]	4,854.00
07/17	Book Transfer Debit A/C: Rsj CO Lp Stamford CT 06901- Ref: Capital Contribution Trn: [REDACTED] YOUR REF: NONREF	17,640,000.00

**Transfer #2A:** \$1.96M transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.

**Transfer #2B:** \$4,875 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.

**Transfer #2C:** \$4,854 transfer from Purdue Pharma L.P. to PLP Associates Holdings Inc.

**Transfer #7:** \$17.64M transfer from Purdue Holdings L.P. to RSJ Company L.P.

## Selection 6 – Ex-US Cash Distribution to Mundipharma KK (aka Mundipharma Japan), July 2017 (cont'd)



JPMorgan Chase Bank, N.A.  
Northeast Market  
P O Box 659754  
San Antonio, TX 78265 - 9754

July 01, 2017 through July 31, 2017

Account Number: [REDACTED]

### Customer Service Information

If you have any questions about your statement, please contact your Customer Service Professional.

00050681 WBS 802 211 21317 NNNNNNNNNN 1 000000000 80 0000

BR HOLDINGS ASSOCIATES L.P.

1 STAMFORD FORUM  
STAMFORD CT 06901-3516

### Deposits and Credits

Ledger Date	Value Date	Description	Amount
07/07		Deposit [REDACTED]	\$1,098.00
		2 DAY FLOAT 07/11	\$1,098.00
07/14		Book Transfer Credit B/O: Plp Associates Holdings L P Stamford CT 06901-3431 Ref: Distribution Trn: [REDACTED] YOUR REF: ATS OF 17/07/14	1,960,000.00

**Transfer #3:** \$1.96M transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

### Withdrawals and Debits

Ledger Date	Value Date	Description	Amount
07/14		Book Transfer Debit A/C: Rosebay Medical CO L P Oklahoma City OK 73134-2617 Ref: Distribution Trn: [REDACTED] YOUR REF: NONREF	\$980,000.00
07/14		Book Transfer Debit A/C: Beacon CO Zurich Switzerland Ch-80-55 Ref: Distribution Trn: [REDACTED] YOUR REF: NONREF	980,000.00

**Transfer #4B:** \$980,000 transfer from BR Holdings Associates L.P. to Rosebay Medical Company L.P.

**Transfer #4A:** \$980,000 transfer from BR Holdings Associates L.P. to Beacon Company.



## Selection 6 – Ex-US Cash Distribution to Mundipharma KK (aka Mundipharma Japan), July 2017 (cont'd)



JPMorgan Chase Bank, N.A.  
Northeast Market  
P O Box 659754  
San Antonio, TX 78265 - 9754

July 01, 2017 through July 31, 2017

Account Number: [REDACTED]

### Customer Service Information

If you have any questions about your statement, please contact your Customer Service Professional.

00022177 WBS 802211 21317 NNNNNNNNNN 1 000000000 80 0000

RSJ CO LP

ONE STAMFORD FORUM  
STAMFORD CT 06901-3516

### Deposits and Credits

Ledger Date	Description	Amount
07/17	Book Transfer Credit B/O: Purdue Holdings L P Stamford CT 06901-3516 Ref: Capital Contribution Trn: [REDACTED] YOUR REF: ATS OF 17/07/14	\$17,640,000.00
07/17	Book Transfer B/O: Beacon CO Zurich Switzerland Ch-80-55 Ref: Beacon Company Vacca Trn: [REDACTED] YOUR REF: OS1 OF 17/07/17	980,000.00
07/20	Book Transfer Credit B/O: Rosebay Medical CO L P Oklahoma City OK 73134-2617 Ref: Rosebay Medical Company Lp Trn: [REDACTED] YOUR REF: ATS OF 17/07/20	980,000.00
<b>Total</b>		<b>\$19,600,000.00</b>

**Transfer #7:** \$17.64M transfer from Purdue Holdings L.P. to RSJ Company L.P.

**Transfer #5A:** \$980K transfer from Beacon Company to RSJ Company L.P.

**Transfer #5B:** \$980K transfer from Rosebay Medical Company L.P. to RSJ Company L.P.

### Withdrawals and Debits


Ledger Date	Description	Amount
07/20	Book Transfer Debit A/C: Sumitomo Mitsui Banking Corporationchiyoda-Ku Tokyo Japan 51500-0 Ben:/3031736 Mundipharma K.K. Ref: Japan Funding Requirement Trn: [REDACTED] YOUR REF: NONREF	\$19,600,000.00
<b>Total</b>		<b>\$19,600,000.00</b>

**Transfer #8:** \$19.6M transfer from RSJ Company L.P. to Mundipharma KK (Mundipharma Japan).



## **Selection 7 Purdue US Partner Cash Distributions (2011)**

## Selection 7 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., June 2011



## Selection 7 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., June 2011 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100087811 Company Code 208 Fiscal Year 2011  
 Doc. Date 12.07.2011 Posting Date 07.07.2011 Period 07  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 07012011 to 07072011

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	102416	Purdue Holdings LP		GEN			200.992.721,00	FUNDING to PURDUE HOLDINGS LP
2	40	100010	Cash Concentration		GEN			50.000.000,00	BofA: SHORT-TERM INVESTMENT
3	40	100010	Cash Concentration		GEN			50.000.000,00	GOLDMAN SACHS MONEY MARKET DRAW-DOWN
4	40	100010	Cash Concentration		GEN			26.394.129,54	CARDINAL HEALTH
5	40	100010	Cash Concentration		GEN			17.624.116,55	MCKESSON

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100087811 Company Code 208 Fiscal Year 2011  
 Doc. Date 12.07.2011 Posting Date 07.07.2011 Period 07  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 07012011 to 07072011

**Transfer #1:** \$200,992,721  
 transfer from Purdue Pharma  
 L.P. to Purdue Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
107	50	100010	Cash Concentration		GEN			200.992.721,00	FUNDING to PURDUE HOLDINGS LP
108	50	100450	BOA Money Market		GEN			50.000.000,00	BofA: SHORT-TERM INVESTMENT
109	50	100430	Money Mkt Goldman		GEN			50.000.000,00	GOLDMAN SACHS MONEY MARKET DRAW-DOWN
110	50	100110	Lockbox Clearing		GEN			26.394.129,54	CARDINAL HEALTH
111	50	100110	Lockbox Clearing		GEN			17.624.116,55	MCKESSON

## Selection 7 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., June 2011 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000109 Company Code 416 Fiscal Year 2011  
 Doc. Date 12.07.2011 Posting Date 07.07.2011 Period 07  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CIW 07012011 to 07072011

**Transfer #2A:** \$497,457  
 transfer from Purdue Holdings  
 L.P. to Purdue Pharma Inc.

**Transfer #1:** \$200,992,721  
 transfer from Purdue Pharma  
 L.P. to Purdue Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			200.992.721,00	FUNDING from PURDUE PHARMA L.P.
2	40	102401	PLP Assoc Holdings		GEN			200.000.000,00	FUNDING to PLP ASC. HOLDINGS LP
3	40	102301	Purdue Pharma Inc.		GEN			497.457,00	FUNDING to PURDUE PHARMA, INC.
4	40	102402	PLP Assoc Holdings		GEN			495.264,00	FUNDING to PLP ASC. HOLDINGS, INC.
5	50	102208	Purdue Pharma L.P.		GEN			200.992.721,00	FUNDING from PURDUE PHARMA L.P.
6	50	100010	Cash Concentration		GEN			200.000.000,00	FUNDING to PLP ASC. HOLDINGS LP
7	50	100010	Cash Concentration		GEN			497.457,00-	FUNDING to PURDUE PHARMA, INC.
8	50	100010	Cash Concentration		GEN			495.264,00-	FUNDING to PLP ASC. HOLDINGS, INC.

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000467 Company Code 402 Fiscal Year 2011  
 Doc. Date 12.07.2011 Posting Date 07.07.2011 Period 07  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CIW 07012011 to 07072011

**Transfer #2B:** \$495,264  
 transfer from Purdue Holdings  
 L.P. to PLP Associates Holdings  
 Inc.

**Transfer #2C:** \$200M transfer  
 from Purdue Holdings L.P. to  
 PLP Associates Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			495.264,00	FUNDING from PURDUE HOLDINGS LP
2	50	102416	Purdue Holdings LP		GEN			495.264,00-	FUNDING from PURDUE HOLDINGS LP

## Selection 7 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., June 2011 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000698 Company Code 301 Fiscal Year 2011  
 Doc. Date 12.07.2011 Posting Date 07.07.2011 Period 07  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 07012011 to 07072011

**Transfer #2A:** \$497,457  
 transfer from Purdue Holdings  
 L.P. to Purdue Pharma Inc.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			497.457,00	FUNDING from PURDUE HOLDINGS LP
2	50	102416	Purdue Holdings LP		GEN			497.457,00-	FUNDING from PURDUE HOLDINGS LP

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000764 Company Code 401 Fiscal Year 2011  
 Doc. Date 12.07.2011 Posting Date 07.07.2011 Period 07  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 07012011 to 07072011

**Transfer #3:** \$200M transfer  
 from PLP Associates Holdings  
 L.P. to BR Holdings Associates  
 L.P.

**Transfer #2C:** \$200M transfer  
 from Purdue Holdings L.P. to  
 PLP Associates Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			200.000.000,00	FUNDING from PURDUE HOLDINGS LP
2	40	102413	BR Holdings Assoc LP		GEN			200.000.000,00	FUNDING to BR HOLDINGS ASC. LP
3	50	102416	Purdue Holdings LP		GEN			200.000.000,00-	FUNDING from PURDUE HOLDINGS LP
4	50	100010	Cash Concentration		GEN			200.000.000,00-	FUNDING to BR HOLDINGS ASC. LP



## Selection 7 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., June 2011 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000379 Company Code 413 Fiscal Year 2011  
 Doc. Date 12.07.2011 Posting Date 07.07.2011 Period 07  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 07012011 to 07072011

**Transfer #3:** \$200M transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			200.000.000,00	FUNDING from PLP ASC. HOLDINGS LP
2	50	102401	PLP Assoc Holdings		GEN			200.000.000,00-	FUNDING from PLP ASC. HOLDINGS LP

Doc.Type : KZ ( Vendor payment ) Normal document

Doc. Number 1500000024 Company Code 413 Fiscal Year 2011  
 Doc. Date 07.07.2011 Posting Date 08.07.2011 Period 07  
 Calculate Tax ☐  
 Ref.Doc. WIRE TRANSFER  
 Doc. Currency USD

**Transfer #4A:** \$100M transfer from BR Holdings Associates L.P. to Beacon Company.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			100.000.000,00-	
2	25	1029154	BEACON CO		GEN			100.000.000,00	

Doc.Type : KZ ( Vendor payment ) Normal document

Doc. Number 1500000025 Company Code 413 Fiscal Year 2011  
 Doc. Date 07.07.2011 Posting Date 08.07.2011 Period 07  
 Calculate Tax ☐  
 Ref.Doc. WIRE TRANSFER  
 Doc. Currency USD

**Transfer #4B:** \$100M transfer from BR Holdings Associates L.P. to Rosebay Medical Company L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			100.000.000,00-	
2	25	1016497	ROSEBAY MEDICAL COMP		GEN			100.000.000,00	

## Selection 7 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., June 2011 (cont'd)

[DRAFT - June 30, 2011]

**DECISION**  
June 24, 2011

Purdue Pharma L.P. — 2Q 2011 Distribution


It was decided that Purdue Pharma L.P. ("PPLP") distribute \$200,992,721 for the quarter ending June 30, 2011 as follows:

1. PPLP will distribute \$200,992,721 to Purdue Holdings L.P. ("PHLP");
2. PHLP will then distribute \$200,992,721 as follows:
 

Company	Amount
Purdue Pharma Inc.	\$ 497,457
PLP Associates Holdings Inc.	495,264
PLP Associates Holdings L.P.	\$ 200,000,000
<b>TOTAL</b>	<b>\$ 200,992,721</b>
3. PLP Associates Holdings L.P. will thereafter distribute \$200,000,000 to BR Holdings Associates L.P.; and
4. BR Holdings Associates L.P. will then distribute \$200,000,000 as follows:
 

Company	Amount
Beacon Company	\$ 100,000,000
Rosebay Medical Company L.P.	100,000,000
<b>TOTAL</b>	<b>\$ 200,000,000</b>

(Decision of the Board of Directors of Purdue Pharma Inc., as the general partner of Purdue Pharma L.P.)

  
 Okay to Pay

CPANE-4045731.1

**Transfer #1:** Authorization for \$200,992,721 transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

**Transfer #3:** Authorization for \$200M transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

**Transfers #2A, #2B, and #2C:** Authorization for transfers from Purdue Holdings L.P. in amounts of \$497,457, \$495,264, and \$200M to Purdue Pharma Inc., PLP Associates Holdings Inc., and PLP Associates Holdings L.P., respectively.

**Transfers #4A and #4B:** Authorization for \$100M transfer from BR Holdings Associates L.P. to each of Beacon Company and Rosebay Medical Company L.P.

## Selection 7 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., June 2011 (cont'd)

**Transfer #4A:** Authorization for \$100M transfer from BR Holdings Associates L.P. to Beacon Company.

PURDUE WIRE TRANSFER REQUEST			
<b>FOR ACCOUNTS PAYABLE USE ONLY</b>  <b>SAP PAYMENT DUE DATE:</b>  <b>SAP VENDOR NUMBER:</b> <b>1029154</b>  <b>INVOICE NO. / PO NO.:</b>  <b>SAP DOCUMENT NUMBER:</b>  <b>WIRE TRANSFER DOCUMENT NUMBER:</b>	DATE:	6-Jul-2011	Bank Acct Name: JPMorganChase
	FROM CO. NAME:	BR Holdings Associates LP	Bank Acct Number: [REDACTED]
	PAYEE VENDOR NAME:	BEACON CO	
	STREET ADDRESS:		
	CITY, STATE, ZIP:		
	RECIPIENT BANK NAME:	JPMorganChase	
	BANK STREET ADDRESS:	1411 AVE OF THE AMERICAS	
	CITY, STATE, ZIP:	New York, NY 10041	
	ACCOUNT NUMBER:	[REDACTED]	
	ABA NUMBER:	021000021	
REQUESTED BY:			
	TOTAL WIRE TRANSFER AMOUNT:	\$ 100,000,000.00	
	PAYMENT DESCRIPTION:	2Q11 Partner Distribution	
Required: Company/ExpenseAcct/Cost Center/Proj			
	GL Date:	413-302044	\$ Amount \$ 100,000,000.00
	GL Date:		\$ Amount \$
	GL Date:		Total Amount \$ 100,000,000.00
NOTE: Wire Transfer Amounts less than \$500,000.01 do not require an authorized signature (below) Amounts between \$ 500,000.01 and \$500,000 require one A or B Group Signer Amounts over \$500,000 require one signer from each group Amounts over \$1,000,000.01, one of the signers must be an EVP (EVP: John Stewart, Ed Mahony, David Long, James Dolan)			
Group A Signer [REDACTED] [REDACTED] [REDACTED] Group B Signer [REDACTED] [REDACTED] [REDACTED]			
<b>TREASURY USE ONLY</b> Created By: JHL 7 JUL Approved By: JHL Released By: JHL Repetitive Name:			
<b>ACCOUNTS PAYABLE REVIEW</b> REVIEWED BY: [REDACTED] EXT 7061 Instructions: A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z A. NO FURTHER APPROVAL REQUIRED OR B. MATCHED TO SAP GL, RECEIVING ENHANCED C. BY APPROVE, SIGNATURE NEEDED, OR D. NO PD, NO NET VISA RECORD APPROVE E. SIGNATURE NEEDED IN RESOURCES APPROVAL FOR F. PRICE AND QTY G. [REDACTED]			

**Transfer #4B:** Authorization for \$100M transfer from BR Holdings Associates L.P. to Rosebay Medical Company L.P.

## Selection 7 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., June 2011 (cont'd)

**Transfer #4A:** Confirmation for \$100M transfer from BR Holdings Associates L.P. to Beacon Company.

07/JUL/11\* 12:27 Transaction DetSession No000-1562  
Status Released

TYPE PAY BANK CHASE LOC NYC CUST LINRBEACON  
METHOD BKT ACCOUNT [REDACTED]  
TFR DATED 07/JUL/11 VALUE 07/JUL/11 AMOUNT USD 100,000,000.00  
CONFIRMATION NUM 2507100198J00000

ULTIMATE BENEFICIARY  
Acct No [REDACTED] 7  
Name Beacon Co  
Address :

Advice :  
Instr :

BENEFICIARY BANK  
Acct No/ID:  
Name :  
Address :

Advice :  
Instr :

CORRESPONDENT / PAY THROUGH BANK  
Acct No/ID:  
Name :  
Address :

Advice :  
Instr :

BY ORDER OF  
Name :  
Address :

CUST REF :

REFERENCE TEXT  
2Q11 Partner Distribution

**RECEIVED**  
JUL 08 2011  
BY: \_\_\_\_\_

Page : 6

## Selection 7 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., June 2011 (cont'd)

**Transfer #4B:** Confirmation for \$100M transfer from BR Holdings Associates L.P. to Rosebay Medical Company L.P.

07/JUL/11 12:27 Transaction Det:Session No000-1563  
Status:Released

TYPE PAY BANK CHASE 100 000000 CUST LIN:ROSEBAY MEDICAL  
METHOD SBT ACCOUNT [REDACTED]  
TFR DATE:07/JUL/11 VALUE 07/JUL/11 AMOUNT USD 100,000,000.00  
CONFIRMATION NUM:2507200188J00000

ULTIMATE BENEFICIARY  
Acct No [REDACTED]  
Name Rosebay Medical Company LP  
Address c/o: North Bay Associates  
Oklahoma City OK 73134

Advice :  
Instr :

BENEFICIARY BANK  
Acct No/ID:  
Name :  
Address :

Advice :  
Instr :

CORRESPONDENT / PAY THROUGH BANK  
Acct No/ID:  
Name :  
Address :

Advice :  
Instr :

BY ORDER OF  
Name :  
Address :

CUST RIF :  
REFERENCE TEXT  
2Q11 Partner Distribution

**RECEIVED**  
JUL 08 2011  
BY: \_\_\_\_\_


Page : 7



## **Selection 8 Purdue US Partner Cash Distributions (2009)**



## Selection 8 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., March 2009



## Selection 8 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., March 2009 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number100050281

Company Code208

Fiscal Year2009

Doc. Date17.03.2009

Posting Date16.03.2009

Period03

Calculate Tax☐

Doc. CurrencyUSD

Doc. Hdr TextCTW 03102009 to 03162009

Transfer #1A: \$497,457

transfer from Purdue Pharma L.P. to Purdue Pharma Inc.

Transfer #1B: \$495,264

transfer from Purdue Pharma L.P. to PLP Associates Holdings Inc.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
176	50	100010	Cash Concentration		GEN			500.000,00-	I/E PPLP TO PURDUE PHARMA TECHNOLOGIES, INC.
177	50	100010	Cash Concentration		GEN			497.457,00-	FUNDING to PURDUE PHARMA, INC.
178	50	100010	Cash Concentration		GEN			495.264,00-	FUNDING to PLP ASC. HOLDINGS, INC.
179	50	100110	Lockbox Clearing		GEN			467.234,06-	AR LOCKBOX

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number100050281

Company Code208

Fiscal Year2009

Doc. Date17.03.2009

Posting Date16.03.2009

Period03

Calculate Tax☐

Doc. CurrencyUSD

Doc. Hdr TextCTW 03102009 to 03162009

Transfer #1C: \$200M transfer from Purdue Pharma L.P. to PLP Associates Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
319	50	100010	Cash Concentration		GEN			200.000.000,00-	3/11/2009 ADVANCE to PLP ASC. HOLDINGS LP
156	50	100430	Money Mkt Goldman		GEN			105.000.000,00-	GOLDMAN SACHS MONEY MARKET DRAW-DOWN
320	50	100450	BOA Money Market		GEN			100.000.000,00-	3/11/2009 MIC / BofA money market
321	50	100400	Temp. Invest. Chase		GEN			30.000.000,00-	3/12/2009 MIC / BofA SHORT-TERM INVESTMENT

## Selection 8 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., March 2009 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document  
 Doc. Number 100000312 Company Code 301 Fiscal Year 2009  
 Doc. Date 17.03.2009 Posting Date 16.03.2009 Period 03  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 03102009 to 03162009

**Transfer #1A:** \$497,457  
 transfer from Purdue Pharma  
 L.P. to Purdue Pharma Inc.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			497.457,00	PPLP ADVANCE TO PURDUE PHARMA INC.
2	50	102208	Purdue Pharma L.P.		GEN			497.457,00-	PPLP ADVANCE TO PURDUE PHARMA INC.

Doc.Type : SA ( G/L account document ) Normal document  
 Doc. Number 100000191 Company Code 402 Fiscal Year 2009  
 Doc. Date 17.03.2009 Posting Date 16.03.2009 Period 03  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 03102009 to 03162009

**Transfer #1B:** \$495,264  
 transfer from Purdue Pharma  
 L.P. to PLP Associates Holdings  
 Inc.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			495.264,00	ADVANCE from PPLP
2	50	102208	Purdue Pharma L.P.		GEN			495.264,00-	ADVANCE from PPLP

Doc.Type : SA ( G/L account document ) Normal document  
 Doc. Number 100000394 Company Code 401 Fiscal Year 2009  
 Doc. Date 17.03.2009 Posting Date 16.03.2009 Period 03  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 03102009 to 03162009

**Transfer #1C:** \$200M transfer  
 from Purdue Pharma L.P. to PLP  
 Associates Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			200.000.000,00	ADVANCE from PPLP
2	50	102208	Purdue Pharma L.P.		GEN			200.000.000,00-	ADVANCE from PPLP

## Selection 8 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., March 2009 (cont'd)

Doc.Type : KZ ( Vendor payment ) Normal document

Doc. Number 1500000056 Company Code 401 Fiscal Year 2009  
 Doc. Date 11.03.2009 Posting Date 12.03.2009 Period 03  
 Calculate Tax ☐  
 Ref.Doc. WIRE TRANSFER  
 Doc. Currency USD

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			95.000.000,00-	
2	25	1016449	BEACON TRUST COMPANY		GEN			95.000.000,00	

Doc.Type : KZ ( Vendor payment ) Normal document

Doc. Number 1500000058 Company Code 401 Fiscal Year 2009  
 Doc. Date 11.03.2009 Posting Date 11.03.2009 Period 03  
 Calculate Tax ☐  
 Ref.Doc. WIRE TRANSFER  
 Doc. Currency USD

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			5.000.000,00-	
2	25	1029154	BEACON CO		GEN			5.000.000,00	

Doc.Type : KZ ( Vendor payment ) Normal document

Doc. Number 1500000057 Company Code 401 Fiscal Year 2009  
 Doc. Date 11.03.2009 Posting Date 12.03.2009 Period 03  
 Calculate Tax ☐  
 Ref.Doc. WIRE TRANSFER  
 Doc. Currency USD


Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			100.000.000,00-	
2	25	1016497	ROSEBAY MEDICAL COMP		GEN			100.000.000,00	

**Transfer #2A and 2B:** \$100M transfer from PLP Associates Holdings L.P. to Beacon Company.

- **Transfer 2A:** \$95M paid to Beacon Trust Company.
- **Transfer 2B:** \$5M paid to Beacon Company (different vendor codes)

**Transfer #2C:** \$100M transfer from PLP Associates Holdings L.P. to Rosebay Medical Company L.P.

## Selection 8 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., March 2009 (cont'd)





## Selection 8 – US Partner Cash Distribution to Beacon Company, Beacon Trust Co. Limited and Rosebay Medical Company L.P., March 2009 (cont'd)

**Transfer #2A:** Confirmation of \$5M transfer from PLP Associates Holdings L.P. to Beacon Co.

11/MAR/09 09:42 Transaction CSession 00-4865  
StatuReleased

TYPE PA'BANCHASE LOONYCUST LINE:  
METH:BKTACCO [REDACTED]  
TFR D:11/MARVALL11/MAFAMOLUS5,000,000.00  
CONFIRMATI:0876600070JO0000

ULTIMATE BENEFICIARY  
Acct No. [REDACTED]  
Name BEACON COMPANY  
Address :

Advice :  
Instr :

BENEFICIARY BANK  
Acct No/ID:  
Name Jpmorgan Chase Bank  
AddressNew York Ny 10004

Advice :  
Instr :

CORRESPONDENT / PAY THROUGH BANK  
Acct No/ID:  
Name :  
Address :

Advice :  
Instr :

BY ORDER OF  
Name :  
Address :

CUST REF :

REFERENCE TEXT  
IPRIORITY!



## Selection 8 – US Partner Cash Distribution to Beacon Company, Beacon Trust Co. Limited and Rosebay Medical Company L.P., March 2009 (cont'd)

Transfer #2B: Authorization  
for \$95M transfer from PLP  
Associates Holdings L.P. to  
Beacon Trust Co.

**PURDUE WIRETRANSFER REQUEST**

**WIRE TYPE:**  
☐ RECURRING WIRE ☐ STANDARD WIRE ☐ ACH WIRE ☐ FOREIGN WIRE ☐ DIRECT DEBIT

**DATE:** 10-Mar-2009 **Payer Bank Acct Name:** JPMorgan Chase

**FROM/TO NAME:** PLP ASSOCIATES HOLDINGS L.P. Bank Acct Number: [REDACTED]

**PAYEE/VENDOR/USE:** Beacon Trust Co LTD as trustee settlement dated 31 Dec 1993

**STREET ADDRESS:**

**CITY, STATE, ZIP:**

**RECIPIENT BANK NAME:** Citibank (Guernsey) Limited

**BANK STREET ADDRESS:** PO Box 100

**CITY, STATE, ZIP:** St. Peter Port Guernsey Channel Islands GU11 1AA

**ACCOUNT NUMBER:** [REDACTED]

**BANK:**

**ABA NUMBER:** SWIFT Address CRESGG33

**Pay Through Bank:** Bank of New York  
SWIFT Code BNYUS33

**TOTAL WIRE TRANSFER AMOUNT:** \$95,000,000.00

**EXAMINER'S SIGNATURE:**

**Required: Company/Expense/Account/Contact/Message/Project**

**GL Date:** **\$ Amount:** \$ 95,000,000.00

**GL Date:** **\$ Amount:**

**GL Date:** **Total Amount:** \$ 95,000,000.00

**NOTE: Wire Transfer Amounts \$100,000 or less do not require an Authorized signature (below)**

**Authorized Signer 1:**  
Signature Required \$100,000.01 - \$500,000 [REDACTED]

**Authorized Signer 2:**  
Signature Required \$500,000.01 up to \$1,000,000 [REDACTED]

**\$1,000,000.01 and above, one of the signers must be an EVP** (EVP: John Stewart, Ed Mahoney, Howard Gittel, Raymond Sackler)  
**NOTE: Both "A" & "B" Signers are authorized to sign up to \$500,000 singly, and jointly (one "A" + one "B" signer) \$500,000.01 up to \$1,000,000**

**TREASURY USE ONLY**

**Created By:** SAC

**Approved By:** SAC 7/1

**Reviewed By:**

**DO NOT SIGN**

**AP SYSTEM**

**SWIFT Revision: TR00P**

## Selection 8 – US Partner Cash Distribution to Beacon Company, Beacon Trust Co. Limited and Rosebay Medical Company L.P., March 2009 (cont'd)

**Transfer #2B:** Confirmation of \$95M transfer from PLP Associates Holdings L.P. to Beacon Trust Co.

11/MAR/09 09:42 Transaction CSession 00-4866  
StatuReleased

TYPE PA'BANCHASE LOCNYCUST LINE:  
METHICHFACCO020910355  
TFR D,11/MARVALL11/MAFAMOLUS\$5,000,000.00  
CONFIRMATI0876700070JO0000

**ULTIMATE BENEFICIARY**

Acct No. [REDACTED]  
Name BEACON TRUST LIMITED  
Address AS TRUSTEE OF A SETTLEMENT DATED  
31 DECEMBER 1993

Advice :  
Instr :

**BENEFICIARY BANK**

Acct No. [REDACTED]  
Name CREDIT SUISSE (GUERNSEY) LIMITED  
Address PO BOX 368  
ST PETER PORT  
GB GUERNSEY GY1 3YJ CHANNEL ISLANDS

Advice :  
Instr :

**CORRESPONDENT / PAY THROUGH BANK**

Acct No. [REDACTED]  
Name The Bank Of New York Mellon  
Address 48 Wall St  
New York Ny 10005-2901

Advice :  
Instr :

**BY ORDER OF**

Name :  
Address :

**CUST REF :**

REFERENCE TEXT  
ACCOUNT NO [REDACTED] TAX PAID  
ACCOUNT

## Selection 8 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., March 2009 (cont'd)

**Transfer #2C:** Authorization for \$100M transfer from PLP Associates Holdings L.P. to Rosebay Medical Company L.P.

**PURDUE WIRE TRANSFER REQUEST**

WIRE TYPE: ☐ RECURRING WIRE ☒ STANDARD WIRE ☐ ACH WIRE ☐ FOREIGN WIRE

ACCOUNTS PAYABLE USE ONLY

SAP PAYMENT DATE: 1016497

INVOICE NO. / PO NO: 31009

SAP DOCUMENT NUMBER: 190000164

WIRE TRANSFER DOCUMENT NUMBER: 150000057

DATE: 10-Mar-2009

FROM CO. NAME: PLP Associates Holdings LP

PAYEE/BENEFICIARY NAME: Rosebay Medical Company

STREET ADDRESS: c/o North Bay Associates

CITY, STATE, ZIP: Oklahoma City, OK 73134

REQUEST BANK NAME: JPMorgan Chase

BANK STREET ADDRESS: 55 Water Street

CITY, STATE, ZIP: New York, NY 20041

ACCOUNT NUMBER: [REDACTED]

ABA NUMBER: 021000021

REQUESTED BY: [REDACTED]

TOTAL WIRE TRANSFER AMOUNT: \$ 100,000,000.00

PAYMENT DESCRIPTION: Top-up Distribution

Required Company Expense/Asset Cost Center/Item/Project

GL Date: 4/1/2009 \$ Amount: \$ 100,000,000.00

GL Desc: [REDACTED] \$ Amount: [REDACTED]

GL Date: [REDACTED] Total Amount: \$ 100,000,000.00

NOTE: Wire Transfer Amounts \$100,000 or less do not require an authorized signature (initials)

Authorized Signer 1: [REDACTED]

Signature Required \$100,000.01 - \$500,000

Authorized Signer 2: [REDACTED]

2nd Signature Required \$500,000.01 up to \$1,000,000

\$1,000,000.01 and above, one of the signers must be an EVP

NOTE: Both "A" & "B" Signers are authorized to sign up to \$100,000 singly, and jointly (one "A" + one "B" signer) \$100,000.01 up to \$1,000,000

Created By: [REDACTED]

Approved By: [REDACTED]

Released By: [REDACTED]

Reviewed/Released For Payment Per SOP # 20.5 By: [REDACTED] Disbursement Control Group

Reviewed/Released For Payment Per SOP # 20.5 By: [REDACTED] Disbursement Control Group

REMARK: 31003

## Selection 8 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., March 2009 (cont'd)

**Transfer #2C:** Confirmation of \$100M transfer from PLP Associates Holdings L.P. to Rosebay Medical Company L.P.

11/MAR/09 09:42 Transaction CSession 00-4864  
Status: Released

TYPE PA'BANCHASE LOCNYCUST LINE:  
METH@KTACC [REDACTED]  
TFR D.11/MARVALL11/MAFAMOLUSI100,000,000.00  
CONFIRMATI0876500070JO0000

ULTIMATE BENEFICIARY  
Acct No [REDACTED]  
Name ROSEBAY MEDICAL COMPANY  
Address CO NORTH BAY ASSOCIATES  
OKLAHOMA CITY OK 73134

Advice :  
Instr :

BENEFICIARY BANK  
Acct No/ID:  
Name Jpmorgan Chase Bank  
Address New York Ny 10004

Advice :  
Instr :

CORRESPONDENT / PAY THROUGH BANK  
Acct No/ID:  
Name :  
Address :

Advice :  
Instr :

BY ORDER OF  
Name :  
Address :

CUST REF :

REFERENCE TEXT  
IPRIORITYI

RECEIVED

Page : 2

## Selection 8 – US Partner Cash Distribution to Beacon Company and Rosebay Medical Company L.P., March 2009 (cont'd)

### PPLP Distribution - Profit Share

	<u>YTD Including Feb Distribution</u>	<u>YTD Distributions</u>	<u>Payout</u>	
PPLP Distribution	268,325,282	\$ (67,332,561)	\$ 200,992,721	
Purdue Pharma Inc.	664,105	(166,648)	497,457	0.2475
PLP Associates Holdings Inc.	661,177	(165,913)	495,264	(244.55/99000) * (100% - 0.2475%)
PLP Associates Holdings L.P.	267,000,000	(67,000,000)	200,000,000	(98755.45/99000) * (100% - 0.2475%)
<b>To BR Holdings and then Partners</b>	<b>267,000,000</b>	<b>(67,000,000)</b>	<b>200,000,000</b>	
Reigo (50%)	\$ 133,500,000	\$ (33,500,000)	\$ 100,000,000	
Rosebay (50%)	\$ 133,500,000	\$ (33,500,000)	\$ 100,000,000	

**Transfer #1:** Authorization for \$200,992,721 transfer from Purdue Pharma L.P., including \$497,457 to Purdue Pharma Inc., \$495,264 to PLP Associates Holdings Inc., and \$200M to PLP Associates Holdings L.P.


**Transfer #2:** Authorization for \$100M transfers from PLP Associates Holdings L.P. to each of Reigo Company (name later changed to Beacon Company) and Rosebay Medical Company L.P.

No documentation was identified in the SAP general ledger system evidencing that funds flowed from PLP Associates Holdings L.P. (Company #401) to BR Holdings L.P. before flowing to Beacon Company, Beacon Trust Company or Rosebay Medical Company L.P. Instead, documentation in the SAP general ledger system indicates that funds flowed directly from PLP Associates Holdings L.P. (Company #401) to Beacon Company, Beacon Trust Company Limited and Rosebay Medical Company L.P. Beacon Company and Beacon Trust Company Limited were formerly known as Reigo Company.



## **Selection 9 Purdue US Partner Cash Distributions (2012)**

## Selection 9 – US Partner Cash Distributions to Purdue Pharma Inc. and PLP Associates Holdings Inc., December 2012





## Selection 9 – US Partner Cash Distributions to Purdue Pharma Inc. and PLP Associates Holdings Inc., December 2012 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document  
 Doc. Number 100114404 Company Code 208 Fiscal Year 2012  
 Doc. Date 01/03/2013 Posting Date 12/31/2012 Period 12  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 12172012 to 12312012

**Transfer #2:** \$6 million transfer from Purdue Pharma L.P. to PLP Associates Holdings Inc.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
297	50	100110	Lockbox Clearing		GEN			6,329,907.22-	AMERISOURCE
298	50	100010	Cash Concentration		GEN			6,000,000.00-	FUNDING to PLP ASC. HOLDINGS, INC.
299	50	100010	Cash Concentration		GEN			6,000,000.00-	FUNDING to PURDUE PHARMA, INC.

**Transfer #1:** \$6 million transfer from Purdue Pharma L.P. to Purdue Pharma Inc.

## Selection 9 – US Partner Cash Distributions to Purdue Pharma Inc. and PLP Associates Holdings Inc., December 2012 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100000913	Company Code	301	Fiscal Year	2012
Doc. Date	01/03/2013	Posting Date	12/31/2012	Period	12
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	USD				
Doc. Hdr Text	CTW 12172012 to 12312012				

**Transfer #1:** \$6 million transfer from Purdue Pharma L.P. to Purdue Pharma Inc.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			6,000,000.00	PPLP ADVANCE TO PURDUE PHARMA INC.
2	40	100010	Cash Concentration		GEN			149,237.00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
3	40	100010	Cash Concentration		GEN			2,083.33	FUNDING from COVENTRY TECHNOLOGIES, LP (11c)
4	40	100010	Cash Concentration		GEN			1,076.87	FUNDING from PURDUE HOLDINGS LP
5	50	102208	Purdue Pharma L.P.		GEN			6,000,000.00	PPLP ADVANCE TO PURDUE PHARMA INC.
6	50	107416	Invest - PH LP		GEN			149,237.00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
7	50	102230	Coventry Tech. LLC		GEN			2,083.33	FUNDING from COVENTRY TECHNOLOGIES, LP (11c)
8	50	102416	Purdue Holdings LP		GEN			1,076.87	FUNDING from PURDUE HOLDINGS LP

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100000638	Company Code	402	Fiscal Year	2012
Doc. Date	01/03/2013	Posting Date	12/31/2012	Period	12
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	USD				
Doc. Hdr Text	CTW 12172012 to 12312012				

**Transfer #2:** \$6 million transfer from Purdue Pharma L.P. to PLP Associates Holdings Inc.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			6,000,000.00	ADVANCE from PPLP
2	40	100010	Cash Concentration		GEN			148,579.00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
3	40	100010	Cash Concentration		GEN			1,072.09	FUNDING from PURDUE HOLDINGS LP
4	50	102208	Purdue Pharma L.P.		GEN			6,000,000.00	ADVANCE from PPLP
5	50	107416	Invest - PH LP		GEN			148,579.00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
6	50	102416	Purdue Holdings LP		GEN			1,072.09	FUNDING from PURDUE HOLDINGS LP

## Selection 9 – US Partner Cash Distributions to Purdue Pharma Inc. and PLP Associates Holdings Inc., December 2012 (cont'd)

Doc.Type : KR ( Vendor invoice ) Normal document					
Doc. Number	1900000341	Company Code	301	Fiscal Year	2012
Doc. Date	12/19/2012	Posting Date	12/19/2012	Period	12
Calculate Tax	<input checked="" type="checkbox"/>				
Ref.Doc.	121912				
Doc. Currency	USD				

**Transfer #4A:** \$3 million dividend from Purdue Pharma Inc. to Banela Corporation.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1025491	BANELA CORPORATION		GEN		U1	3,000,000.00-	
2	40	303001	Partnership Earn Adj		GEN			3,000,000.00	

Doc.Type : KR ( Vendor invoice ) Normal document					
Doc. Number	1900000340	Company Code	301	Fiscal Year	2012
Doc. Date	12/19/2012	Posting Date	12/21/2012	Period	12
Calculate Tax	<input checked="" type="checkbox"/>				
Ref.Doc.	121912				
Doc. Currency	USD				

**Transfer #4C:** \$1.5 million dividend from Purdue Pharma Inc. to Perthlite Holdings LLC.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1032484	RAYMOND R SACKLER TR		GEN		U1	1,500,000.00-	
2	40	320000	Corporations RE		GEN			1,500,000.00	

Doc.Type : KR ( Vendor invoice ) Normal document					
Doc. Number	1900000339	Company Code	301	Fiscal Year	2012
Doc. Date	12/19/2012	Posting Date	12/21/2012	Period	12
Calculate Tax	<input checked="" type="checkbox"/>				
Ref.Doc.	121912				
Doc. Currency	USD				

**Transfer #4B:** \$1.5 million dividend from Purdue Pharma Inc. to Linarite Holdings LLC.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1032483	RAYMOND R SACKLER TR		GEN		U1	1,500,000.00-	
2	40	320000	Corporations RE		GEN			1,500,000.00	

## Selection 9 – US Partner Cash Distributions to Purdue Pharma Inc. and PLP Associates Holdings Inc., December 2012 (cont'd)

Doc.Type : KR ( Vendor invoice ) Normal document

Doc. Number 1900000208 Company Code 402 Fiscal Year 2012  
 Doc. Date 12/19/2012 Posting Date 12/19/2012 Period 12  
 Calculate Tax ☒  
 Ref.Doc. 121912A  
 Doc. Currency USD

**Transfer #3A:** \$3 million dividend from PLP Associates Holdings Inc. to Banela Corporation.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1025491	BANELA CORPORATION		GEN		U1	3,000,000.00-	
2	40	303001	Partnership Earn Adj		GEN			3,000,000.00	

Doc.Type : KR ( Vendor invoice ) Normal document

Doc. Number 1900000206 Company Code 402 Fiscal Year 2012  
 Doc. Date 12/19/2012 Posting Date 12/21/2012 Period 12  
 Calculate Tax ☒  
 Ref.Doc. 121912A  
 Doc. Currency USD

**Transfer #3C:** \$1.5 million dividend from PLP Associates Holdings Inc. to Perthlite Holdings LLC.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1032484	RAYMOND R SACKLER TR		GEN		U1	1,500,000.00-	
2	40	320000	Corporations RE		GEN			1,500,000.00	

Doc.Type : KR ( Vendor invoice ) Normal document

Doc. Number 1900000205 Company Code 402 Fiscal Year 2012  
 Doc. Date 12/19/2012 Posting Date 12/21/2012 Period 12  
 Calculate Tax ☒  
 Ref.Doc. 121912A  
 Doc. Currency USD

**Transfer #3B:** \$1.5 million dividend from PLP Associates Holdings Inc. to Linarite Holdings LLC.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1032483	RAYMOND R SACKLER TR		GEN		U1	1,500,000.00-	
2	40	320000	Corporations RE		GEN			1,500,000.00	

## Selection 9 – US Partner Cash Distributions to Purdue Pharma Inc. and PLP Associates Holdings Inc., December 2012 (cont'd)

**DECISION**  
December 17, 2012

2012 Dividends - PLP Associates Holdings Inc.

It was decided that PLP Associates Holdings Inc. declare and pay dividends in the aggregate amount of \$6 million on or before December 31, 2012 payable as follows:


- \$3 million to Banela Corporation, a British Virgin Island's company
- \$1.5 million to Linarite Holdings LLC, a Delaware Limited Liability Company (held 100% by Anthony M. Roncalli, as Trustee under Trust Agreement dated December 23, 1989 F.B.O. the issue of Richard S. Sackler, M.D.)
- \$1.5 million to Perthlite Holdings LLC, a Delaware Limited Liability Company (held 100% by Jeffrey A. Robins, as Trustee under Trust Agreement dated December 23, 1989 F.B.O. the issue of Jonathan D. Sackler)

(Decision of the Board of Directors of PLP Associates Holdings Inc.)

**Transfer #3A:** Authorization to transfer \$3.0 million cash payment from PLP Associates Holdings Inc. to Banela Corporation.  
  
**Transfer #3B:** Authorization to transfer \$1.5 million cash payment from PLP Associates Holdings Inc. to Linarite Holdings LLC.  
  
**Transfer #3C:** Authorization to transfer \$1.5 million cash payment from PLP Associates Holdings Inc. to Perthlite Holdings LLC.

[Redacted Signature]  
 On To Pay  
 Edward R. Mahony

## Selection 9 – US Partner Cash Distribution to Purdue Pharma Inc. and PLP Associates Holdings Inc., December 2012 (cont'd)



Source: Decision of Board of Directors of Purdue Pharma Inc. dated 12/17/2012

Raymond R Sackler Trust 1B is the name on the bank account of the trust that owns Linarte Holdings LLC

Raymond R Sackler Trust 2B is the name on the bank account of the trust that owns Perthlite Holdings LLC




## Purdue Tax Distributions





## **Selection 10 Purdue Tax Distributions (2014)**

## Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014



<sup>1</sup> State and other federal tax payments identified in Purdue's Internal Distribution Analysis and SAP General Ledger detail. We are unable to determine from the books and records maintained by Purdue whether Rosebay Medical Company L.P. or Beacon Company used the distributions to make tax-related payments to the appropriate taxing authorities. Under IRC Sect on 1446, BR Holdings Associates L.P. is required to withhold taxes on behalf of its foreign partner, Beacon Company. The \$4,815,669 Tax Distribution to Beacon Company related to Medicare taxes. Under IRC Section 1446, the withholding agent is not required to withhold the 3.8% Medicare tax to remit to the US Treasury.

## Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100138421 Company Code 208 Fiscal Year 2014  
 Doc. Date 09/23/2014 Posting Date 09/14/2014 Period 09  
 Calculate Tax ☐  
 Ref.Doc. CWS Overall No. 0100138421208 14  
 Doc. Currency USD  
 Doc. Hdr Text CTW208 09082014-09142014

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
98	50	100010	Cash Concentration		GEN			60,368,169.00-	██████████ PURDUE HOLDINGS L P 1 STAMFORD F
116	50	100010	Cash Concentration		GEN			50,334,331.00-	██████████ PURDUE HOLDINGS L P 1 STAMFORD F
164	50	100400	Temp. Invest. Chase		GEN			50,000,000.00-	FEDERAL HOME LOAN BANKS DISCOUNT NOTE

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100138421 Company Code 208 Fiscal Year 2014  
 Doc. Date 09/23/2014 Posting Date 09/14/2014 Period 09  
 Calculate Tax ☐  
 Ref.Doc. CWS Overall No. 0100138421208 14  
 Doc. Currency USD  
 Doc. Hdr Text CTW208 09082014-09142014

**Transfers #1A and #1B:**  
 \$60.4M and \$50.3M transfers  
 from Purdue Pharma L.P. to  
 Purdue Holdings L.P., totaling  
 \$110.7M.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
229	40	102416	Purdue Holdings LP		GEN			110,702,500.00	

## Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000472 Company Code 416 Fiscal Year 2014  
 Doc. Date 09/23/2014 Posting Date 09/14/2014 Period 09  
 Calculate Tax ☐  
 Ref.Doc. CWS Overall No. 0100138421208 14  
 Doc. Currency USD  
 Doc. Hdr Text CTW208 09082014-09142014

**Transfers #1A and #1B:**  
 \$60.4M and \$50.3M transfers  
 from Purdue Pharma L.P. to  
 Purdue Holdings L.P., totaling  
 \$110.7M.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			60,368,169.00	PURDUE HOLDINGS L P 1 STAMFORD F
2	40	100010	Cash Concentration		GEN			50,334,331.00	PURDUE HOLDINGS L P 1 STAMFORD F
3	50	102208	Purdue Pharma L.P.		GEN			110,702,500.00	

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000474 Company Code 416 Fiscal Year 2014  
 Doc. Date 09/23/2014 Posting Date 09/14/2014 Period 09  
 Calculate Tax ☐  
 Ref.Doc. CWS Overall No. 0100000474416 14  
 Doc. Currency USD  
 Doc. Hdr Text CTW416 09082014-09142014

**Transfers #2A and #2B:**  
 \$60.4M and \$50.3M transfers  
 from Purdue Holdings L.P. to BR  
 Holdings Associates L.P.,  
 totaling \$110.7M.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			256,000.00	CORP PAY
2	50	100010	Cash Concentration		GEN			60,368,169.00	BR HOLDINGS ASSOCIATES L.P. 1 ST
3	50	100010	Cash Concentration		GEN			50,334,331.00	BR HOLDINGS ASSOCIATES L.P. 1 ST
4	50	102208	Purdue Pharma L.P.		GEN			256,000.00	
5	40	102413	BR Holdings Assoc LP		GEN			110,702,500.00	

## Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000676 Company Code 413 Fiscal Year 2014  
 Doc. Date 09/23/2014 Posting Date 09/14/2014 Period 09  
 Calculate Tax ☐  
 Ref.Doc. CWS Overall No. 0100000474416 14  
 Doc. Currency USD  
 Doc. Hdr Text CTW416 09082014-09142014

### Transfers #2A and #2B:

\$60.4M and \$50.3M transfers from Purdue Holdings L.P. to BR Holdings Associates L.P., totaling \$110.7M.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			60,368,169.00	BR HOLDINGS ASSOCIATES L.P. 1 ST
2	40	100010	Cash Concentration		GEN			50,334,331.00	BR HOLDINGS ASSOCIATES L.P. 1 ST
3	50	102416	Purdue Holdings LP		GEN			110,702,500.00-	

Doc.Type : KZ ( Vendor payment ) Normal document

Doc. Number 1500000175 Company Code 413 Fiscal Year 2014  
 Doc. Date 11.09.2014 Posting Date 22.09.2014 Period 09  
 Calculate Tax ☐  
 Ref.Doc. WIRES TRANSFER  
 Doc. Currency USD

**Transfer #3:** \$55M transfer from BR Holdings Associates L.P. to Rosebay Medical Company L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			55.000.000,00-	
2	25	1016497	ROSEBAY MEDICAL COMP		GEN			55.000.000,00	

## Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014 (cont'd)

Doc.Type : KZ ( Vendor payment ) Normal document

Doc. Number 1500000173 Company Code 413 Fiscal Year 2014  
 Doc. Date 09/03/2014 Posting Date 09/19/2014 Period 09  
 Calculate Tax ☐  
 Ref.Doc. WIRES TRANSFER  
 Doc. Currency USD

**Transfer #4:** \$50.2M transfer from BR Holdings Associates L.P. to U.S. Treasury.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			50,184,331.00-	
2	25	1004240	UNITED STATES TREASU		GEN			50,184,331.00	

Doc.Type : KZ ( Vendor payment ) Normal document

Doc. Number 1500000178 Company Code 413 Fiscal Year 2014  
 Doc. Date 09/11/2014 Posting Date 09/22/2014 Period 09  
 Calculate Tax ☐  
 Ref.Doc. WIRES TRANSFER  
 Doc. Currency USD

**Transfer #5:** \$4.8M transfer from BR Holdings Associates L.P. to Beacon Company.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			4,815,669.00-	
2	25	1029154	BEACON CO		GEN			4,815,669.00	

## Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014 (cont'd)

**3Q14 Federal Estimated Payment**

ROSEBAY  
Purdue Pharma L.P.

Federal	\$ 55,000,000.00
GRAND TOTAL	<u>\$ 55,000,000.00</u>

Prepared by: \_\_\_\_\_ DATE: 9-4-14  
\_\_\_\_\_

Reviewed by: \_\_\_\_\_ DATE: 9/7/14  
\_\_\_\_\_

Approved by: \_\_\_\_\_ DATE: 9/2/14  
\_\_\_\_\_

\_\_\_\_\_ DATE: 9/9/14  
Edward Mahony

**Transfer #3:** Q3 2014 federal tax payment of \$55M for Rosebay Medical Company L.P.



## Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014 (cont'd)

3rd Quarter 2014 Tax Payments		
ITEM #	325.000	
Entity		
Entity #	413	
Taxpayer	Rosebay Medical Company L.P.	
Jurisdiction	Federal	
Tax Type	Income Tax (Distrib. by BRHALP to Ros)	
Underlying Pre-Tax Income		473,301,714 <sup>B</sup>
State Tax Adjustments		-
Adjusted Pre-Tax Income		473,301,714
Partner %, if applicable		50.000%
Taxable Income		236,650,857
Apportionment		100.00%
Post-Apportioned Income		236,650,857
Tax Rate		43.400%
Tax Due		102,706,472
Minimum Tax		-
Additional Other Tax (e.g., Franchise)		-
Total Tax Due		102,706,472
G/L Coding:	413-302027-0000000	
Payments:		
2013 Overpayment Credit		-
Q1	12,500,000	
Q2	12,500,000	
Q3	55,000,000 <sup>D</sup>	
Q4	22,706,472	
Additional Q4	-	
Extension	-	
Total Payments		102,706,472
Net Under (Over) Payment		-

**Transfer #3:** Q3 2014 federal tax payment of \$55M for Rosebay Medical Company L.P.

# Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014 (cont'd)

**Transfer #3:** Confirmation of \$55.0M transfer from BR Holdings Associates L.P. to Rosebay Medical Company L.P.

**PURDUE PHARMA L.P.**  
 \*\* All values are subject to verification and adjustments. \*\*  
 Payment Report - Detail Payment Release Date: Today

---

Creation Method: From Template, Online      Template Name: BR-Rosebay      Template Type: Standard  
 Status: Delivered

---

**PAYMENT INFORMATION**

From Account: [REDACTED]	Account Currency: USD	Account Name: BR HOLDINGS ASSOCIATES LP
Bank: 02100003 - JPMORGAN CHASE NEW YORK		
Payment Method: Bank Transfer	Value Date: 09/11/2014	Bank to Bank Transfer: No
Payment Amount: USD 55,000,000.00	Bank Reference: [REDACTED]	
Payment ID: 2784588	Settlement Reference:	

---

**BENEFICIARY**

Beneficiary ID: [REDACTED]	Address: US - United States
Beneficiary ID Type: JPM US Account	
Beneficiary Name: Rosebay Medical Co LP	

---

**REFERENCE INFORMATION**

**PAYMENT DETAILS**  
 3Q14 FED Estimated Payment

---

**BANK TO BANK**

Correspondent Bank Charges: Remitter	Priority Payment: NO
--------------------------------------	----------------------

---

**HISTORY**

Event	Date / Time	Actioned By	User ID / Approval Category	Additional Information
Delivered	09/10/2014 04:03 PM EDT	System	System	
Released	09/10/2014 04:02 PM EDT	[REDACTED]	[REDACTED]	
Digital Signature	09/10/2014 04:02 PM EDT	[REDACTED]	[REDACTED]	
Approved	09/10/2014 03:59 PM EDT	[REDACTED]	[REDACTED]	
Submitted	09/10/2014 03:08 PM EDT	[REDACTED]	[REDACTED]	Created from Template: BR-Rosebay

---

Payment Report - Detail  
 Created On: 09/10/2014 04:05 PM EDT Page 21 of 22

# Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014 (cont'd)

1900000296

**BR Holdings Associates L.P.**  
 3Q14 Estimated Payment  
 ACH DEBIT TRANSACTION

**Debit Date:** 09/03/14 1500000173

<b>Vendor #1004240</b> United States Treasury IRS Service Center Philadelphia, PA	<b>GL Code</b> 413-302026-0000000 Capital #26-Distribution-Beacon	<b>Amount</b> \$50,184,331.00
--	---	----------------------------------

\$50,184,331.00

**Description:**  
 3Q14 Estimated Payment 000 Beacon

**Prepared by:**  
 [Redacted]  
 [Redacted]

**DATE:** 9-4-14

**Reviewed by:**  
 [Redacted]  
 [Redacted]

**DATE:** 9/7/14

**Approved by:**  
 [Redacted]  
 [Redacted]  
 [Redacted]  
 Edward Mahony  
 [Redacted]  
 [Redacted]  
 [Redacted]  
 "B" Signer [Redacted]

**DATE:** 9/9/14  
**DATE:** 9-10-14  
**DATE:** 9-10-14

(CA)

**Transfer #4:** Authorization for \$50,184,331 transfer from BR Holdings Associates L.P. to U.S. Treasury.

## Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014 (cont'd)

3rd Quarter 2014 Tax Payments		
ITEM #	324.000	
Entity		
Entity #	413	
Taxpayer	Beacon Company	
Jurisdiction	Federal	
Tax Type	Withholding Tax - Partner Information.	
Underlying Pre-Tax Income	473,301,714	
State Tax Adjustments	-	
Adjusted Pre-Tax Income	473,301,714	
Partner %, if applicable	50.000%	
Taxable Income	236,650,857	
Apportionment	100.00%	
Post-Appportioned Income	236,650,857	
Tax Rate	39.600%	
Tax Due	93,713,739	
Minimum Tax	-	
Additional Other Tax (e.g., Franchise)	-	
Total Tax Due	93,713,739	
G/L Coding:	413-302026-0000000	
Payments:		
2013 Overpayment Credit	-	
Q1	11,405,530	
Q2	11,405,530	
Q3	50,184,331	
Q4	20,718,348	
Additional Q4	-	
Extension	-	
Total Payments	93,713,739	
Net Under (Over) Payment	-	

**Transfer #4:** Q3 2014 estimated federal tax payment of \$50.2M to US Treasury for Beacon Company.

## Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014 (cont'd)

**Transfer #4:** Confirmation of \$50.2M payment for Q3 2014 federal tax from BR Holdings Associates L.P. to the US Treasury on behalf of Beacon Company.

TAXPAYER NAME: BR HOLDINGS ASSOCIATES LP TIN [REDACTED]

### Deposit Confirmation

Your payment has been accepted.

### Payment Successful

An EFT Acknowledgement Number has been provided for this payment. Please keep this number for your records.

**REMINDER: REMEMBER TO FILE ALL RETURNS WHEN DUE!**

<b>EFT ACKNOWLEDGEMENT NUMBER:</b>	270465554218142
------------------------------------	-----------------

Payment Information	Entered Data
<b>Taxpayer EIN</b>	[REDACTED]
<b>Tax Form</b>	8804 Annual Return Partnership W/H
<b>Tax Type</b>	Balance due on return or notice
<b>Tax Period</b>	December/2014
<b>Payment Amount</b>	\$50,184,331.00
<b>Settlement Date</b>	09/12/2014

# Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014 (cont'd)

**Transfer #5:** Confirmation of \$4.8M transfer from BR Holdings Associates L.P. to Beacon Company.

**PURDUE PHARMA L.P.**  
 \*\* All values are subject to verification and adjustments. \*\*

Payment Report - Detail Payment Release Date: Today

---

Account Name: BR HOLDINGS ASSOCIATES LP  
 Account Number: [REDACTED]  
 Currency: USD US Dollar  
 Bank: 02100002 - JP MORGAN CHASE NEW YORK  
 ACH Company Name ID: BR HOLDINGS [REDACTED]

---

Creation Method: Free Form, Online  
 Status: Delivered

---

**PAYMENT INFORMATION**

Method/Description	Value Date	Payment Amount
ACH Corporate/Vendor Payments	09/11/2014	USD 4,815,669.00 CR

---

Payment ID: 106441969 Descriptive Date: 140911 Batch Description: CORP PAY

---

Account Name: BR HOLDINGS ASSOCIATES LP  
 Bank: 021000021 - JP MORGAN CHASE NEW YORK  
 Company Name: BR HOLDINGS  
 Company ID: [REDACTED]

---

**BENEFICIARIES**

Beneficiary Name	Beneficiary ID	Account / Type	Bank ABA	Payment ID	DD	Amount
Beacon Company	[REDACTED]	[REDACTED]	021000021	106441969		4,815,669.00 CR

Payment Details: 3Q14 CT Estimated Tax

---

**HISTORY**

Event	Date / Time	Actioned By	User ID / Approval Category	Additional Information
Delivered	09/10/2014 03:37 PM EDT	System	System	
Released	09/10/2014 03:11 PM EDT	[REDACTED]	[REDACTED]	
Digital Signature	09/10/2014 03:11 PM EDT	[REDACTED]	[REDACTED]	
Approved	09/10/2014 03:01 PM EDT	[REDACTED]	[REDACTED]	
Submitted	09/10/2014 12:42 PM EDT	[REDACTED]	[REDACTED]	Copied from Payment: 106441422

---

Payment Report - Detail  
 Created On: 09/10/2014 04:05 PM EDT Page 18 of 22

## Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014 (cont'd)

**Transfer #5:** Q3 2014 estimated federal Medicare tax payment of \$4.8M for Beacon Company.

<u>3Q14 Federal Estimated Payment - 3.8% Medicare Tax</u>	
BEACON	
BR Holdings Associates L.P.	
Federal	\$ 4,815,669.00
GRAND TOTAL	<u>\$ 4,815,669.00</u>

Prepared by: \_\_\_\_\_ DATE: 9-4-14

Reviewed by: \_\_\_\_\_ DATE: 9/7/14

Approved by: \_\_\_\_\_ DATE: 9/11/14

\_\_\_\_\_ DATE: 9/9/14

Edward Mahony



# Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014 (cont'd)

3rd Quarter 2014 Tax Payments	
ITEM #	324.100
Entity	
Entity #	413
Taxpayer	Beacon Company
Jurisdiction	Federal - 3.8% Medicare Portion
Tax Type	Withholding Tax - Partner Information.
Underlying Pre-Tax Income	473,301,714 <sup>B</sup>
State Tax Adjustments	-
Adjusted Pre-Tax Income	473,301,714
Partner %, if applicable	50.000%
Taxable Income	236,650,857
Apportionment	100.00%
Post-Apportioned Income	236,650,857
Tax Rate	3.800%
Tax Due	8,992,733
Minimum Tax	-
Additional Other Tax (e.g., Franchise)	-
Total Tax Due	8,992,733
G/L Coding:	413-302026-0000000
Payments:	
2013 Overpayment Credit	-
Q1	1,094,470
Q2	1,094,470
Q3	4,815,669
Q4	1,988,124
Additional Q4	-
Extension	-
Total Payments	8,992,733
Net Under (Over) Payment	-

**Transfer #5:** Q3 2014 estimated federal Medicare tax payment of \$4.8M for Beacon Company.



# Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014 (cont'd)



JPMorgan Chase Bank, N.A.  
Northeast Market  
P O Box 659754  
San Antonio, TX 78265 - 9754

August 30, 2014 through September 30, 2014

Account Number: [REDACTED]

## Customer Service Information

If you have any questions about your statement, please contact your Customer Service Professional.



00092854 WBS 802 211 27414 NNNNNNNNNNN 1 000000000 80 0000

PURDUE HOLDINGS L P  
1 STAMFORD FORUM  
STAMFORD CT 06901-3516

## Deposits and Credits

Ledger Date	Description	Amount
09/02	Orig CO Name:208 Orig ID:[REDACTED] Desc Date:140902 CO Entry Descr:Corp Pay Sec:CCD Trace#[REDACTED] Eed:140902 Ind ID:[REDACTED] Ind Name:Purdue Holdings Lp Funding Trn:	\$9,000,000.00
09/11	Book Transfer Credit B/O: Purdue Pharma L P Stamford CT 06901-3431 Ref: Tax Distribution Trn:[REDACTED] YOUR REF: ATS OF 14/09/11	60,368,169.00
09/11	Orig CO Name:208 Orig ID:[REDACTED] Desc Date:140911 CO Entry Descr:Corp Pay Sec:CCD Trace#[REDACTED] Eed:140911 Ind ID:[REDACTED] Ind Name:Purdue Holdings Lp Funding Trn:	256,000.00
09/12	Book Transfer Credit B/O: Purdue Pharma L P Stamford CT 06901-3431 Ref: Tax Distribution Trn:[REDACTED] YOUR REF: ATS OF 14/09/12	50,334,331.00
09/18	Orig CO Name:208 Orig ID:[REDACTED] Desc Date:140918 CO Entry Descr:Corp Pay Sec:CCD Trace#[REDACTED] Eed:140918 Ind ID:[REDACTED] Ind Name:Purdue Holdings Lp Funding Trn:	1,769,892.00

**Transfer #1A:** \$60.4M transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

**Transfer #1B:** \$50.3M transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

# Selection 10 – Tax Distribution for estimated federal tax payment, Q3 2014 (cont'd)



JPMorgan Chase Bank, N.A.  
Northeast Market  
P O Box 659754  
San Antonio, TX 78265-9754

August 30, 2014 through September 30, 2014

Account Number: [REDACTED]

## Customer Service Information

If you have any questions about your statement, please contact your Customer Service Professional.



00092911 WBS 802 211 27414 NNNNNNNNNN 1 000000000 80 0000

**BR HOLDINGS ASSOCIATES L.P.**

1 STAMFORD FORUM  
STAMFORD CT 06901-3516

## Deposits and Credits

Ledger Date	Value Date	Description	Amount
09/11		Book Transfer Credit B/O: Purdue Holdings L P Stamford CT 06901-3516 Ref: Tax Distribution Tm: [REDACTED] YOUR REF: ATS OF 14/09/11	\$60,368,169.00
09/11		Orig CO Name:Holdings Orig ID:[REDACTED] Desc Date:140911 CO Entry Descr:Corp Pay Sec:CCD Trace#[REDACTED] Eed:140911 Ind ID:[REDACTED] Ind Name:Br Holdings Assoc Lp Funding Tm:	381,000.00
09/12		Book Transfer Credit B/O: Purdue Holdings L P Stamford CT 06901-3516 Ref: Tax Distribution Tm: [REDACTED] YOUR REF: ATS OF 14/09/12	50,334,331.00

## Withdrawals and Debits

Ledger Date	Value Date	Description	Amount
09/11		Book Transfer Debit A/C: Rosebay Medical CO L P Oklahoma City OK 73134-2617 Ref: 3Q14 Fed Estimated Payment Tm: [REDACTED] YOUR REF: NONREF	\$55,000,000.00
09/11		Orig CO Name:Br Holdings Orig ID:[REDACTED] Desc Date:140911 CO Entry Descr:Corp Pay Sec:CCD Trace#[REDACTED] Eed:140911 Ind ID:Batch Offset Ind Name:Br Holdings Tm:[REDACTED]	4,815,669.00
09/11		Orig CO Name:Br Holdings Orig ID:[REDACTED] Desc Date:140911 CO Entry Descr:Corp Pay Sec:CCD Trace#[REDACTED] Eed:140911 Ind ID:Batch Offset Ind Name:Br Holdings Tm:[REDACTED]	282,500.00
09/11		Orig CO Name:Br Holdings Orig ID:[REDACTED] Desc Date:140911 CO Entry Descr:Corp Pay Sec:CCD Trace#[REDACTED] Eed:140911 Ind ID:Batch Offset Ind Name:Br Holdings Tm:[REDACTED]	270,000.00
09/12		Orig CO Name:Irs Orig ID:[REDACTED] Desc Date:091214 CO Entry Descr:Usatxpymtsec:CCD Trace#[REDACTED] Eed:140912 Ind ID:[REDACTED] Ind Name:Br Holdings Associates Tm:	50,184,331.00

**Transfer #2A:** \$60.4M transfer from Purdue Holdings L.P. to BR Holdings Associates L.P.

**Transfer #2B:** \$50.3M transfer from Purdue Holdings L.P. to BR Holdings Associates L.P.

**Transfer #3:** \$55.0M transfer from BR Holdings Associates L.P. to Rosebay Medical Company L.P.


**Transfer #5:** \$4.8M transfer from BR Holdings Associates L.P. to Beacon Company.

**Transfer #4:** \$50.2M transfer from BR Holdings Associates L.P. to U.S. Treasury.



## **Selection 11 Purdue Tax Distributions (2016)**

# Selection 11 – Tax Distribution for estimated federal tax payment, Q1 2016



Purdue
Affiliated Entity - Books and Records Maintained in the same SAP System as Purdue
Beacon/Rosebay
Taxing Authority

<sup>1</sup> State and other federal tax payments identified in Purdue's Internal Distribution Analysis and SAP General Ledger detail.

We are unable to determine from the books and records maintained by Purdue whether Rosebay Medical Company L.P. used the distributions to make tax-related payments to the appropriate taxing authorities.

## Selection 11 – Tax Distribution for estimated federal tax payment, Q1 2016 (cont'd)

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100156882 Company Code 208 Fiscal Year 2016  
 Doc. Date 01.04.2016 Posting Date 31.03.2016 Period 03  
 Calculate Tax ☐  
 Ref.Doc. CWS Overall No. 0100156882208 16  
 Doc. Currency USD  
 Doc. Hdr Text CTW208 03302016-03312016

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
41	50	100010	Cash Concentration		GEN			35.000.000,00-	MIC MERRILL LYNCH PIERCE FENNER SMITH FFC:
28	50	100010	Cash Concentration		GEN			29.893.503,00-	PURDUE HOLDINGS L P 1 STAMFORD F
48	50	100110	Lockbox Clearing		GEN			11.951.628,33-	AMERISOURCE BERG
63	50	105120	Exchange Other		GEN			7.975.000,00-	BEACON CO REVINOVA TREUHAND AG F
69	50	100430	Money Mkt Goldman		GEN			5.000.000,00-	GOLDMAN SACHS TRUST ON BEHALF OF ITS PO
49	50	605275	Medco Pharmacy	2570208	GEN			589.825,56-	CIGNA
85	50	102112	CT Avenue Realty		GEN			565.000,00-	

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100156882 Company Code 208 Fiscal Year 2016  
 Doc. Date 01.04.2016 Posting Date 31.03.2016 Period 03  
 Calculate Tax ☐  
 Ref.Doc. CWS Overall No. 0100156882208 16  
 Doc. Currency USD  
 Doc. Hdr Text CTW208 03302016-03312016

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
81	40	100450	BOA Money Market		GEN			35.000.000,00	MIC MERRILL LYNCH PIERCE FENNER SMITH FFC:
68	40	302045	Dist #45 PH LP		GEN			29.893.503,00	PURDUE HOLDINGS L P 1 STAMFORD F
2	40	100010	Cash Concentration		GEN			11.951.628,33	AMERISOURCE BERG
21	40	100010	Cash Concentration		GEN			7.975.000,00	BEACON CO REVINOVA TREUHAND AG F
29	40	100010	Cash Concentration		GEN			5.000.000,00	GOLDMAN SACHS TRUST ON BEHALF OF ITS PO
3	40	100010	Cash Concentration		GEN			589.825,56	CIGNA

**Transfer #1:** \$29.9M transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

## Selection 11 – Tax Distribution for estimated federal tax payment, Q1 2016 (cont'd)

G/L account document						
Overall No. 0100000681416 16 Doc. Currency USD						

CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference	Crcy	
Itm	PK	Account	Account short text	Assignment		Tx	Amount	Text

416	100000681	2016	SA	01.04.2016	31.03.2016	CWS	USD	
1	40	100010	Cash Concentration	20160401			29.893.503,00	PURDUE PHARMA L P ONE STAMFORD F
2	50	100010	Cash Concentration	20160401			29.893.503,00-	BR HOLDINGS ASSOCIATES L.P. 1 ST
3	40	100010	Cash Concentration	20160401			207.500,00	CORP PAY
4	50	107204	Invest - PPLP	20160401			29.893.503,00-	PURDUE PHARMA L P ONE STAMFORD F
5	50	102208	Purdue Pharma L.P.	20160401			207.500,00-	
6	40	102413	BR Holdings Assoc LP	20160401			29.893.503,00	

413	100000801	2016	SA	01.04.2016	31.03.2016	CWS	USD	
1	40	100010	Cash Concentration	20160401			29.893.503,00	BR HOLDINGS ASSOCIATES L.P. 1 ST
2	50	102416	Purdue Holdings LP	20160401			29.893.503,00-	

**Transfer #1:** \$29.9M transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

**Transfer #2:** \$29.9M transfer from Purdue Holdings L.P. to BR Holdings Associates L.P.

## Selection 11 – Tax Distribution for estimated federal tax payment, Q1 2016 (cont'd)

Doc.Type : KZ ( Vendor payment ) Normal document

Doc. Number 1500000263 Company Code 413 Fiscal Year 2016  
 Doc. Date 30.03.2016 Posting Date 30.03.2016 Period 03  
 Calculate Tax ☐  
 Ref.Doc. WIRE TRANSFER  
 Doc. Currency USD

**Transfer #3:** \$10.3M transfer from BR Holdings Associates L.P. to Rosebay Medical Company L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			10.300.000,00-	
2	25	1016497	ROSEBAY MEDICAL COMP		GEN			10.300.000,00	

Doc.Type : KZ ( Vendor payment ) Normal document

Doc. Number 1500000256 Company Code 413 Fiscal Year 2016  
 Doc. Date 30.03.2016 Posting Date 30.03.2016 Period 03  
 Calculate Tax ☐  
 Ref.Doc. WIRE TRANSFER  
 Doc. Currency USD

**Transfer #4:** \$10.3M transfer from BR Holdings Associates L.P. to US Treasury.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			10.300.000,00-	
2	25	1004240	UNITED STATES TREASU		GEN			10.300.000,00	



## Selection 11 – Tax Distribution for estimated federal tax payment, Q1 2016 (cont'd)

**Transfer #3:** Authorization for \$10.3M payment from BR Holdings Associates L.P. to Rosebay Medical Company L.P. for Q1 2016 estimated federal tax.

<u>Q1 2016 Federal Extension</u>	
ROSEBAY Purdue Pharma L.P. Federal	10,300,000.00
Prepared by: [REDACTED]	DATE: 2/18/16
Reviewed by: [REDACTED]	DATE: 3/28/16
Approved by: [REDACTED]	DATE: 3/28/16
JJ Charhon	DATE: 3/28/16



## Selection 11 – Tax Distribution for estimated federal tax payment, Q1 2016 (cont'd)

<b>1st Quarter 2016 Tax Payments</b>			
ITEM #	325.000		
Entity			
Entity #	413		
Taxpayer	Rosebay Medical Company L.P.		
Jurisdiction	Federal		
Tax Type	Income Tax (Distrib. by BRHALP to Rosebay to pay)		
Underlying Pre-Tax Income		153,687,024	
State Tax Adjustments		-	
Adjusted Pre-Tax Income		153,687,024	242
Partner %, if applicable	50.000%		
Taxable Income		76,843,512	
Apportionment		100.00%	
Post-Apportioned Income		76,843,512	
Tax Rate		39.600%	
Tax Due		30,430,031	
Minimum Tax		-	
Additional Other Tax (e.g., Franchise)		-	If applicable, see
Total Tax Due		30,430,031	
G/L Coding:	413-302027-0000000		
Payments:			
2015 Overpayment Credit	484,069		
Q1	10,300,000		
Q2	4,430,927		
Q3	7,607,508		
Q4	7,607,508		
Additional Q4	-		
Extension	-		
Payment with Return	-		
Total Payments		30,430,031	
Net Under (Over) Payment		-	

**Transfer #3:** Q1 2016  
estimated federal tax for  
Rosebay Medical Company L.P.

# Selection 11 – Tax Distribution for estimated federal tax payment, Q1 2016 (cont'd)

**Transfer #3:** Confirmation of \$10.3M payment from BR Holdings L.P. to Rosebay Medical Company L.P. for Q1 2016 estimated federal tax.

**PURDUE PHARMA L.P.**  
 \*\* All values are subject to verification and adjustments. \*\*  
**Payment Report - Detail** Payment Release Date: Today

---

Account Name: BR HOLDINGS ASSOCIATES LP  
 Account Number: [REDACTED]  
 Currency: USD US DOLLAR  
 Bank: 02100002 - JPMORGAN CHASE NEW YORK  
 ACH Company Name-ID: BR HOLDINGS [REDACTED]

---

Creation Method: From Template, Online Template Name: BR-Rosebay Template Type: Standard

Status: Completed

---

**PAYMENT INFORMATION**

From Account: [REDACTED] Account Currency: USD Account Name: BR HOLDINGS ASSOCIATES LP

Bank: 02100002 - JPMORGAN CHASE NEW YORK

Payment Method: Bank Transfer Value Date: 03/30/2016 Bank to Bank Transfer: No

Payment Amount: USD 10,300,000.00 Bank Reference: [REDACTED]

Payment ID: 21706285 Settlement Reference: JPM Ref. [REDACTED]

---

**BENEFICIARY**

Beneficiary ID: [REDACTED] Address: US - UNITED STATES

Beneficiary ID Type: [REDACTED]

Beneficiary Name: Rosebay Medical Co LP

---

**REFERENCE INFORMATION**

**PAYMENT DETAILS**  
 1Q16 Federal Estimated

---

**BANK TO BANK**

Correspondent Bank Charges: Remitter Priority Payment: NO

---

**HISTORY**

Event	Date / Time	Actioned By	User ID / Approval Category	Additional Information
Completed	03/30/2016 01:05 PM EDT	System	System	
Delivered	03/30/2016 01:03 PM EDT	System	System	
Digital Signature	03/30/2016 01:01 PM EDT	[REDACTED]	[REDACTED]	
Released	03/30/2016 01:01 PM EDT	[REDACTED]	[REDACTED]	
Approved	03/30/2016 12:00 PM EDT	[REDACTED]	[REDACTED]	
Submitted	03/30/2016 11:39 AM EDT	[REDACTED]	[REDACTED]	Created from Template: BR-Rosebay

---

Payment Report - Detail  
 Created On: 03/30/2016 02:58 PM EDT Page 34 of 40

# Selection 11 – Tax Distribution for estimated federal tax payment, Q1 2016 (cont'd)

191438 15/256

**BR Holdings Associates L.P.**  
 2016 Q1 Payment OBO Beacon  
 ACH DEBIT TRANSACTION

Debit Date: 03/30/16

<u>Vendor #1004240</u> United States Treasury IRS Service Center Philadelphia, PA	<u>GL Code</u> 413-302026-0000000 Capital #26-Distribution-Beacon	<u>Amount</u> \$10,300,000.00 <hr/> \$10,300,000.00
--	---	---

Description:  
**2016 Q1 Payment OBO Beacon**

Prepared by: \_\_\_\_\_  
 \_\_\_\_\_  
 DATE: 3/28/16

Approved by: \_\_\_\_\_  
 \_\_\_\_\_  
 DATE: 3/28/16

Approved by: \_\_\_\_\_  
 \_\_\_\_\_  
 DATE: 3/28/16

Approved by: \_\_\_\_\_  
 \_\_\_\_\_  
 DATE: 3/28/16

JJ Charhoh \_\_\_\_\_  
 \_\_\_\_\_  
 DATE: 3/28/16

\*A\* Signer \_\_\_\_\_  
 \_\_\_\_\_  
 DATE: 3/28/16

\*B\* Signer \_\_\_\_\_  
 \_\_\_\_\_  
 DATE: 3/28/16

**Transfer #4:** Authorization for \$10.3M transfer from BR Holdings Associates L.P. to US Treasury on behalf of Beacon Company.

## Selection 11 – Tax Distribution for estimated federal tax payment, Q1 2016 (cont'd)

<b>1st Quarter 2016 Tax Payments</b>			
ITEM #	324.000		
Entity			
Entity #	413		
Taxpayer	Beacon Company		
Jurisdiction	Federal		
Tax Type	Withholding Tax - Partner Information.		
Underlying Pre-Tax Income		153,687,024	
State Tax Adjustments		-	
Adjusted Pre-Tax Income		153,687,024	242
Partner %, if applicable	50.000%		
Taxable Income		76,843,512	
Apportionment		100.00%	
Post-Apportioned Income		76,843,512	
Tax Rate		39.600%	
Tax Due		30,430,031	
Minimum Tax		-	
Additional Other Tax (e.g., Franchise)		-	If applicable, see
Total Tax Due		30,430,031	
G/L Coding:	413-302026-0000000		
Payments:			
2015 Overpayment Credit	(2,247,056)		
Q1	10,300,000		
Q2	7,162,071		
Q3	7,607,508		
Q4	7,607,508		
Additional Q4	-		
Extension	-		
Payment with Return	-		
Total Payments		30,430,031	
Net Under (Over) Payment		-	

**Transfer #4:** Q1 2016 estimated federal tax for Beacon Company.

# Selection 11 – Tax Distribution for estimated federal tax payment, Q1 2016 (cont'd)

3/29/2016 Welcome To EFTPS - Payments

**EFTPS** Electronic Federal Tax Payment System

HOME ENROLLMENT MY PROFILE PAYMENTS HELP & INFORMATION CONTACT US LOGOUT

TAXPAYER NAME: BR HOLDINGS ASSOCIATES LP TIN: [REDACTED]

### Deposit Confirmation

Your payment has been accepted.

**Payment Successful**

An EFT Acknowledgement Number has been provided for this payment. Please keep this number for your records.

**REMINDER: REMEMBER TO FILE ALL RETURNS WHEN DUE!**

EFT ACKNOWLEDGEMENT NUMBER: 270649062844063

Payment Information	Entered Data
Taxpayer EIN	[REDACTED]
Tax Form	9901 Annual Return Partnership With
Tax Type	Balance due on return or notice
Tax Period	December 2016
Payment Amount	\$10,300,000.00
Settlement Date	03/30/2016
Account Number	[REDACTED]
Account Type	CHECKING
Routing Number	021000021
Bank Name	JPMORGAN CHASE BANK, NA


Home Enrollment My Profile Payments Help & Information Contact Us Logout

USA.gov IRS.gov Treasury.gov

Electronic Federal Tax Payment System® and EFTPS® are registered servicemarks of the U.S. Department of the Treasury's Financial Management Service.

**Transfer #4:** Confirmation of \$10.3M 1Q16 Federal tax payment from BR Holdings Associates L.P. to US Treasury on behalf of Beacon Company.

# Selection 11 – Tax Distribution for estimated federal tax payment, Q1 2016 (cont'd)

**CHASE** 


JPMorgan Chase Bank, N.A.  
Northeast Market  
P O Box 659754  
San Antonio, TX 78265 -9754

March 01, 2016 through March 31, 2016  
Account Number: XXXXXXXXXX

---

**Customer Service Information**

If you have any questions about your statement, please contact your Customer Service Professional.

  
00059079 WBS 802 211 09216 NNNNNNNNNN 1 000000000 80 0000

**PURDUE HOLDINGS L P**  
1 STAMFORD FORUM  
STAMFORD CT 06901-3516

---

**Deposits and Credits** *(continued)*

Ledger Date	Description	Amount
03/30	Book Transfer Credit B/O: Purdue Pharma L P Stamford CT 06901-3431 Ref: Br Tax Distribution Trn: <span style="background-color: black; color: black;">XXXXXXXXXX</span> YOUR REF: ATS OF 16/03/30	29,893,503.00

**Transfer #1:** \$29.9M transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

# Selection 11 – Tax Distribution for estimated federal tax payment, Q1 2016 (cont'd)

**CHASE**  
JPMorgan Chase Bank, N.A.  
Northeast Market  
P O Box 659754  
San Antonio, TX 78265 - 9754

March 01, 2016 through March 31, 2016

Account Number [REDACTED]

### Customer Service Information

If you have any questions about your statement, please contact your Customer Service Professional.

00075295 W09 802 211 09216 \*\*\*\*\* 1 000000000 00 0000

**BR HOLDINGS ASSOCIATES L.P.**

1 STAMFORD FORUM  
STAMFORD CT 06901-3516

### Deposits and Credits

Ledger Date	Value Date	Description	Amount
03/24		Orig CO Name:401 Orig ID: [REDACTED] Desc Date:160324 CO Entry Descr:Corp Pay Sec:CCD Trace#: [REDACTED] Ed:160324 Ind ID: [REDACTED] Ind Name:Br Holdings Associates Distribution Trn:	\$343,000.00
03/30		Book Transfer Credit B/O: Purdue Holdings L.P Stamford CT 06901-3516 Ref: Br Tax Distribution Trn: [REDACTED] YOUR REF: ATS OF 16/03/30	29,893,503.00

**Transfer #2:** \$29.9M transfer from Purdue Holdings L.P. to BR Holdings Associates L.P.

### Withdrawals and Debits

Ledger Date	Value Date	Description	Amount
03/15		Account Analysis Settlement Charge	\$95.49
03/24		Book Transfer Debit A/C: Beacon CO Zurich Switzerland Ch-80-55 Ref: Distribution-Mundipharma Kk Funding Trn: [REDACTED] YOUR REF: NONREF	171,500.00
03/24		Book Transfer Debit A/C: Rosebay Medical CO L.P Oklahoma City OK 73134-2617 Ref: Distribution-Mundipharma Kk Funding Trn: [REDACTED] YOUR REF: NONREF	171,500.00
03/30		Book Transfer Debit A/C: Rosebay Medical CO L.P Oklahoma City OK 73134-2617 Ref: 1Q16 Federal Estimated Trn: [REDACTED] YOUR REF: NONREF	10,800,000.00
03/30		Book Transfer Debit A/C: Rosebay Medical CO L.P Oklahoma City OK 73134-2617 Ref: 2015 Federal Extension Trn: [REDACTED] YOUR REF: NONREF	3,500,000.00
03/30		Book Transfer Debit A/C: Rosebay Medical CO L.P Oklahoma City OK 73134-2617 Ref: 15 Extension Payment:IL Equalizati Trn: [REDACTED] YOUR REF: NONREF	437,338.00
03/30		Book Transfer Debit A/C: Rosebay Medical CO L.P Oklahoma City OK 73134-2617 Ref: 15 Extension Payment:CA,CO,KY,OR Trn: [REDACTED] YOUR REF: NONREF	237,436.00
03/30		Book Transfer Debit A/C: Rosebay Medical CO L.P Oklahoma City OK 73134-2617 Ref: 15 Extension Payment:AZ,DE,MN,My Trn: [REDACTED] YOUR REF: NONREF	235,000.00
03/30		Book Transfer Debit A/C: Rosebay Medical CO L.P Oklahoma City OK 73134-2617 Ref: 1Q16 Tax Payment:AZ,DE,MN,NY Trn: [REDACTED] YOUR REF: NONREF	135,000.00
03/30		Book Transfer Debit A/C: Rosebay Medical CO L.P Oklahoma City OK 73134-2617 Ref: 1Q16 Estimated: CA,CO,KY Trn: [REDACTED] YOUR REF: NONREF	100,000.00
03/30		Orig CO Name:Irs Orig ID: [REDACTED] Desc Date:033016 CO Entry Descr:Usatxm1sec:CCD Trace#: [REDACTED] Ed:160330 Ind ID: [REDACTED] Ind Name:Br Holdings Associates Trn: 0902705107/c	10,300,000.00
03/30		Orig CO Name:Irs Orig ID: [REDACTED] Desc Date:033016 CO Entry Descr:Usatxm1sec:CCD Trace#: [REDACTED] Ed:160330 Ind ID: [REDACTED] Ind Name:Br Holdings Associates Trn:	3,500,000.00

**Transfer #4:** \$10.3M transfer from BR Holdings Associates L.P. to US Treasury.

**Transfer #2:** \$29.9M transfer from Purdue Holdings L.P. to BR Holdings Associates L.P.

**Transfer #3:** \$10.3M transfer from BR Holdings Associates L.P. to Rosebay Medical Company L.P.


**Transfer #4:** \$10.3M transfer from BR Holdings Associates L.P. to US Treasury.



## **Selection 12 Purdue Tax Distributions (2015)**



## Selection 12 – Tax Distribution for estimated Connecticut state tax, Q3 2015



## Selection 12 – Tax Distribution for estimated Connecticut state tax, Q3 2015 (cont'd)

Doc.Type : KZ ( Vendor payment ) Normal document

Doc. Number 1500010363 Company Code 208 Fiscal Year 2015  
 Doc. Date 11.09.2015 Posting Date 14.09.2015 Period 09  
 Calculate Tax ☐  
 Ref.Doc. WIRE TRANSFER  
 Doc. Currency USD

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			6.775.000,00-	
2	25	1016497	ROSEBAY MEDICAL COMP		GEN			6.775.000,00	

**Transfer #1:** \$6.8M transfer from Purdue Pharma L.P. to Rosebay Medical Company L.P.

Doc.Type : KZ ( Vendor payment ) Normal document

Doc. Number 1500010362 Company Code 208 Fiscal Year 2015  
 Doc. Date 11.09.2015 Posting Date 14.09.2015 Period 09  
 Calculate Tax ☐  
 Ref.Doc. WIRE TRANSFER  
 Doc. Currency USD

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			6.775.000,00-	
2	25	1029154	BEACON CO		GEN			6.775.000,00	

**Transfer #2:** \$6.8M transfer from Purdue Pharma L.P. to Beacon Company.

## Selection 12 – Tax Distribution for estimated Connecticut state tax, Q3 2015 (cont'd)

**Transfer #1:** Q3 2015 estimated Connecticut state tax payment of \$6.8M for Rosebay Medical Company L.P.

<b>3rd Quarter 2015 Tax Payments</b>			
ITEM #	168.000		
Entity			
Entity #	416		
Taxpayer	Rosebay Medical Company L.P.		
Jurisdiction	Connecticut		
Tax Type	Income Tax (Distrib. by BRHALP to Rosebay to pay)		
Underlying Pre-Tax Income	596,757,388	B	
State Tax Adjustments	127,594,441		
Adjusted Pre-Tax Income	724,351,828		214
Partner %, if applicable	49.753%		
Taxable Income	360,387,127		
Apportionment	29.70%		
Post-Apportioned Income	107,037,231		
Tax Rate	6.700%		
Tax Due	7,171,494		
Minimum Tax	-		
Additional Other Tax (e.g., Franchise)	-		If applicable, see
Total Tax Due	7,171,494		
G/L Coding:	208-302027-0000000		
Payments:			
2014 Overpayment Credit	-		
Q1	400,000		
Q2	-		
Q3	6,775,000		
Q4	-		
Additional Q4 Extension	-		
Total Payments	7,175,000		
Net Under (Over) Payment	(3,506)		

## Selection 12 – Tax Distribution for estimated Connecticut state tax, Q3 2015 (cont'd)

**Transfer #1:** Authorization for \$6.8M payment from Purdue Pharma L.P. to Rosebay Medical Company L.P. for Q3 2015 estimated Connecticut state tax.

PPLP	6,775,000.00
CT	
GRAND TOTAL	<u>\$ 6,775,000.00</u>

Prepared by: \_\_\_\_\_ DATE: 9/9/2015

Approved by: \_\_\_\_\_ DATE: 9/9/15

Approved by: \_\_\_\_\_ DATE: 9/2/15

Approved by: \_\_\_\_\_ DATE: \_\_\_\_\_

JJ Charhon/Ed Mahony

## Selection 12 – Tax Distribution for estimated Connecticut state tax, Q3 2015 (cont'd)

**Transfer #1:** Confirmation of \$6.8M payment from Purdue Pharma L.P. to Rosebay Medical Company L.P. for Q3 2015 estimated Connecticut state tax.

**PURDUE PHARMA L.P.**  
 \*\* All values are subject to verification and adjustments. \*\*  
 Payment Report - Detail Payment Release Date: Today

---

Creation Method: From Template, Online      Template Name: PPLP - Rosebay      Template Type: Standard  
 Status: Completed

---

**PAYMENT INFORMATION**

From Account: [REDACTED]	Account Currency: USD	Account Name: PURDUE PHARMA L.P.
Bank: 02100002 - JPMORGAN CHASE NEW YORK		
Payment Method: Bank Transfer	Value Date: 09/11/2015	Bank to Bank Transfer: NO
Payment Amount: USD 6,775,000.00	Bank Reference: [REDACTED]	
Payment ID: 13013997	Settlement Reference: JPM Ref [REDACTED]	

---

**BENEFICIARY**

Beneficiary ID: [REDACTED]	Address: US - United States
Beneficiary ID Type: JPM US Account	
Beneficiary Name: Rosebay Medical Co. LP	

---

**REFERENCE INFORMATION**

**PAYMENT DETAILS**  
 3Q15 CT Estimated Tax Payments-

---

**BANK TO BANK**

Correspondent Bank Charges: [REDACTED]	Priority Payment: NO
Remitter: [REDACTED]	

---

**HISTORY**

Event	Date / Time	Actioned By	User ID / Approval Category	Additional Information
Completed	09/11/2015 01:23 PM EDT	System	System	
Delivered	09/11/2015 01:22 PM EDT	System	System	
Released	09/11/2015 01:20 PM EDT	[REDACTED]	[REDACTED]	
Digital Signature	09/11/2015 01:20 PM EDT	[REDACTED]	[REDACTED]	
Approved	09/13/2015 03:54 PM EDT	[REDACTED]	[REDACTED]	
Submitted	09/13/2015 02:54 PM EDT	[REDACTED]	[REDACTED]	Created from Template: PPLP - Rosebay

---

Payment Report - Detail  
 Created On: 09/11/2015 02:26 PM EDT Page 6 of 17

## Selection 12 – Tax Distribution for estimated Connecticut state tax, Q3 2015 (cont'd)

<b>3rd Quarter 2015 Tax Payments</b>		
ITEM #	167.000	
Entity		
Entity #	416	
Taxpayer	Beacon Company	
Jurisdiction	Connecticut	
Tax Type	Income Tax (Distrib. by BRHALP to Beacon to repay at €	
Underlying Pre-Tax Income	596,757,388	b
State Tax Adjustments	127,594,441	
Adjusted Pre-Tax Income	724,351,828	214
Partner %, if applicable	49.753%	
Taxable Income	360,387,127	
Apportionment	29.70%	
Post-Appportioned Income	107,037,231	
Tax Rate	0.000%	
Tax Due	-	
Minimum Tax	-	
Additional Other Tax (e.g., Franchise)	-	If applicable, see
Total Tax Due	-	
G/L Coding:	208-302026-0000000	
Payments:		
2014 Overpayment Credit	-	
Q1	400,000	
Q2	-	
Q3	6,775,000	
Q4	-	
Additional Q4	-	
Extension	(7,175,000)	
Total Payments	-	
Net Under (Over) Payment	-	

**Transfer #2:** Q3 2015 estimated Connecticut state tax payment of \$6.8M for Beacon Company.

## Selection 12 – Tax Distribution for estimated Connecticut state tax, Q3 2015 (cont'd)

**Transfer #2:** Authorization for \$6.8M payment from Purdue Pharma L.P. to Beacon Company for Q3 2015 estimated Connecticut state tax.

### 3Q 2015 CT Estimated Tax Payment

Beacon	
Purdue Pharma L.P.	
Connecticut	\$ 6,775,000.00
<b>GRAND TOTAL</b>	<b><u>\$ 6,775,000.00</u></b>

Prepared by:

[REDACTED]

DATE:

9/9/15

Approved by:

[REDACTED]

DATE:

7/6/15

Approved by:

[REDACTED]

DATE:

9/9/15

Approved by:

[REDACTED]

DATE:

JJ Charhon/Ed Mahony

## Selection 12 – Tax Distribution for estimated Connecticut state tax, Q3 2015 (cont'd)

**Transfer #2:** Confirmation of \$6.8M payment from Purdue Pharma L.P. to Beacon Company for Q3 2015 estimated Connecticut tax.

PURDUE PHARMA L.P.		Payment Release Date: Today		
Payment Report - Detail				
Creation Method From Template, Online	Template Name PPLP-Beacon	Template Type Standard		
Status Completed				
PAYMENT INFORMATION				
From Account [REDACTED]	Account Currency USD	Account Name PURDUE PHARMA L.P.		
Bank 02300002 - JPMORGAN CHASE NEW YORK	Payment Method Bank Transfer	Value Date 09/11/2015	Bank to Bank Transfer No	
Payment Amount USD 6,775,000.00	Bank Reference [REDACTED]			
Payment ID 15015996	Settlement Reference JPM Ref. [REDACTED]			
BENEFICIARY				
Beneficiary ID [REDACTED]	Address US - United States			
Beneficiary ID Type JPM US Account				
Beneficiary Name Beacon Co				
REFERENCE INFORMATION				
PAYMENT DETAILS 3Q15 CT Estimated Tax Payment				
BANK TO BANK				
Correspondent Bank Charges Remitter	Priority Payment	NO		
HISTORY				
Event	Date / Time	Actioned By	User ID / Approval Category	Additional Information
Completed	09/11/2015 01:23 PM EDT	System	System	
Delivered	09/11/2015 01:22 PM EDT	System	System	
Released	09/11/2015 01:20 PM EDT	[REDACTED]	[REDACTED]	
Digital Signature	09/11/2015 01:20 PM EDT	[REDACTED]	[REDACTED]	
Approved	09/10/2015 03:55 PM EDT	[REDACTED]	[REDACTED]	
Submitted	09/10/2015 02:54 PM EDT	[REDACTED]	[REDACTED]	Created from Template: PPLP-Beacon
Payment Report - Detail Created On: 09/11/2015 02:26 PM EDT				Page 7 of 17



# Selection 12 – Tax Distribution for estimated Connecticut state tax, Q3 2015 (cont'd)



JPMorgan Chase Bank, N.A.  
Northeast Market  
P O Box 659754  
San Antonio, TX 78265 - 9754

September 01, 2015 through September 30, 2015

Account Number: [REDACTED]

## Customer Service Information

If you have any questions about your statement, please contact your Customer Service Professional.



00099509 WBS 802 211 27415 NNNNNNNNNN 1 000000000 C2 0000

PURDUE PHARMA L P  
ATTN ACCOUNTING SERVICES  
ONE STAMFORD FORUM  
STAMFORD CT 06901-3516

## Withdrawals and Debits (continued)

Ledger Date	Description	Amount
09/10	Orig CO Name:Purdue Pharma Lp Orig ID:[REDACTED] Desc Date:150910 CO Entry Desc:Corp Pay Sec:CCD Trace#[REDACTED] Eed:150910 Ind ID:[REDACTED] Ind Name:Purdue Pharma Lp Trn:[REDACTED]	63,752.84
09/10	Orig CO Name:Load # [REDACTED] Orig ID:[REDACTED] Desc Date: CO Entry Desc:Ap Sec:CCD Trace#[REDACTED] Eed:150910 Ind ID:[REDACTED] Ind Name:ACH_Setup Trn:[REDACTED]	56,951.85
09/10	Orig CO Name:Ceridian Aka Cdc Orig ID:[REDACTED] Desc Date:150909 CO Entry Desc:Wage Att Sec:CCD Trace#[REDACTED] Eed:150910 Ind ID:[REDACTED] Ind Name:Purdue Pharma L P Wage Attachment Payment Trn:[REDACTED]	11,450.21
09/10	Orig CO Name:Purdue Pharma Lp Orig ID:[REDACTED] Desc Date:150910 CO Entry Desc:Corp Pay Sec:CCD Trace#[REDACTED] Eed:150910 Ind ID:[REDACTED] Ind Name:Purdue Pharma Lp Trn:[REDACTED]	215.00
09/11	Chips Debit Via: Deutsche Bank Trust Company America/0103 A/C: Fprs Depository Account New York NY 10006 US Ref: Purdue Plan [REDACTED] Ssn: [REDACTED] Trn:[REDACTED] YOUR REF: NONREF	735,547.79
09/11	Fedwire Debit Via: Wells Fargo NA/121000248 A/C: Sei Private Trust Company Oaks, PA 19456 US Ref: Ffc Sei Account 15816-Pplp Purdue Pharma Lp Pension Plan Contributionp Lan Year Imad: [REDACTED] Trn:[REDACTED] YOUR REF: NONREF	1,500,000.00
09/11	Fedwire Debit Via: Wells Fargo NA/121000248 A/C: Optumrx Inc US Ref: Invoice II Max1336 Summary Run ID: 93503. Optumrx Med D Estimated Paym Ent For July 2015 Imad: [REDACTED] Trn:[REDACTED] YOUR REF: NONREF	11,067,418.41
09/11	Book Transfer Debit A/C: Rosebay Medical CO L P Oklahoma City OK 73134-2617 Ref: 3Q15 CT Estimated Tax Payments- Trn:[REDACTED] YOUR REF: NONREF	6,775,000.00
09/11	Book Transfer Debit A/C: Beacon CO Zurich Switzerland Ch-80-55 Ref: 3Q15 CT Estimated Tax Payment Trn:[REDACTED] YOUR REF: NONREF	6,775,000.00

**Transfer #1:** \$6.8M transfer from Purdue Pharma L.P. to Rosebay Medical Company L.P.

**Transfer #2:** \$6.8M transfer from Purdue Pharma L.P. to Beacon Company.



## **Exhibit F – Rhodes Cash Distributions Tracing Analysis**

# Rhodes Cash Distributions Tracing Analysis - Objectives

## Objective

1. Trace Rhodes Cash Distributions identified in Rhodes's SAP accounts payable ledger to the available third-party bank statements in order to validate if the distributions amounts, posting/transaction dates, payee/beneficiary names and payor entities were consistent and/or similar in both sources of information.

## Procedures Performed

1. Determined time period and entities to review based on Rhodes and Purdue's Internal Distribution Analysis and our reconciliation work. Bank statements were available for July 2014 onwards unless specifically requested from storage by TXP.
2. Reviewed bank statements to determine account holder entity name and time period represented.
3. Each Rhodes Cash Distribution identified in Purdue's SAP accounts payable ledger was compared to the available bank statements in order to find a match by payor entity, payee name, posting/transaction date and amount.
4. Certain transactions were assumed to be matches even if certain criteria were not an exact match. For example, if a distribution amount matched, but the payee name was not included in the bank statement and the posting date was within 60 days (before or after) of the transaction date included on the bank statement, then the distribution was generally considered to be a match.
  - If any of the criteria were not a match, the discrepancy was noted.
  - For payee name mismatches, the most common reason was that the bank statement did not include a payee name.

## Rhodes Cash Distributions Tracing Analysis – Sources Relied Upon

The following sources of information were accessed and reviewed from Purdue, Rhodes and TXP:

1. Cash Distributions identified in Rhodes's SAP accounts payable ledger; and
2. Bank statements for Rhodes and Affiliated Entities from the below periods highlighted in green:

Coventry Technologies L.P. (Company #230)												
Bank Statement Periods Received												
Year	Q1			Q2			Q3			Q4		
	J	F	M	A	M	J	J	A	S	O	N	D
2014												
2015												
2016												
2017												
2018												

SVC Pharma L.P. (Company #507)												
Bank Statement Periods Received												
Year	Q1			Q2			Q3			Q4		
	J	F	M	A	M	J	J	A	S	O	N	D
2014												
2015												
2016												
2017												
2018												

# Rhodes Cash Distributions Tracing Analysis - Observations and Findings

Based upon on the tracing work performed on the Rhodes Cash Distributions recorded in the SAP accounts payable ledger to the available third-party bank statements, we have the following observations:

1. The available third-party bank statements included 75 transactions totaling \$53.28 million, of which matches between the two sources of information (SAP accounts payable ledger and Bank Statements) were identified for 75 transactions (*100% of total*) totaling \$53.28 million (*100% of total*).

Company Name (Company #)	Transactions in SAP Accounts Payable Ledger within Bank Statement periods		Transactions in SAP Accounts Payable Ledger Matched to Bank Statements	
	# Trx	\$ Amount	# Trx	\$ Amount
Coventry Technologies L.P. (Company #230)	63	\$ 52,644,200	63	\$ 52,644,200
SVC Pharma L.P. (Company #507)	12	\$ 630,882	12	\$ 630,882
Rhodes Technologies (Company #227)	-	\$ -	-	\$ -
Rhodes Technologies Inc. (Company #247)	-	\$ -	-	\$ -
Rhodes Pharmaceuticals LP (Company #250)	-	\$ -	-	\$ -
Rhodes Pharmaceuticals Inc. (Company #251)	-	\$ -	-	\$ -
	<b>75</b>	<b>\$ 53,275,082</b>	<b>75</b>	<b>\$ 53,275,082</b>
As % of Transactions within Bank Statement periods	100%	100%	100%	100%

<sup>1</sup> SAP accounts payable ledger posting date considered a match if within +/- 60 days of bank statement transaction date.

# Rhodes Cash Distributions Tracing Analysis - Observations and Findings

## 2. For Coventry Technologies L.P. (Entity #230):

<b>Periods for which statements are available:</b>	Jul. 2014 – Dec. 2018
<b>Number of transactions in SAP accounts payable ledger within available bank statement periods:</b>	63 – \$52.6m
<b>Number of transactions matched to bank statements (and as % of total for available statement periods):</b>	63 (100%) – \$52.6m (100%)
<b>Number of exact matches (payee, amount and date):</b>	14 – \$6.49m
<b>Number of payee and amount matches with close posting date match<sup>1</sup>:</b>	27 – \$44.96m <ul style="list-style-type: none"> <li>• 2 payments to Rosebay Medical Company LP totaling \$14.65m were combined into a single transaction in the bank statement</li> </ul>
<b>Number of amount matches with close posting date match<sup>1</sup> (no payee name listed in bank statement):</b>	22 – \$1.19m <ul style="list-style-type: none"> <li>• All are checks for tax-related payments</li> </ul>

<sup>1</sup> SAP accounts payable ledger posting date considered a match if within +/- 60 days of bank statement transaction date.

# Rhodes Cash Distributions Tracing Analysis - Observations and Findings

## 3. For SVC Pharma L.P. (Entity #507):

<b>Periods for which statements are available:</b>	Aug. 2014 – Dec. 2018
<b>Number of transactions in AP Extract file:</b>	21 – \$1.17m
<b>Number of transactions in AP Extract file within available bank statement periods:</b>	12 – \$631k
<b>Number of transactions matched to bank statements (and as % of total for available statement periods):</b>	12 (100%) – \$631k (100%)
<b>Number of exact matches (payee, amount and date):</b>	0
<b>Number of payee and amount matches with close posting date match<sup>1</sup>:</b>	2 – \$186k
<b>Number of amount matches with close posting date match<sup>1</sup> (no payee name listed in bank statement):</b>	10 – \$445k <ul style="list-style-type: none"> <li>All are checks recorded in SAP as payable to Comptroller of Maryland</li> </ul>

<sup>1</sup> SAP accounts payable ledger posting date considered a match if within +/- 60 days of bank statement transaction date.

# Rhodes Cash Distributions Tracing Analysis - Observations and Findings

## 4. For Rhodes Technologies (Entity #227):

<b>Periods for which statements are available:</b>	Jul. 2014 – Dec. 2018
<b>Number of transactions in SAP accounts payable ledger within available bank statement periods:</b>	0
<b>Number of transactions matched to bank statements:</b>	0
<b>Number of exact matches (payee, amount and date):</b>	n/a
<b>Number of payee and amount matches with close posting date match<sup>1</sup>:</b>	n/a
<b>Number of amount matches with close posting date match<sup>1</sup> (no payee name listed in bank statement):</b>	n/a

<sup>1</sup> SAP accounts payable ledger posting date considered a match if within +/- 60 days of bank statement transaction date.



# Rhodes Cash Distributions Tracing Analysis - Observations and Findings

## 5. For Rhodes Technologies Inc. (Entity #247):

<b>Periods for which statements are available:</b>	Aug. 2014 – Dec. 2018
<b>Number of transactions in SAP accounts payable ledger within available bank statement periods:</b>	0
<b>Number of transactions matched to bank statements:</b>	0
<b>Number of exact matches (payee, amount and date):</b>	n/a
<b>Number of payee and amount matches with close posting date match<sup>1</sup>:</b>	n/a
<b>Number of amount matches with close posting date match<sup>1</sup> (no payee name listed in bank statement):</b>	n/a

<sup>1</sup> SAP accounts payable ledger posting date considered a match if within +/- 60 days of bank statement transaction date.

# Rhodes Cash Distributions Tracing Analysis - Observations and Findings

## 6. For Rhodes Pharmaceuticals L.P. (Entity #250):

<b>Periods for which statements are available:</b>	Aug. 2014 – Dec. 2018
<b>Number of transactions in SAP accounts payable ledger within available bank statement periods:</b>	0
<b>Number of transactions matched to bank statements:</b>	0
<b>Number of exact matches (payee, amount and date):</b>	n/a
<b>Number of payee and amount matches with close posting date match<sup>1</sup>:</b>	n/a
<b>Number of amount matches with close posting date match<sup>1</sup> (no payee name listed in bank statement):</b>	n/a

<sup>1</sup> SAP accounts payable ledger posting date considered a match if within +/- 60 days of bank statement transaction date.

# Rhodes Cash Distributions Tracing Analysis - Observations and Findings

## 7. For Rhodes Pharmaceuticals Inc. (Entity #251):

<b>Periods for which statements are available:</b>	Aug. 2014 – Dec. 2018
<b>Number of transactions in SAP accounts payable ledger within available bank statement periods:</b>	0
<b>Number of transactions matched to bank statements:</b>	0
<b>Number of exact matches (payee, amount and date):</b>	n/a
<b>Number of payee and amount matches with close posting date match<sup>1</sup>:</b>	n/a
<b>Number of amount matches with close posting date match<sup>1</sup> (no payee name listed in bank statement):</b>	n/a

<sup>1</sup> SAP accounts payable ledger posting date considered a match if within +/- 60 days of bank statement transaction date.

## Rhodes Cash Distributions Tracing Analysis - Observations and Findings

8. Statements for the following entities were provided, but no transactions were identified in the SAP accounts payable ledger:

Rhodes Technologies (Company #227)									
Bank Statement Periods Received									
Year	Q1			Q2			Q3		
	J	F	M	A	M	J	J	A	S
2014									
2015									
2016									
2017									
2018									

Rhodes Technologies Inc. (Company #247)									
Bank Statement Periods Received									
Year	Q1			Q2			Q3		
	J	F	M	A	M	J	J	A	S
2014									
2015									
2016									
2017									
2018									

Rhodes Pharmaceuticals LP (Company #250)									
Bank Statement Periods Received									
Year	Q1			Q2			Q3		
	J	F	M	A	M	J	J	A	S
2014									
2015									
2016									
2017									
2018									

Rhodes Pharmaceuticals Inc. (Company #251)									
Bank Statement Periods Received									
Year	Q1			Q2			Q3		
	J	F	M	A	M	J	J	A	S
2014									
2015									
2016									
2017									
2018									



# Rhodes Cash Distributions Flow of Funds Analysis

## Flow of Funds Analysis – Cash Distribution and Capital Contribution Testing Selections

As illustrated in this section of the Cash Distribution and Capital Contributions Analysis, we performed a flow of funds analysis on each classification of Cash Distributions (Non-Tax and Tax) made (“Rhodes Cash Distribution Testing Selections”) and Capital Contributions received (“Rhodes Capital Contributions Testing Selections”) by Rhodes (collectively referred to as the “Rhodes Cash Distribution and Capital Contribution Testing Selections”):

### Rhodes Cash Distribution Testing Selections

- **Selection 1** – Non-Tax Cash Distribution from Rhodes Technologies to Beacon Company and Rosebay Medical Company L.P., December 2011
- **Selection 2** – Tax Distribution for Estimated Federal Tax Payment, Q4 2014

### Rhodes Capital Contribution Testing Selections

- **Selection 1** – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012
- **Selection 2** – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013
- **Selection 3** – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

## Rhodes Flow of Funds Analysis – Observations and Findings

The following summary of observations and findings is based upon our review and analysis of various sources of information that we obtained from Rhodes related to the Rhodes Cash Distribution and Capital Contribution Testing Selections:

1. Rhodes Cash Distribution Testing Selection 1 was classified by Rhodes as a Non-Tax Cash Distribution that flowed from Rhodes Technologies up to and through Coventry Technologies L.P. and then from Coventry Technologies L.P. to Beacon Company and Rosebay Medical Company L.P.
  - It is our understanding from Rhodes that this flow of funds pattern is generally consistent with the other Non-Tax Cash Distributions made by Rhodes.
2. Rhodes Cash Distribution Testing Selection 2 was classified by Rhodes as a Tax Distribution that flowed from Coventry Technologies L.P. to Rosebay Medical Company L.P., Beacon Company and the United States Treasury and such classification is consistent with the documentation supporting this transaction.<sup>1</sup>
  - It is our understanding from Rhodes that this flow of funds pattern is generally consistent with the other Tax Distributions made by Rhodes.
3. Rhodes Capital Contribution Testing Selections 1 through 3 flowed from Purdue Pharma L.P. up to PRA L.P. and through other holdings companies, and then to Beacon Company and Rosebay Medical Company L.P., which made contributions to Rhodes Technologies or Rhodes Pharmaceuticals L.P. through Coventry Technologies L.P.
  - It is our understanding from Rhodes that this flow of funds pattern is generally consistent with the other Capital Contributions received by Rhodes.
4. Rhodes's accounting for the Rhodes Cash Distribution and Capital Contribution Testing Selections flow of funds is consistent with the available written approval and authorization documents supporting these transactions.
5. For the Rhodes Cash Distribution Testing Selections, the payee/beneficiary name recorded in Rhodes's accounts payable detail of the SAP general ledger system matches the payee/beneficiary name reported in Rhodes's Internal Distribution Analysis.

<sup>1</sup> We are unable to determine from the books and records maintained by Purdue and Rhodes whether Rosebay Medical Company L.P. or Beacon Company used the distributions to make tax-related payments to the appropriate taxing authorities.




# Rhodes Cash Distribution Testing Selections





## **Selection 1 Rhodes Non-Tax Cash Distributions (2011)**

## Selection 1 – Non-Tax Cash Distribution from Rhodes Technologies to Beacon Company and Rosebay Medical Company L.P., December 2011



<sup>1</sup> For consistency with PPLP's classification of Non-Tax Cash Distributions, this Non-Tax Cash Distribution by Rhodes that flowed up to Beacon Company and Rosebay Medical L.P. has been treated as a US Partner Cash Distribution in the Cash Distributions Analysis.

# Selection 1 – Non-Tax Cash Distribution from Rhodes Technologies to Beacon Company and Rosebay Medical Company L.P., December 2011

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100029607 Company Code 227 Fiscal Year 2011  
Doc. Date 12/12/2011 Posting Date 12/08/2011 Period 12  
Calculate Tax ☐  
Doc. Currency USD  
Doc. Hdr Text CTW 12062011 to 12082011

**Transfer #1:** \$25,000,000  
transfer from Rhodes  
Technologies to Coventry  
Technologies L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	102230	Coventry Tech. LLC		GEN			25,000,000.00	FUNDING to COVENTRY TECHNOLOGIES LLC
2	40	201150	Payroll Suspense		GEN			802,328.85	PAYROLL PAYMENT
3	40	100040	Chase Control ZBA		GEN			191,806.91	CONTROL DISBURSEMENT ACCOUNT FUNDING
4	40	100040	Chase Control ZBA		GEN			106,816.54	CONTROL DISBURSEMENT ACCOUNT FUNDING
5	40	100040	Chase Control ZBA		GEN			10,894.94	CONTROL DISBURSEMENT ACCOUNT FUNDING
6	40	100010	Cash Concentration		GEN			357.09	MISCELLANEOUS BANK DEPOSIT
7	50	100010	Cash Concentration		GEN			25,000,000.00-	FUNDING to COVENTRY TECHNOLOGIES LLC

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000222 Company Code 230 Fiscal Year 2011  
Doc. Date 12/12/2011 Posting Date 12/08/2011 Period 12  
Calculate Tax ☐  
Doc. Currency USD  
Doc. Hdr Text CTW 12062011 to 12082011

**Transfer #1:** \$25,000,000  
transfer from Rhodes  
Technologies to Coventry  
Technologies L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			25,000,000.00	FUNDING from RHODES TECHNOLOGIES (227)
2	50	102227	Rhodes Technologies		GEN			25,000,000.00-	FUNDING from RHODES TECHNOLOGIES (227)

# Selection 1 – Non-Tax Cash Distribution from Rhodes Technologies to Beacon Company and Rosebay Medical Company L.P., December 2011

Doc.Type : KR ( Vendor invoice ) Normal document

Doc. Number 1900000073 Company Code 230 Fiscal Year 2011  
 Doc. Date 12/07/2011 Posting Date 12/12/2011 Period 12  
 Calculate Tax ☒  
 Ref.Doc. 120711  
 Doc. Currency USD

**Transfer #2a:** \$12,500,000  
 transfer from Coventry  
 Technologies L.P. to Beacon  
 Company.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1029154	BEACON CO		GEN			12,500,000.00-	4QTR 2011 PARTNER DISTRIBUTION
2	40	302044	Dist #44 PLPAH LP		GEN			12,500,000.00	4QTR 2011 PARTNER DISTRIBUTION

Doc.Type : KR ( Vendor invoice ) Normal document

Doc. Number 1900000072 Company Code 230 Fiscal Year 2011  
 Doc. Date 12/07/2011 Posting Date 12/12/2011 Period 12  
 Calculate Tax ☒  
 Ref.Doc. 120711  
 Doc. Currency USD

**Transfer #2b:** \$12,500,000  
 transfer from Coventry  
 Technologies L.P. to Rosebay  
 Medical Company L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1016497	ROSEBAY MEDICAL COMP		GEN			12,500,000.00-	
2	40	302044	Dist #44 PLPAH LP		GEN			12,500,000.00	

## Selection 1 – Non-Tax Cash Distribution from Rhodes Technologies to Beacon Company and Rosebay Medical Company L.P., December 2011

COVENTRY TECHNOLOGIES L.P.

---

Written Consent of General Partner

---


The undersigned, Purdue Pharma Inc. (the "General Partner"), a New York corporation and the General Partner of Coventry Technologies L.P., a Delaware limited partnership (the "Partnership"), hereby consents to the taking of the following action and directs that this consent be filed with the records of proceedings of the Partnership:


WHEREAS, the Partnership is to receive a distribution from Rhodes Technologies ("Rhodes") in the amount of \$25,000,000 on or before December 9, 2011 (the "Distribution").

NOW, THEREFORE, be it

RESOLVED, that upon receipt of the Distribution from Rhodes, the Partnership be and it hereby is authorized to distribute \$12,500,000 to Beacon Company and \$12,500,000 to Rosebay Medical Company L.P.

Date: December 8, 2011

  
Edward P. Mahoney

COVENTRY TECHNOLOGIES L.P.  
by its general partner,  
Purdue Pharma Inc.  
By:   
Stuart D. Baker  
Executive Vice President,  
Counsel to the Board


**Transfer #1:** Confirmation of \$25,000,000 transfer from Rhodes Technologies to Coventry Technologies L.P.

**Transfers #2a and #2b:** Authorization for \$12,500,000 transfers from Coventry Technologies L.P. to Beacon Company and Rosebay Medical Company L.P., totaling \$25,000,000 in distributions.



## **Selection 2 Rhodes Tax Distribution (2014)**

## Selection 2 – Tax Distribution for Estimated Federal Tax Payment, Q4 2014



Affiliated Entity - Books and Records  
Maintained in the same SAP System as Purdue



Beacon/Rosebay



Taxing Authority

## Selection 2 – Tax Distribution for Estimated Federal Tax Payment, Q4 2014

Doc.Type : KR ( Vendor invoice ) Normal document

Doc. Number	1900000203	Company Code	230	Fiscal Year	2014
Doc. Date	12/08/2014	Posting Date	12/12/2014	Period	12
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	120814E				
Doc. Currency	USD				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1016497	ROSEBAY MEDICAL COMP		GEN			14,500,000.00-	4QTR 2014 FEDERAL ESTIMATED TAX PAYMENT
2	40	302027	Capital #27 Distrib.		GEN			14,500,000.00	4QTR 2014 FEDERAL ESTIMATED TAX PAYMENT

**Transfer #1: \$14,500,000**  
transfer from Coventry  
Technologies L.P. to Rosebay  
Medical Company L.P.



## Selection 2 – Tax Distribution for Estimated Federal Tax Payment, Q4 2014

Doc.Type : KR ( Vendor invoice ) Normal document

Doc. Number 1900000204 Company Code 230 Fiscal Year 2014

Doc. Date 12/08/2014 Posting Date 12/16/2014 Period 12

Calculate Tax ☒

Ref.Doc. 120814A

Doc. Currency USD

**Transfer #2:** Q4 2014 federal tax payment of \$13,232,217 for Beacon Company.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1004240	UNITED STATES TREASU		GEN		U1	13,232,217.00-	
2	40	302026	Capital #26 Distrib.		GEN			13,232,217.00	

Doc.Type : KR ( Vendor invoice ) Normal document

Doc. Number 1900000201 Company Code 230 Fiscal Year 2014

Doc. Date 12/08/2014 Posting Date 12/12/2014 Period 12

Calculate Tax ☐

Ref.Doc. 120814

Doc. Currency USD

**Transfer #3:** Q4 2014 federal tax payment of \$1,267,783 for Beacon Company.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1029154	BEACON CO		GEN			1,267,783.00-	4QTR 2014 ESTIMATED 3.8% MEDICARE TAX
2	40	302026	Capital #26 Distrib.		GEN			1,267,783.00	4QTR 2014 ESTIMATED 3.8% MEDICARE TAX

## Selection 2 – Tax Distribution for Estimated Federal Tax Payment, Q4 2014

4Q14 Federal Estimated Payment

ROSEBAY  
Coventry Technologies L.P.

Federal	\$ 14,500,000.00
GRAND TOTAL	<u>\$ 14,500,000.00</u>

Prepared by: \_\_\_\_\_ DATE: 12-8-14

Reviewed by: \_\_\_\_\_ DATE: 12/8/14

Approved by: \_\_\_\_\_ DATE: 12/10/14

Ed Mahony \_\_\_\_\_

**Transfer #1:** Q4 2014 federal tax payment of \$14,500,000 for Rosebay Medical Company L.P.

## Selection 2 – Tax Distribution for Estimated Federal Tax Payment, Q4 2014

4th Quarter 2014 Tax Payments		
ITEM #	247.000	
Entity		
Entity #	230	
Taxpayer	Rosebay Medical Company L.P.	
Jurisdiction	Federal	
Tax Type	Income Tax (Distrib. by Coventry to Ros-	
Underlying Pre-Tax Income	88,614,805	
State Tax Adjustments	-	
Adjusted Pre-Tax Income	88,614,805	
Partner %, if applicable	50.000%	
Taxable Income	44,307,402	
Apportionment	100.00%	
Post-Apportioned Income	44,307,402	
Tax Rate	43.400%	
Tax Due	19,229,413	
Minimum Tax	-	
Additional Other Tax (e.g., Franchise)	-	
Total Tax Due	19,229,413	
G/L Coding:	230-302027-0000000	
Payments:		
2013 Overpayment Credit	1	
Q1	1,250,000	
Q2	2,000,000	
Q3	1,500,000	
Q4	14,500,000	
Additional Q4	-	
Extension	-	
Total Payments	19,250,001	
Net Under (Over) Payment	(20,588)	

**Transfer #1:** Q4 2014 federal tax payment of \$14,500,000 for Rosebay Medical Company L.P.

# Selection 2 – Tax Distribution for Estimated Federal Tax Payment, Q4 2014

Paid 12-12-14

<b>Coventry Technologies L.P.</b> 4Q14 Estimated Payment ACH DEBIT TRANSACTION		
--	--	--

**Debit Date:** 12/08/14

<b>Vendor #1004240</b> United States Treasury IRS Service Center Philadelphia, PA	<b>GL Code</b> 230-302026-0000000 Capital #26-Distribution-Beacon	<b>Amount</b> \$13,232,217.00
--	---	----------------------------------

\$13,232,217.00

**Description:**  
 4Q14 Estimated Payment

Prepared by: \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_

DATE: 12-8-14

Reviewed by: \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_

DATE: 12/8/14

Approved by: \_\_\_\_\_  
 Ed Mahony

DATE: 12/10/14

\_\_\_\_\_  
 \_\_\_\_\_

DATE: 12-11-14

\_\_\_\_\_  
 \_\_\_\_\_

DATE: \_\_\_\_\_

Additional "B" Signature \_\_\_\_\_

**Transfer #2:** Q4 2014 federal tax payment of \$13,232,217 for Beacon Company.

## Selection 2 – Tax Distribution for Estimated Federal Tax Payment, Q4 2014

TAXPAYER NAME: COVENTRY TECHNOLOGIES LP

TIN: [REDACTED]

### Deposit Confirmation

Your payment has been accepted.

### Payment Successful

An EFT Acknowledgement Number has been provided for this payment. Please keep this number for your records.

**Transfer #2:** Confirmation of Q4 2014 federal tax payment of \$13,232,217 for Beacon Company.

**REMINDER: REMEMBER TO FILE ALL RETURNS WHEN DUE!**

**EFT ACKNOWLEDGEMENT NUMBER:**

270474683366697

Payment Information	Entered Data
Taxpayer EIN	[REDACTED]
Tax Form	8804 Annual Return Partnership W/H
Tax Type	Balance due on return or notice
Tax Period	December/2014
Payment Amount	\$13,232,217.00
Settlement Date	12/12/2014

## Selection 2 – Tax Distribution for Estimated Federal Tax Payment, Q4 2014

Transfer #3: Q4 2014 federal tax payment of \$1,267,783 for Beacon Company.

PURDUE WIRE TRANSFER REQUEST	
<b>WIRE TYPE:</b> <input type="checkbox"/> RECURRING WIRE <input checked="" type="checkbox"/> STANDARD WIRE <input type="checkbox"/> ACH WIRE <input type="checkbox"/> FOREIGN WIRE <input type="checkbox"/> DIRECT DEBIT	
DATE: 12/8/2014	Payer Bank Acct Name: JPMorganChase
FROM CO. NAME: Coventry Technologies LP	Bank Acct Number: [REDACTED]
PAYEE VENDOR NAME: Beacon Company [REDACTED]	
STREET ADDRESS:	
CITY, STATE, ZIP:	
RECIPIENT BANK NAME: JPMorgan Private Bank	
BANK STREET ADDRESS:	
CITY, STATE, ZIP:	
ACCOUNT NUMBER: [REDACTED]	ABA NUMBER: 021000021
IBAN NUMBER: [REDACTED]	SWIFT CODE: CHASUS33
REQUESTED BY: Sue Kowalski	
NOTE: BANKING INSTRUCTIONS MUST BE ATTACHED TO EACH WIRE SUBMISSION	
TOTAL WIRE TRANSFER AMOUNT:	\$ 1,267,783.00
PAYMENT DESCRIPTION: 4Q14 Federal Estimated Payment - 3.8% Medicare Tax	
Required: Company Code/GL Expense Acct/Cont Contact/Misc/Project	
GA. Distr. 230-302026-0000000	\$ Amount \$ 1,267,783.00
GA. Distr. Capital #26-Distributions-Beacon	\$ Amount
GA. Distr.	Total \$ Amount \$ 1,267,783.00
NOTE: 1) Wire Transfer Amounts \$100,000 or less do not require an authorized signature (below)	
NOTE: 2) The same individual may not sign as both Signer 1 and Signer 2 (below)	
Authorized Signer 1	[REDACTED]
Signature Required \$100,000.01 up to \$500,000 (Group A)	[REDACTED]
Authorized Signer 2	[REDACTED]
2nd Signature Required \$500,000.01 up to \$1MM (Group A)	[REDACTED]
\$1,000,000.01 and above, one of the signers must be: (Group B): >\$1MM - Edward Mahony	[REDACTED]
NOTE: Both Groups of "A" Signers are authorized to sign up to \$500,000 singly (which includes Raymond Beckler), and jointly (two "A" signers) \$500,000.01 up to \$1MM	
TREASURY USE ONLY	
Created By:	Notation
Approved By:	Required
Released By:	Required Name
DCB STAMP	ASP STAMP
to AP 12-12-14	

Last Revision: 10/26/11




# Rhodes Capital Contribution Testing Selections



## **Selection 1 Rhodes Capital Contribution (2012)**



## Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012



# Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100101884 Company Code 208 Fiscal Year 2012  
 Doc. Date 04/20/2012 Posting Date 04/17/2012 Period 04  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 04102012 to 04172012

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
176	50	100010	Cash Concentration		GEN			85,500,000.00-	FUNDING to BR HOLDINGS ASC. L.P.
177	50	100110	Lockbox Clearing		GEN			33,332,742.90-	CARDINAL HEALTH
178	50	100110	Lockbox Clearing		GEN			25,722,461.96-	CARDINAL HEALTH
179	50	100010	Cash Concentration		GEN			25,124,090.00-	DISTRIBUTION FUNDING to PURDUE HOLDINGS LP

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100101884 Company Code 208 Fiscal Year 2012  
 Doc. Date 04/20/2012 Posting Date 04/17/2012 Period 04  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 04102012 to 04172012

**Transfer #1:** \$25,124,090  
 transfer from Purdue Pharma  
 L.P. to Purdue Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	102413	BR Holdings Assoc LP		GEN			85,500,000.00	FUNDING to BR HOLDINGS ASC. L.P.
2	40	100010	Cash Concentration		GEN			33,332,742.90	CARDINAL HEALTH
3	40	100010	Cash Concentration		GEN			25,722,461.96	CARDINAL HEALTH
4	40	302045	Dist #45 PH LP		GEN			25,124,090.00	DISTRIBUTION FUNDING to PURDUE HOLDINGS LP

## Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000206 Company Code 416 Fiscal Year 2012  
Doc. Date 04/19/2012 Posting Date 04/17/2012 Period 04  
Calculate Tax ☐  
Doc. Currency USD  
Doc. Hdr Text CTW 04102012 to 04172012

**Transfer #1:** \$25,124,090  
transfer from Purdue Pharma L.P.  
to Purdue Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Ix	Amount	Text
1	40	100010	Cash Concentration		GEN			25,124,090.00	DISTRIBUTION FUNDING from PURDUE PHARMA L.P.
2	40	302044	Dist #44 PLPAH LP		GEN			25,000,000.00	DISTRIBUTION FUNDING to PLP ASC. HOLDINGS LP
3	40	100010	Cash Concentration		GEN			33,124.35	FX INTEREST DUE
4	50	107204	Invest - PPLP		GEN			25,124,090.00-	DISTRIBUTION FUNDING from PURDUE PHARMA L.P.
5	50	100010	Cash Concentration		GEN			25,000,000.00-	DISTRIBUTION FUNDING to PLP ASC. HOLDINGS LP
6	50	102233	Lucien Holdings Sarl		GEN			33,124.35-	FX INTEREST DUE
7	40	302042	Dist #42 PP Inc		GEN			62,182.00	DISTRIBUTION FUNDING 4/17/2012 to PURDUE PHARMA, I
8	40	302043	Dist #43 PLPAH Inc		GEN			61,908.00	DISTRIBUTION FUNDING 4/17/2012 to PLP ASC. HOLDING
9	50	100010	Cash Concentration		GEN			62,182.00-	DISTRIBUTION FUNDING 4/17/2012 to PURDUE PHARMA, I
10	50	100010	Cash Concentration		GEN			61,908.00-	DISTRIBUTION FUNDING 4/17/2012 to PLP ASC. HOLDING

**Transfer #2b:** \$62,182 transfer  
from Purdue Holdings L.P. to Purdue  
Pharma Inc.

**Transfer #2c:** \$61,908 transfer  
from Purdue Holdings L.P. to  
PLP Assoc Holdings Inc.

**Transfer #2a:** \$25,000,000  
transfer from Purdue Holdings L.P.  
to PLP Associates Holdings L.P.

# Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000831 Company Code 301 Fiscal Year 2012

Doc. Date 04/19/2012 Posting Date 04/17/2012 Period 04

Calculate Tax ☐

Doc. Currency USD

Doc. Hdr Text CTW 04102012 to 04172012

**Transfer #2b:** \$62,182 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			62,182.00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
2	50	107416	Invest - PH LP		GEN			62,182.00-	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000571 Company Code 402 Fiscal Year 2012

Doc. Date 04/19/2012 Posting Date 04/17/2012 Period 04

Calculate Tax ☐

Doc. Currency USD

Doc. Hdr Text CTW 04102012 to 04172012

**Transfer #2c:** \$61,908 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			61,908.00	DISTRIBUTION FUNDING 4/17/2012 from PURDUE HOLDING
2	50	107416	Invest - PH LP		GEN			61,908.00-	DISTRIBUTION FUNDING 4/17/2012 from PURDUE HOLDING

# Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000857 Company Code 401 Fiscal Year 2012  
 Doc. Date 04/19/2012 Posting Date 04/17/2012 Period 04  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 04102012 to 04172012

**Transfer #2a:** \$25,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			25,000,000.00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
2	40	302032	Capital #32 Dist BR		GEN			25,000,000.00	DISTRIBUTION FUNDING to BR HOLDINGS ASC. LP
3	50	107416	Invest - PH LP		GEN			25,000,000.00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
4	50	100010	Cash Concentration		GEN			25,000,000.00	DISTRIBUTION FUNDING to BR HOLDINGS ASC. LP

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000478 Company Code 413 Fiscal Year 2012  
 Doc. Date 04/19/2012 Posting Date 04/17/2012 Period 04  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 04102012 to 04172012

**Transfer #3:** \$25,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

**Transfer #3:** \$25,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			85,500,000.00	FUNDING from PURDUE PHARMA L.P.
2	40	100010	Cash Concentration		GEN			25,000,000.00	DISTRIBUTION FUNDING from PLP ASC. HOLDINGS LP
3	40	100010	Cash Concentration		GEN			1,470,000.00	FUNDING from PURDUE PHARMA L.P.
4	40	100010	Cash Concentration		GEN			655,000.00	FUNDING from PURDUE PHARMA L.P.
5	40	100010	Cash Concentration		GEN			255,000.00	FUNDING from PURDUE PHARMA L.P.
6	50	102208	Purdue Pharma L.P.		GEN			85,500,000.00	FUNDING from PURDUE PHARMA L.P.
7	50	107401	Invest. PLP Asc.Hold		GEN			25,000,000.00	DISTRIBUTION FUNDING from PLP ASC. HOLDINGS LP
8	50	102208	Purdue Pharma L.P.		GEN			1,470,000.00	FUNDING from PURDUE PHARMA L.P.
9	50	102208	Purdue Pharma L.P.		GEN			655,000.00	FUNDING from PURDUE PHARMA L.P.
10	50	102208	Purdue Pharma L.P.		GEN			255,000.00	FUNDING from PURDUE PHARMA L.P.

# Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012

Doc.Type : KR ( Vendor invoice ) Normal document

Doc. Number 1900000088 Company Code 413 Fiscal Year 2012  
 Doc. Date 04/16/2012 Posting Date 04/18/2012 Period 04  
 Calculate Tax ☒  
 Ref.Doc. 41612  
 Doc. Currency USD

**Transfer #4a:** \$12,500,000 transfer from BR Holdings Associates L.P. to Beacon Company.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1029154	BEACON CO		GEN		U1	12,500,000.00-	
2	40	302026	Capital #26 Distrib.		GEN			12,500,000.00	

Doc.Type : KR ( Vendor invoice ) Normal document

Doc. Number 1900000089 Company Code 413 Fiscal Year 2012  
 Doc. Date 04/16/2012 Posting Date 04/18/2012 Period 04  
 Calculate Tax ☒  
 Ref.Doc. 41612  
 Doc. Currency USD

**Transfer #4b:** \$12,500,000 transfer from BR Holdings Associates L.P. to Rosebay Medical Company L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1016497	ROSEBAY MEDICAL COMP		GEN		U1	12,500,000.00-	
2	40	302027	Capital #27 Distrib.		GEN			12,500,000.00	



# Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000240 Company Code 230 Fiscal Year 2012  
 Doc. Date 04/25/2012 Posting Date 04/22/2012 Period 04  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 04182012 to 04222012

**Transfer #5a:** \$12,500,000 transfer from Beacon Company to Coventry Technologies L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	102227	Rhodes Technologies		GEN			25,000,000.00	FUNDING to RHODES TECHNOLOGIES
2	50	100010	Cash Concentration		GEN			25,000,000.00-	FUNDING to RHODES TECHNOLOGIES
3	40	100010	Cash Concentration		GEN			12,500,000.00	4/28/2012 ROSEBAY MEDICAL COMPANY
4	40	100010	Cash Concentration					12,500,000.00	4/18/2012 BEACON COMPANY
5	50	301027	Capital #27Contrib.					12,500,000.00-	4/28/2012 ROSEBAY MEDICAL COMPANY
6	50	301026	Capital #26Contrib.					12,500,000.00-	4/18/2012 BEACON COMPANY

**Transfer #6:** \$25,000,000 transfer from Coventry Technologies L.P. to Rhodes Technologies.

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100032222 Company Code 227 Fiscal Year 2012  
 Doc. Date 04/25/2012 Posting Date 04/22/2012 Period 04  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 04182012 to 04222012

**Transfer #5b:** \$12,500,000 transfer from Rosebay Medical Company L.P. to Coventry Technologies L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100450	BOA Money Market		GEN			25,000,000.00	MIC / BofA MONEY MARKET
2	40	100010	Cash Concentration		GEN			25,000,000.00	FUNDING from COVENTRY TECHNOLOGIES, LP
3	40	100040	Chase Control ZBA		GEN			65,377.20	CONTROL DISBURSEMENT ACCOUNT FUNDING
4	40	100040	Chase Control ZBA		GEN			7,515.95	CONTROL DISBURSEMENT ACCOUNT FUNDING
5	40	100040	Chase Control ZBA		GEN			1,012.07	CONTROL DISBURSEMENT ACCOUNT FUNDING
6	50	100010	Cash Concentration		GEN			25,000,000.00-	MIC / BofA MONEY MARKET
7	50	102230	Coventry Tech. LLC		GEN			25,000,000.00-	FUNDING from COVENTRY TECHNOLOGIES, LP

## Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012

**Transfer #1:** Authorization for \$25,124,190<sup>1</sup> transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

million distribution for Rhodes Technologies. As you will see the \$25 million is to be covered by a distribution by Purdue Pharma L.P. 50/50 to Beacon Company and Rosebay Medical Company L.P. in the net amount of \$25 million (\$12.5 million each).

In accordance with the foregoing, please arrange for a distribution from Purdue Pharma L.P. in the gross amount of \$25,124,190 in the amounts indicated as follows:

Purdue Pharma L.P. Distribution	\$25,124,190
---------------------------------	--------------

Purdue Holdings L.P. Distribution	\$25,124,190
-----------------------------------	--------------

Purdue Pharma Inc.	\$62,182
--------------------	----------

PLP Associates Holdings Inc.	\$61,908
------------------------------	----------

PLP Associates Holdings L.P.	\$25,000,000
------------------------------	--------------

	<u>\$25,124,190</u>
--	---------------------

To BR Holdings and then Partners	\$25,000,000
----------------------------------	--------------

Beacon (50%)	<u>\$12,500,000</u>
--------------	---------------------

Rosebay (50%)	<u>\$12,500,000</u>
---------------	---------------------

Please let me know the value date once the transfer has been initiated.

Thanks,

Tony

Anthony M. Roncalli  
Chadbourne & Parke LLP  
30 Rockefeller Plaza, New York, NY 10112  
tel 212-408-5281 | eFax 646-710-5281  
aroncalli@chadbourne.com | private fax 212-408-5587

**Transfers #2a, #2b, and #2c:** Authorization for \$25,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.; \$62,182 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.; and \$61,908 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc. totaling \$25,124,090.

**Transfers #4a and #4b:** Authorization for \$12,500,000 transfers from BR Holdings Associates L.P. to Beacon Company and Rosebay Medical Company L.P., totaling \$25,000,000.

<sup>1</sup> A \$100 discrepancy exists between the authorized distribution amount of \$25,124,190 and the distribution that was recorded in SAP of \$25,124,090.



# Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012

## BR HOLDINGS ASSOCIATES L.P.

### Written Consent of General Partner

The undersigned, BR Holdings Associates Inc. (the "General Partner"), a New York corporation and the General Partner of BR Holdings Associates L.P., a Delaware limited partnership (the "Partnership"), hereby consents to the taking of the following action and directs that this consent be filed with the records of proceedings of the Partnership:

**Transfer #3:** \$25,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

WHEREAS, the Partnership is to receive a distribution from PLP Associates Holdings L.P. ("PLP Associates") in the amount of \$25,000,000 (the "Distribution").

NOW, THEREFORE, be it

RESOLVED, that upon receipt of the Distribution from PLP Associates, the Partnership be and it hereby is authorized to distribute \$12,500,000 to Beacon Company and \$12,500,000 to Rosebay Medical Company L.P.

Date: April 9, 2012

BR HOLDINGS ASSOCIATES L.P.  
by its general partner,  
BR Holdings Associates Inc.


By \_\_\_\_\_  
Stuart D. Baker  
Vice President

**Transfers #4a and #4b:**  
\$12,500,000 transfers from BR Holdings Associates L.P. to Beacon Company and Rosebay Medical Company L.P., totaling \$25,000,000.



## **Selection 2 Rhodes Capital Contribution (2013)**

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013



## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100122322 Company Code 208 Fiscal Year 2013  
Doc. Date 06/03/2013 Posting Date 05/31/2013 Period 05  
Calculate Tax ☐  
Doc. Currency USD  
Doc. Hdr Text CTW 05272013 to 05312013

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
129	50	100010	Cash Concentration		GEN			13,290,000.00-	MIC / BofA MONEY MARKET
130	50	100110	Lockbox Clearing		GEN			11,858,598.83-	AMERISOURCE
131	50	100010	Cash Concentration		GEN			10,049,636.00-	FUNDING to PURDUE HOLDINGS LP

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100122322 Company Code 208 Fiscal Year 2013  
Doc. Date 06/03/2013 Posting Date 05/31/2013 Period 05  
Calculate Tax ☐  
Doc. Currency USD  
Doc. Hdr Text CTW 05272013 to 05312013

**Transfer #1:** \$10,049,636  
transfer from Purdue Pharma L.P.  
to Purdue Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100450	BOA Money Market		GEN			37,900,000.00	MIC / BofA MONEY MARKET
2	40	100010	Cash Concentration		GEN			30,000,000.00	REDEMPTION of U.S. T-BILLS
3	40	100010	Cash Concentration		GEN			18,901,827.36	MCKESSON
4	40	100010	Cash Concentration		GEN			15,913,999.76	CARDINAL HEALTH
5	40	100450	BOA Money Market		GEN			13,290,000.00	MIC / BofA MONEY MARKET
6	40	100010	Cash Concentration		GEN			11,858,598.83	AMERISOURCE
7	40	102416	Purdue Holdings LP		GEN			10,049,636.00	FUNDING to PURDUE HOLDINGS LP

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000321 Company Code 416 Fiscal Year 2013  
Doc. Date 06/03/2013 Posting Date 05/31/2013 Period 05  
Calculate Tax ☐  
Doc. Currency USD  
Doc. Hdr Text CTW 05272013 to 05312013

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			10,049,636.00	DISTRIBUTION FUNDING from PURDUE PHARMA L.P.
2	40	102401	PLP Assoc Holdings		GEN			10,000,000.00	FUNDING to PLP ASC. HOLDINGS LP
3	40	100010	Cash Concentration		GEN			1,500,000.00	DISTRIBUTION FUNDING from PURDUE PHARMA L.P.
4	40	102301	Purdue Pharma Inc.		GEN			24,873.00	FUNDING to PURDUE PHARMA, INC.
5	40	102402	PLP Assoc Holdings		GEN			24,763.00	FUNDING to PLP
6	50	102208	Purdue Pharma L.P.		GEN			10,049,636.00	DISTRIBUTION FUNDING from PURDUE PHARMA L.P.
7	50	100010	Cash Concentration		GEN			10,000,000.00	FUNDING to PLP
8	50	102208	Purdue Pharma L.P.		GEN			1,500,000.00	DISTRIBUTION FUNDING from PURDUE PHARMA L.P.
9	50	100010	Cash Concentration		GEN			24,873.00	FUNDING to PURDUE PHARMA, INC.
10	50	100010	Cash Concentration		GEN			24,763.00	FUNDING to PLP ASC. HOLDINGS, INC.

**Transfer #2b:** \$24,873 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.

**Transfer #2c:** \$24,763 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc.

**Transfer #1:** \$10,049,636 transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

**Transfer #2a:** \$10,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000979 Company Code 301 Fiscal Year 2013  
 Doc. Date 06/03/2013 Posting Date 05/31/2013 Period 05  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 05272013 to 05312013

**Transfer #2b:** \$24,873 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			24,873.00	FUNDING from PURDUE HOLDINGS LP
2	40	100010	Cash Concentration		GEN			2,083.33	FUNDING from COVENTRY TECHNOLOGIES, LP (11c)
3	50	102416	Purdue Holdings LP		GEN			24,873.00-	FUNDING from PURDUE HOLDINGS LP
4	50	102230	Coventry Tech. LLC		GEN			2,083.33-	FUNDING from COVENTRY TECHNOLOGIES, LP (11c)

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000687 Company Code 402 Fiscal Year 2013  
 Doc. Date 06/03/2013 Posting Date 05/31/2013 Period 05  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 05272013 to 05312013

**Transfer #2c:** \$24,763 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			24,763.00	FUNDING from PURDUE HOLDINGS LP
2	50	102416	Purdue Holdings LP		GEN			24,763.00-	FUNDING from PURDUE HOLDINGS LP

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000921 Company Code 401 Fiscal Year 2013  
Doc. Date 06/03/2013 Posting Date 05/31/2013 Period 05  
Calculate Tax ☐  
Doc. Currency USD  
Doc. Hdr Text CTW 05272013 to 05312013

**Transfer #2a:** \$10,000,000  
transfer from Purdue Holdings L.P.  
to PLP Associates Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			10,000,000.00	FUNDING from PURDUE HOLDINGS LP
2	40	102413	BR Holdings Assoc LP		GEN			10,000,000.00	FUNDING to BR HOLDINGS ASC. LP
3	50	102416	Purdue Holdings LP		GEN			10,000,000.00	FUNDING from PURDUE HOLDINGS LP
4	50	100010	Cash Concentration		GEN			10,000,000.00	FUNDING to BR HOLDINGS ASC. LP

**Transfer #3:** \$10,000,000  
transfer from PLP Associates  
Holdings L.P. to BR Holdings  
Associates L.P.

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000583 Company Code 413 Fiscal Year 2013  
Doc. Date 06/03/2013 Posting Date 05/31/2013 Period 05  
Calculate Tax ☐  
Doc. Currency USD  
Doc. Hdr Text CTW 05272013 to 05312013

**Transfer #3:** \$10,000,000  
transfer from PLP Associates  
Holdings L.P. to BR Holdings  
Associates L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			10,000,000.00	FUNDING from PLP ASC. HOLDINGS LP
2	50	102401	PLP Assoc Holdings		GEN			10,000,000.00	FUNDING from PLP ASC. HOLDINGS LP



## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

Doc.Type : KR ( Vendor invoice ) Normal document

Doc. Number 1900000170 Company Code 413 Fiscal Year 2013  
 Doc. Date 05/22/2013 Posting Date 05/29/2013 Period 05  
 Calculate Tax ☒  
 Ref.Doc. 52213  
 Doc. Currency USD

**Transfer #4a:** \$5,000,000 transfer from BR Holdings Associates L.P. to Beacon Company.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1029154	BEACON CO		GEN		U1	5,000,000.00-	
2	40	302026	Capital #26 Distrib.		GEN			5,000,000.00	

Doc.Type : KR ( Vendor invoice ) Normal document

Doc. Number 1900000171 Company Code 413 Fiscal Year 2013  
 Doc. Date 05/22/2013 Posting Date 05/29/2013 Period 05  
 Calculate Tax ☒  
 Ref.Doc. 52213  
 Doc. Currency USD

**Transfer #4b:** \$5,000,000 transfer from BR Holdings Associates L.P. to Rosebay Medical Company L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1016497	ROSEBAY MEDICAL COMP		GEN		U1	5,000,000.00-	
2	40	302027	Capital #27 Distrib.		GEN			5,000,000.00	



## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

Doc.Type : SA ( G/L account document ) Normal document  
 Doc. Number 100000300 Company Code 230 Fiscal Year 2013  
 Doc. Date 06/03/2013 Posting Date 05/31/2013 Period 05  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 05272013 to 05312013

**Transfer #5a:** \$5,000,000 from Beacon Company to Coventry Technologies L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	102250	Rhodes Pharm LP		GEN			10,000,000.00	FUNDING to RHODES PHARMCEUTICALS LP
2	40	102301	Purdue Pharma Inc.		GEN			2,083.33	FUNDING to PURDUE PHARMA, INC.
3	40	102208	Purdue Pharma L.P.		GEN			255.88	FUNDING to PURDUE PHARMA L.P.
4	50	100010	Cash Concentration					10,000,000.00	FUNDING to RHODES PHARMCEUTICALS LP
5	50	100010	Cash Concentration					2,083.33	FUNDING to PURDUE PHARMA, INC.
6	50	100010	Cash Concentration					255.88	FUNDING to PURDUE PHARMA L.P.
7	40	100010	Cash Concentration					5,000,000.00	5/29/2013 BEACON
8	40	100010	Cash Concentration					5,000,000.00	5/29/2013 ROSEBAY
9	50	700030	Misc. Income	9000230	GEN			5,000,000.00	5/29/2013 BEACON
10	50	700030	Misc. Income	9000230	GEN			5,000,000.00	5/29/2013 ROSEBAY

**Transfer #6:** \$10,000,000 transfer from Coventry Technologies L.P. to Rhodes Pharmaceuticals L.P.

**Transfer #5b:** \$5,000,000 from Rosebay Medical Company L.P. to Coventry Technologies L.P.

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

Doc.Type : SA ( G/L account document ) Normal document  
 Doc. Number 100007858 Company Code 250 Fiscal Year 2013  
 Doc. Date 06/03/2013 Posting Date 05/31/2013 Period 05  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 05272013 to 05312013

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			10,000,000.00	FUNDING to PURDUE PHARMA LP

Doc.Type : SA ( G/L account document ) Normal document  
 Doc. Number 100007858 Company Code 250 Fiscal Year 2013  
 Doc. Date 06/03/2013 Posting Date 05/31/2013 Period 05  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 05272013 to 05312013

**Transfer #6:** \$10,000,000  
 transfer from Coventry  
 Technologies L.P. to Rhodes  
 Pharmaceuticals L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
21	50	102230	Coventry Tech. LLC		GEN			10,000,000.00-	FUNDING to PURDUE PHARMA LP

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

**Liceaga, Juan**

---

**From:** [REDACTED]  
**Sent:** Wednesday, May 22, 2013 2:44 PM  
**To:** [REDACTED]  
**Subject:** FW: Rhodes Pharmaceuticals L.P. - \$10 Million Funding  
**Attachments:** Written Consent of General Partner of Purdue Pharma L.P..pdf; Written Consent of General Partner of PHLP.pdf; Written Consent of General Partner of PLP Associates Holdings L.P..pdf; Written Consent of General Partner of BR Holdings.pdf; Written Consent of General Partner of Coventry Technologies L.P..pdf

**From:** [REDACTED]  
**Sent:** Wednesday, May 22, 2013 2:43 PM  
**To:** [REDACTED]  
**Cc:** [REDACTED] Lowne, Jon; [REDACTED]  
**Subject:** FW: Rhodes Pharmaceuticals L.P. - \$10 Million Funding

[REDACTED]

Please clear with Accounting and process.

Thank you!

[REDACTED] Finance  
Purdue Pharma L.P.  
T [REDACTED] M [REDACTED] E [REDACTED]

**From:** Roncalli, Anthony [mailto:ARoncalli@chadbourne.com]  
**Sent:** Wednesday, May 22, 2013 2:05 PM  
**To:** [REDACTED]  
**Cc:** Baker, Stuart D.; Mahony, Edward; Lowne, Jon; [REDACTED]  
**Subject:** Rhodes Pharmaceuticals L.P. - \$10 Million Funding

Wednesday, May 22, 2013

Dear [REDACTED]

As previously discussed attached are the following signed consents in connection with the anticipated funding of \$10 million ultimately to Rhodes Pharmaceuticals L.P.:

1. Written Consent of General Partner of Purdue Pharma L.P. ("PPLP") authorizing PPLP to distribute \$10,049,636 to Purdue Holdings L.P. ("PHLP");

**Transfer #1:** Authorization for \$10,049,636 transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

2. Written Consent of General Partner of PHLP authorizing PHLP to transfer \$24,873 to Purdue Pharma Inc., \$24,763 to PLP Associates Holdings Inc. and \$10 million to PLP Associates Holdings L.P.;

3. Written Consent of General Partner of PLP Associates Holdings L.P. authorizing PLP Associates Holdings L.P. to transfer \$10 million to BR Holdings Associates L.P. ("BR Holdings");

4. Written Consent of General Partner of BR Holdings authorizing BR Holdings to transfer \$5 million to Beacon Company and \$5 million to Rosebay Medical Company L.P.;

5. Written Consent of General Partner of Coventry Technologies L.P. ("Coventry") authorizing Coventry upon receipt of \$5 million from Beacon Company and \$5 million from Rosebay Medical Company L.P. to transfer the \$10 million to Rhodes Pharmaceuticals L.P.

Please send me the wire transfer instructions to the account of Coventry, and I will make arrangements with each of Beacon Company and Rosebay Medical Company L.P. to transfer the funds to Coventry upon their receipt from BR Holdings. Please also let me know the expected value date so I can give each of Beacon Company and Rosebay Medical Company L.P. a heads up as to when they will be expected to receive and transfer the funds to Coventry.

Thanks,

Tony

Anthony M. Roncalli  
Chadbourne & Parke LLP  
30 Rockefeller Plaza, New York, NY 10112  
tel 212-408-5281 | efax 646-710-5281  
aroncalli@chadbourne.com | private fax 212-408-5587

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please notify me by replying to this message and permanently delete the original and any copy of this e-mail and any printout thereof.

For additional information about Chadbourne & Parke LLP and Chadbourne & Parke (London) LLP, including a list of attorneys, please see our website at <http://www.chadbourne.com>

**Transfers #2a, #2b, and #2c:** Authorization for \$10,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.; \$24,873 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.; and \$24,763 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc. totaling \$10,049,636.

**Transfers #4a and #4b** Authorization for \$5,000,000 transfers from BR Holdings Associates L.P. to Beacon Company and Rosebay Medical Company L.P., totaling \$10,000,000

**Transfer #3:** Authorization for \$10,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

**Transfer #6:** Authorization for \$10,000,000 transfer from Coventry Technologies L.P. to Rhodes Pharmaceuticals L.P. upon receipt of \$5,000,000 transfers from Beacon Company and Rosebay Medical Company L.P., totaling \$10,000,000

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

**Transfer #3:** \$10,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

BR HOLDINGS ASSOCIATES L.P.

---

Written Consent of General Partner

---

The undersigned, BR Holdings Associates Inc. (the "General Partner"), a New York corporation and the General Partner of BR Holdings Associates L.P., a Delaware limited partnership (the "Partnership"), hereby consents to the taking of the following actions and directs that this consent be filed with the records of proceedings of the Partnership:

WHEREAS, the Partnership is to receive a distribution from PLP Associates Holdings L.P., a Delaware limited partnership ("PLP Associates"), in the amount of \$10,000,000 (the "Distribution").

NOW, THEREFORE, be it

RESOLVED, that upon receipt of the Distribution from PLP Associates, the Partnership be and it hereby is authorized to distribute \$5,000,000 to Beacon Company and \$5,000,000 to Rosebay Medical Company L.P.

RESOLVED, that the proper officers of the General Partner be and each of them hereby is authorized and directed to make, execute and deliver, or cause to be made, executed and delivered on behalf of itself and the Partnership all such agreements, documents, instruments and other papers as they may deem necessary or appropriate to carry out the purposes and intent of the foregoing resolution.

Date: May 22, 2013

BR HOLDINGS ASSOCIATES L.P.  
by its general partner,  
BR Holdings Associates Inc.

By: [Redacted]  
Stuart D. Baker  
Vice President


OK To Pay  
Edward B. Mahony

**Transfers #4a and #4b:** \$5,000,000 transfers from BR Holdings Associates L.P. to Beacon Company and Rosebay Medical Company L.P., totaling \$10,000,000



## **Selection 3 Rhodes Capital Contribution (2013)**

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013





# Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100129346 Company Code 208 Fiscal Year 2013  
 Doc. Date 10/25/2013 Posting Date 10/23/2013 Period 10  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 10162013 to 10232013

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
179	50	100110	Lockbox Clearing		GEN			18,622,831.65-	MCKESSON
180	50	100110	Lockbox Clearing		GEN			14,578,759.19-	AMERISOURCE
181	50	100110	Lockbox Clearing		GEN			14,502,799.96-	CARDINAL HEALTH
182	50	100010	Cash Concentration		GEN			10,049,636.00-	FUNDING to PURDUE HOLDINGS LP

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100129346 Company Code 208 Fiscal Year 2013  
 Doc. Date 10/25/2013 Posting Date 10/23/2013 Period 10  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 10162013 to 10232013

**Transfer #1:** \$10,049,636  
 transfer from Purdue Pharma L.P.  
 to Purdue Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	102416	Purdue Holdings LP		GEN			131,147,751.00	FUNDING to PURDUE HOLDINGS LP
2	40	100450	BOA Money Market		GEN			100,000,000.00	MIC / BofA MONEY MARKET
3	40	102416	Purdue Holdings LP		GEN			41,500,000.00	FUNDING to PURDUE HOLDINGS LP
4	40	100450	BOA Money Market		GEN			36,000,000.00	MIC / BofA MONEY MARKET
5	40	100010	Cash Concentration		GEN			30,000,000.00	REDEMPTION of U.S. T-BILLS
6	40	100430	Money Mkt Goldman		GEN			25,000,000.00	GOLDMAN SACHS - MONEY MARKET
7	40	100450	BOA Money Market		GEN			20,500,000.00	MIC / BofA MONEY MARKET
8	40	100010	Cash Concentration		GEN			18,622,831.65	MCKESSON
9	40	100010	Cash Concentration		GEN			14,578,759.19	AMERISOURCE
10	40	100010	Cash Concentration		GEN			14,502,799.96	CARDINAL HEALTH
11	40	102416	Purdue Holdings LP		GEN			10,049,636.00	FUNDING to PURDUE HOLDINGS LP



## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000366 Company Code 416 Fiscal Year 2013

Doc. Date 25.10.2013 Posting Date 23.10.2013 Period 10

Calculate Tax ☐

Doc. Currency USD

Doc. Hdr Text CTW 10162013 to 10232013

**Transfer #1:** \$10,049,636 transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

Itm	PK	Account	Account short text	Tx	Amount	Text
1	40	100010	Cash Concentration		131.147.751,00	FUNDING from PURDUE PHARMA L.P.
2	40	100010	Cash Concentration	GEN	41.500.000,00	FUNDING from PURDUE PHARMA L.P.
3	40	102413	BR Holdings Assoc LP	GEN	41.500.000,00	FUNDING to BR HOLDINGS ASC. LP
4	40	100010	Cash Concentration	GEN	10.049.636,00	FUNDING from PURDUE PHARMA L.P.
5	50	102208	Purdue Pharma L.P.	GEN	131.147.751,00-	FUNDING from PURDUE PHARMA L.P.
6	50	102208	Purdue Pharma L.P.	GEN	41.500.000,00-	FUNDING from PURDUE PHARMA L.P.
7	50	100010	Cash Concentration	GEN	41.500.000,00-	FUNDING to BR HOLDINGS ASC. LP
8	50	102208	Purdue Pharma L.P.	GEN	10.049.636,00-	FUNDING from PURDUE PHARMA L.P.
9	40	302044	Dist #44 PLPAH LP	GEN	130.500.000,00	DISTRIBUTION to PLP ASC. HOLDINGS LP 10/17
10	40	302044	Dist #44 PLPAH LP	GEN	10.000.000,00	DISTRIBUTION to PLP ASCS HOLDINGS LP 10/16
11	40	302042	Dist #42 PP Inc	GEN	324.591,00	DISTRIBUTION to PURDUE PHARMA, INC. 10/17
12	40	302043	Dist #43 PLPAH Inc	GEN	323.160,00	DISTRIBUTION to PLP ASC HOLDINGS, INC.
13	40	302042	Dist #42 PP Inc	GEN	24.873,00	DISTRIBUTION to PURDUE PHARMA, INC. 10/16
14	40	302043	Dist #43 PLPAH Inc	GEN	24.763,00	DISTRIBUTION to PLP ASC. HOLDINGS, INC. 10/16
15	50	100010	Cash Concentration	GEN	130.500.000,00-	DISTRIBUTION to PLP ASC. HOLDINGS LP 10/17
16	50	100010	Cash Concentration	GEN	10.000.000,00-	DISTRIBUTION to PLP ASCS HOLDINGS LP 10/16
17	50	100010	Cash Concentration	GEN	324.591,00-	DISTRIBUTION to PURDUE PHARMA, INC. 10/17
18	50	100010	Cash Concentration	GEN	323.160,00-	DISTRIBUTION to PLP ASC HOLDINGS, INC.
19	50	100010	Cash Concentration	GEN	24.873,00-	DISTRIBUTION to PURDUE PHARMA, INC. 10/16
20	50	100010	Cash Concentration	GEN	24.763,00-	DISTRIBUTION to PLP ASC. HOLDINGS, INC. 10/16

**Transfer #2c:** \$24,763 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc.

**Transfer #2b:** \$24,873 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.

**Transfer #2a:** \$10,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100001021 Company Code 301 Fiscal Year 2013

Doc. Date 10/25/2013 Posting Date 10/23/2013 Period 10

Calculate Tax ☐

Doc. Currency USD

Doc. Hdr Text CTW 10162013 to 10232013

**Transfer #2b:** \$24,873 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			24,873.00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
2	50	107416	Invest - PH LP		GEN			24,873.00-	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
3	40	100010	Cash Concentration		GEN			324,591.00	DISTRIBUTION from PURDUE HOLDINGS LP 10/17
4	50	107416	Invest - PH LP		GEN			324,591.00-	DISTRIBUTION from PURDUE HOLDINGS LP 10/17

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000720 Company Code 402 Fiscal Year 2013

Doc. Date 10/25/2013 Posting Date 10/23/2013 Period 10

Calculate Tax ☐

Doc. Currency USD

Doc. Hdr Text CTW 10162013 to 10232013

**Transfer #2c:** \$24,763 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			24,763.00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
2	50	107416	Invest - PH LP		GEN			24,763.00-	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
3	40	100010	Cash Concentration		GEN			323,160.00	DISTRIBUTION from PURDUE HOLDINGS LP 10/17
4	50	107416	Invest - PH LP		GEN			323,160.00-	DISTRIBUTION from PURDUE HOLDINGS LP 10/17

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000943 Company Code 401 Fiscal Year 2013  
 Doc. Date 25.10.2013 Posting Date 23.10.2013 Period 10  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 10162013 to 10232013

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			10.000.000,00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
2	50	107416	Invest - PH LP		GEN			10.000.000,00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
3	40	100010	Cash Concentration		GEN			130.500.000,00	DISTRIBUTION from PURDUE HOLDINGS LP 10/17
4	40	302032	Capital #32 Dist BR		GEN			130.500.000,00	DISTRIBUTION to BR HOLDINGS ASC. LP 10/17/2013
5	40	302032	Capital #32 Dist BR		GEN			10.000.000,00	DISTRIBUTION to BR HOLDINGS ASC. LP 10/16
6	50	107416	Invest - PH LP		GEN			130.500.000,00	DISTRIBUTION from PURDUE HOLDINGS LP 10/17
7	50	100010	Cash Concentration		GEN			130.500.000,00	DISTRIBUTION to BR HOLDINGS ASC. LP 10/17/2013
8	50	100010	Cash Concentration		GEN			10.000.000,00	DISTRIBUTION to BR HOLDINGS ASC. LP 10/16

**Transfer #2a:** \$10,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100000611 Company Code 413 Fiscal Year 2013  
 Doc. Date 10/25/2013 Posting Date 10/23/2013 Period 10  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 10162013 to 10232013

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			41,500,000.00	FUNDING from PURDUE HOLDINGS LP
2	40	100010	Cash Concentration		GEN			10,000,000.00	DISTRIBUTION FUNDING from PLP ASC. HOLDINGS LP
3	50	102416	Purdue Holdings LP		GEN			41,500,000.00	FUNDING from PURDUE HOLDINGS LP
4	50	107401	Invest. PLP Asc.Hold		GEN			10,000,000.00	DISTRIBUTION FUNDING from PLP ASC. HOLDINGS LP
5	40	100010	Cash Concentration		GEN			130,500,000.00	DISTRIBUTION from PLP ASC. HOLDINGS LP 10/17/2013
6	50	107401	Invest. PLP Asc.Hold		GEN			130,500,000.00	DISTRIBUTION from PLP ASC. HOLDINGS LP 10/17/2013

**Transfer #3:** \$10,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

**Transfer #3:** \$10,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : KR ( Vendor invoice ) Normal document

Doc. Number	1900000199	Company Code	413	Fiscal Year	2013
Doc. Date	09/24/2013	Posting Date	10/16/2013	Period	10
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	92413				
Doc. Currency	USD				

**Transfer #4a:** \$5,000,000 transfer from BR Holdings Associates L.P. to Beacon Company.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1029154	BEACON CO		GEN			5,000,000.00	PARTNER DIST. RHODES PHARMACEUTICAL FUNDING
2	40	302026	Capital #26 Distrib.		GEN			5,000,000.00	PARTNER DIST. RHODES PHARMACEUTICAL FUNDING

Doc.Type : KR ( Vendor invoice ) Normal document

Doc. Number	1900000200	Company Code	413	Fiscal Year	2013
Doc. Date	09/24/2013	Posting Date	10/16/2013	Period	10
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	92413				
Doc. Currency	USD				

**Transfer #4b:** \$5,000,000 transfer from BR Holdings Associates L.P. to Rosebay Medical Company L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1016497	ROSEBAY MEDICAL COMP		GEN			5,000,000.00	PARTNER DIST. RHODES PHARMACEUTICAL FUNDING
2	40	302027	Capital #27 Distrib.		GEN			5,000,000.00	PARTNER DIST. RHODES PHARMACEUTICAL FUNDING

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100000331	Company Code	230	Fiscal Year	2013
Doc. Date	11/11/2013	Posting Date	11/06/2013	Period	11
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	USD				
Doc. Hdr Text	CTW 11012013 to 11062013				

**Transfer #5a:** \$5,000,000 from Beacon Company to Coventry Technologies L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	102250	Rhodes Pharm LP		GEN			5,000,000.00	FUNDING to RHODES PHARMCEUTICALS LP
2	50	100010	Cash Concentration		GEN			5,000,000.00-	FUNDING to RHODES PHARMCEUTICALS LP
3	40	100010	Cash Concentration		GEN			5,000,000.00	11/1/2013 BEACON CO.
4	50	301026	Capital #26Contrib.					5,000,000.00-	11/1/2013 BEACON CO.

**Transfer #6a:** \$5,000,000 transfer from Coventry Technologies L.P. to Rhodes Pharmaceuticals L.P.

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100000324	Company Code	230	Fiscal Year	2013
Doc. Date	10/25/2013	Posting Date	10/23/2013	Period	10
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	USD				
Doc. Hdr Text	CTW 10162013 to 10232013				

**Transfer #5b:** \$5,000,000 from Rosebay Medical Company L.P. to Coventry Technologies L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			5,000,000.00	FUNDING from RHODES TECHNOLOGIES (227)
2	50	102227	Rhodes Technologies		GEN			5,000,000.00-	FUNDING from RHODES TECHNOLOGIES (227)
3	40	100010	Cash Concentration		GEN			5,000,000.00	10/21/2013 ROSEBAY MEDICAL COMPANY
4	50	103040	AR Other		GEN			5,000,000.00-	10/21/2013 ROSEBAY MEDICAL COMPANY

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100000327	Company Code	230	Fiscal Year	2013
Doc. Date	11/01/2013	Posting Date	10/31/2013	Period	10
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	USD				
Doc. Hdr Text	CTW 10292013 to 10312013				

**Transfer #6b:** \$5,000,000 transfer from Coventry Technologies L.P. to Rhodes Pharmaceuticals L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	102250	Rhodes Pharm LP		GEN			5,000,000.00	FUNDING to RHODES PHARMCEUTICALS LP
2	50	100010	Cash Concentration		GEN			5,000,000.00-	FUNDING to RHODES PHARMCEUTICALS LP



## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100009240 Company Code 250 Fiscal Year 2013

Doc. Date 11/01/2013 Posting Date 10/31/2013 Period 10

Calculate Tax ☐

Doc. Currency USD

Doc. Hdr Text CTW 10292013 to 10312013

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			5,000,000.00	FUNDING to PURDUE PHARMA LP
2	40	100010	Cash Concentration		GEN			294,320.04	MORRIS & DICKSON A/R RECEIPT
3	40	100010	Cash Concentration		GEN			37,604.30	INDIVIDUAL LOCKBOX DEPOSIT
4	40	100010	Cash Concentration		GEN			7,818.09	SMITH DRUG COMPANY
5	40	100010	Cash Concentration		GEN			4,798.08	INDIVIDUAL LOCKBOX DEPOSIT
6	40	100010	Cash Concentration		GEN			3,361.38	ROCHESTER DRUG
7	40	100010	Cash Concentration		GEN			2,056.94	PBA TRUECARE
8	40	100010	Cash Concentration		GEN			2,009.90	DAKOTA DRUG, INC.
9	50	102230	Coventry Tech. LLC		GEN			5,000,000.00-	FUNDING to PURDUE PHARMA LP

**Transfer #6b:** \$5,000,000  
transfer from Coventry  
Technologies L.P. to Rhodes  
Pharmaceuticals L.P.

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number 100009359 Company Code 250 Fiscal Year 2013

Doc. Date 11/11/2013 Posting Date 11/06/2013 Period 11

Calculate Tax ☐

Doc. Currency USD

Doc. Hdr Text CTW 11012013 to 11062013

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			5,000,000.00	FUNDING to PURDUE PHARMA LP
2	40	100010	Cash Concentration		GEN			691,969.75	MORRIS & DICKSON A/R RECEIPT
3	40	100010	Cash Concentration		GEN			40,685.60	INDIVIDUAL LOCKBOX DEPOSIT
4	40	100010	Cash Concentration					24,167.86	SMITH DRUG COMPANY
5	40	100010	Cash Concentration					20,998.19	INDIVIDUAL LOCKBOX DEPOSIT
6	40	100010	Cash Concentration					12,031.86	ROCHESTER DRUG
7	40	100010	Cash Concentration					6,620.64	INDIVIDUAL LOCKBOX DEPOSIT
8	40	100010	Cash Concentration					2,205.94	HARVARD DRUG GRP.
9	40	100010	Cash Concentration		GEN			1,262.94	INDIVIDUAL LOCKBOX DEPOSIT
10	40	100010	Cash Concentration		GEN			357.90	NC MUTUAL DRUG
11	50	102230	Coventry Tech. LLC		GEN			5,000,000.00-	FUNDING to PURDUE PHARMA LP

Transfer #6a: \$5,000,000  
transfer from Coventry  
Technologies L.P. to Rhodes  
Pharmaceuticals L.P.



## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

**From:** McClatchey, Ian [mailto:IMcClatchey@chadbourne.com]  
**Sent:** Tuesday, September 10, 2013 8:24 PM  
**To:** [REDACTED]  
**Cc:** Baker, Stuart D.; Mahony, Edward; Lowne, Jon; [REDACTED] Roncalli, Anthony; Quinn-Felice, Jennifer  
**Subject:** Rhodes Pharmaceuticals L.P. - \$10 Million Funding

Tuesday, September 10, 2013

Dear [REDACTED]

Attached are the following signed consents in connection with the anticipated funding of \$10 million ultimately to Rhodes Pharmaceuticals L.P.:

1. Written Consent of General Partner of Purdue Pharma L.P. ("PPLP") authorizing PPLP to distribute \$10,049,636 to Purdue Holdings L.P. ("PHLP");
2. Written Consent of General Partner of PHLP authorizing PHLP to transfer \$24,873 to Purdue Pharma Inc., \$24,763 to PLP Associates Holdings Inc. and \$10 million to PLP Associates Holdings L.P.;
3. Written Consent of General Partner of PLP Associates Holdings L.P. authorizing PLP Associates Holdings L.P. to transfer \$10 million to BR Holdings Associates L.P. ("BR Holdings");
4. Written Consent of General Partner of BR Holdings authorizing BR Holdings to transfer \$5 million to Beacon Company and \$5 million to Rosebay Medical Company L.P.; and
5. Written Consent of General Partner of Coventry Technologies L.P. ("Coventry") authorizing Coventry upon receipt of \$5 million from Beacon Company and \$5 million from Rosebay Medical Company L.P. to transfer the \$10 million to Rhodes Pharmaceuticals L.P.

I will make arrangements with each of Beacon Company and Rosebay Medical Company L.P. to transfer the funds to Coventry's JPMorgan account ending in [REDACTED] upon their receipt from BR Holdings. Please let me know the expected value date so I can give each of Beacon Company and Rosebay Medical Company L.P. a heads up as to when they will be expected to receive and transfer the funds to Coventry.

Please do not hesitate to contact me if you have any questions or if I may be of any assistance regarding this funding request.

Thank you,

Ian

**Transfer #1:** Authorization for \$10,049,636 transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

**Transfer #3:** Authorization for \$10,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

**Transfers #6a and #6b:** Authorization for \$10,000,000 transfer from Coventry Technologies L.P. to Rhodes Pharmaceuticals L.P. upon receipt of \$5,000,000 transfers from Beacon Company and Rosebay Medical Company L.P., totaling \$10,000,000

**Transfers #2a, #2b, and #2c:** Authorization for \$10,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.; \$24,873 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.; and \$24,763 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc. totaling \$10,049,636.

**Transfers #4a and #4b:** Authorization for \$5,000,000 transfers from BR Holdings Associates L.P. to Beacon Company and Rosebay Medical Company L.P., totaling \$10,000,000

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

BR HOLDINGS ASSOCIATES L.P.

Written Consent of General Partner

The undersigned, BR Holdings Associates Inc. (the "General Partner"), a New York corporation and the General Partner of BR Holdings Associates L.P., a Delaware limited partnership (the "Partnership"), hereby consents to the taking of the following actions and directs that this consent be filed with the records of proceedings of the Partnership:

**Transfer #3:** \$10,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

WHEREAS, the Partnership is to receive a distribution from PLP Associates Holdings L.P., a Delaware limited partnership ("PLP Associates"), in the amount of \$10,000,000 (the "Distribution").

NOW, THEREFORE, be it

RESOLVED, that upon receipt of the Distribution from PLP Associates, the Partnership be and it hereby is authorized to distribute \$5,000,000 to Beacon Company and \$5,000,000 to Rosebay Medical Company L.P.; and further

RESOLVED, that the proper officers of the General Partner be and each of them hereby is authorized and directed to make, execute and deliver, or cause to be made, executed and delivered on behalf of itself and the Partnership all such agreements, documents, instruments and other papers as they may deem necessary or appropriate to carry out the purposes and intent of the foregoing resolution.

Date: September 10, 2013

BR HOLDINGS ASSOCIATES L.P.  
by its general partner,  
BR Holdings Associates Inc.

OK To Pay  
Edward B. Mahony

By: [Redacted]  
Stuart D. Baker  
Vice President

Instructions: A, B, or C  
A. MATCHED TO SAP P.O. & RECEIVING REPORT;  
NO FURTHER APPROVAL REQUIRED. OR  
B. MATCHED TO SAP P.O.; RECEIVING EVIDENCED  
BY APPROVAL SIGNATURE HEREIN. OR  
C. NO P.O., NO RECEIVING RECORD; APPROVAL  
SIGNATURE HEREIN EVIDENCES APPROVAL FOR  
ISSUING RECEIPT

**Transfers #4a and #4b:**  
\$5,000,000 transfers from BR Holdings Associates L.P. to Beacon Company and Rosebay Medical Company L.P., totaling \$10,000,000



## **Exhibit G – Analysis of Distributions Referenced in the State Complaints Filed Against Purdue and/or the Sackler Family Members**

# Exhibit G – Analysis of Distributions Referenced in Complaints, Objectives and Procedures Performed

## Objectives

1. Review State Complaints filed against Purdue and/or Sackler Family members to identify allegations of distributions made by Purdue to or for the benefit of the Affiliated Entities.
2. Assess whether the distributions alleged in the State Complaints were or appear to have been included in Purdue's Internal Distribution Analysis and reconcile potential discrepancies.

## Procedures Performed

1. Reviewed State Complaints filed against Purdue and/or Sackler Family members and identified the allegations of distributions made by Purdue to Affiliated Entities.

State	Original/Amended	Date of Complaint
Connecticut	Amended	May 6, 2019
Indiana	Original	May 21, 2019
Iowa	Original	May 16, 2019
Kansas	Original	May 16, 2019
Maryland	Original	May 16, 2019
Massachusetts	Amended	January 31, 2019
New Jersey	Original	May 30, 2019
New York	Amended	March 28, 2019
Oklahoma	Original	June 30, 2017
Oregon	Original	September 18, 2018
Pennsylvania	Original	May 15, 2019
West Virginia	Original	May 16, 2019
Wisconsin	Original	May 16, 2019

2. Quantified the dollar amounts of the distributions made by Purdue to Affiliated Entities as alleged in the State Complaints.
3. Reconciled the distributions made by Purdue to Affiliated Entities as alleged in the State Complaints to the distributions included in Purdue's Internal Distribution Analysis.

## **Exhibit G - Analysis of Distributions Referenced in Complaints - Observations and Findings**

1. For many of the distribution amounts alleged in the State Complaints, we identified either exact or similar dollar amounts at or around the same time period that were included in Purdue's Internal Distribution Analysis.
  - For identification of either exact or similar dollar amounts at or around the same time period, we assumed that those distributions referenced in the State Complaints were included in Purdue's Internal Distribution Analysis.
2. The State Complaints alleged inexact amounts and did not always provide sufficiently detailed information and/or references to supporting documentation in order to assess whether those distributions were included in Purdue's Internal Distribution Analysis.
  - We did not find any instances where distribution amounts alleged in the State Complaints during a particular time period exceeded distributions amounts reported in Purdue's Internal Distribution Analysis for that same time period.

## Exhibit G - Reconciled Distributions Alleged in State Complaints to Purdue's Internal Distribution Analysis

1. The following tables illustrates that the annual distribution amounts reported in Purdue's Internal Distribution Analysis exceeded the alleged distributions that were included in the State Complaints aggregated by year.
  - The following pages identified which individual distributions that were alleged in the State Complaints have been identified in Purdue's Internal Distribution Analysis. The remaining distributions in the State Complaints have been included in the column name "Complaints Unidentified Individual Distributions."
  - After taking into account the Unidentified Individual Distributions, the total annual distributions reported in Purdue's Internal Distribution Analysis exceeded all of the distributions that were alleged in the State Complaints for that same year.

Year	Complaints	Purdue's Internal Distribution Analysis	Complaints Sum of Individual Distributions by Year	Complaints Unidentified Alleged Distributions	Complaints Total Distributions
2008	MA, CT	\$ 1,292,135,359	\$ 1,125,000,000	\$ -	\$ 1,125,000,000
2009	MA	1,594,762,000	535,000,000	-	535,000,000
2010	MA	1,626,663,503	877,650,000	11,350,000	889,000,000
2011	MA	1,254,856,650	530,500,000	20,500,000	551,000,000
2012	MA, CT	1,057,103,806	242,000,000	176,200,000	418,200,000
2013	MA, CT, IN	953,850,252	59,930,000	339,990,000	399,920,000
2014	CT	832,658,451	73,367,059	89,632,941	163,000,000
2015	CT	906,330,390	205,358,000	-	205,358,000
2016	CT	566,875,000	107,000,000	69,142,000	176,142,000
<b>2008-2016 MA,CT,IN</b>		<b>\$ 10,085,235,411</b>	<b>\$ 3,755,805,059</b>	<b>\$ 706,814,941</b>	<b>\$ 4,462,620,000</b>

# Exhibit G - Reconciled Distributions Alleged in State Complaints to Purdue's Internal Distribution Analysis

## Reconciliation of Distributions Listed in State Complaints to Purdue's Internal Distribution Analysis, Page 1 of 2

Result	Complaints Individual Distributions	Complaints Unidentified Alleged Distributions	Total Distributions Amount	Period	Complaints	Page	¶
In Purdue's Internal Distribution Analysis	\$ 250,000,000	\$ -	\$ 250,000,000	2008	MA	81	242
In Purdue's Internal Distribution Analysis	325,000,000	-	325,000,000	2008	MA	83	251
In Purdue's Internal Distribution Analysis	275,000,000	-	275,000,000	2008	CT	42	153
In Purdue's Internal Distribution Analysis	275,000,000	-	275,000,000	2008	CT	42	153
Year: 2008	\$ 1,125,000,000	\$ -	\$ 1,125,000,000				
In Purdue's Internal Distribution Analysis	\$ 200,000,000	\$ -	\$ 200,000,000	2009	MA	83	253
In Purdue's Internal Distribution Analysis	162,000,000	-	162,000,000	2009	MA	85	259
In Purdue's Internal Distribution Analysis	173,000,000	-	173,000,000	2009	MA	87	265
Year: 2009	\$ 535,000,000	\$ -	\$ 535,000,000				
In Purdue's Internal Distribution Analysis	\$ 236,650,000	\$ -	\$ 236,650,000	2010	MA	97	292
In Purdue's Internal Distribution Analysis	141,000,000	-	141,000,000	2010	MA	98	295
In Purdue's Internal Distribution Analysis	260,000,000	-	260,000,000	2010	MA	110	327
In Purdue's Internal Distribution Analysis	240,000,000 <sup>1</sup>	-	240,000,000	2010	MA	108	320
Sum of Multiple Distributions Exceeds Complaint	-	11,350,000	11,350,000	2010	MA	113	336
Year: 2010	\$ 877,650,000	\$ 11,350,000	\$ 889,000,000				
In Purdue's Internal Distribution Analysis	\$ 189,700,000	\$ -	\$ 189,700,000	2011	MA	115	340
In Purdue's Internal Distribution Analysis	200,000,000	-	200,000,000	2011	MA	121	357
In Purdue's Internal Distribution Analysis	140,800,000	-	140,800,000	2011	MA	122	363
Sum of Multiple Distributions Exceeds Complaint	-	20,500,000	20,500,000	2011	MA	123	365
Year: 2011	\$ 530,500,000	\$ 20,500,000	\$ 551,000,000				
In Purdue's Internal Distribution Analysis	\$ 129,000,000	\$ -	\$ 129,000,000	2012	MA	265	866
In Purdue's Internal Distribution Analysis	113,000,000	-	113,000,000	2012	CT	42	153
Sum of Multiple Distributions Exceeds Complaint	-	176,200,000	176,200,000	2012	MA	265	886
Year: 2012	\$ 242,000,000	\$ 176,200,000	\$ 418,200,000				

<sup>1</sup> The \$240 million distribution in 2010 includes a \$30 million distribution from Millsaw Realty L.P., apparently made at the direction of Purdue. The \$30 million distribution was not included in Purdue's combined audited financial statements, Internal Distributions Analysis or the October 19, 2018 MDL Presentation.

# Exhibit G - Reconciled Distributions Alleged in State Complaints to Purdue's Internal Distribution Analysis

## Reconciliation of Distributions Listed in State Complaints to Purdue's Internal Distribution Analysis, Page 2 of 2

Result	Complaints Individual Distributions	Complaints Unidentified Alleged Distributions	Total Distributions Amount	Period	Complaints	Page	↑
In Purdue's Internal Distribution Analysis	\$ 2,930,000	\$ -	\$ 2,930,000	2013	CT	41	151
In Purdue's Internal Distribution Analysis	15,000,000	-	15,000,000	2013	CT	42	152
In Purdue's Internal Distribution Analysis	42,000,000	-	42,000,000	2013	IN	95	313
Sum of Multiple Distributions Exceeds Complaint	-	339,990,000	339,990,000	2013	MA	143	421
Year: 2013	\$ 59,930,000	\$ 339,990,000	\$ 399,920,000				
In Purdue's Internal Distribution Analysis	\$ 367,059	\$ -	\$ 367,059	2014	CT	41	151
In Purdue's Internal Distribution Analysis	57,400,000	-	57,400,000	2014	CT	41	151
In Purdue's Internal Distribution Analysis	15,600,000	-	15,600,000	2014	CT	41	151
Sum of Multiple Distributions Exceeds Complaint	-	89,632,941	89,632,941	2014	CT	42	154
Year: 2014	\$ 73,367,059	\$ 89,632,941	\$ 163,000,000				
In Purdue's Internal Distribution Analysis	\$ 710,500	\$ -	\$ 710,500	2015	CT	41	151
In Purdue's Internal Distribution Analysis	2,160,000	-	2,160,000	2015	CT	41	151
In Purdue's Internal Distribution Analysis	135,000,000	-	135,000,000	2015	CT	41	151
In Purdue's Internal Distribution Analysis	1,975,000	-	1,975,000	2015	CT	41	151
In Purdue's Internal Distribution Analysis	60,000,000	-	60,000,000	2015	CT	41	151
In Purdue's Internal Distribution Analysis	5,512,500	-	5,512,500	2015	CT	42	152
Year: 2015	\$ 205,358,000	\$ -	\$ 205,358,000				
In Purdue's Internal Distribution Analysis	\$ 107,000,000	\$ -	\$ 107,000,000	2016	CT	41	151
Sum of Multiple Distributions Exceeds Complaint	-	69,142,000	69,142,000	2016	CT	42	154
Year: 2016	\$ 107,000,000	\$ 69,142,000	\$ 176,142,000				
	\$ 3,755,805,059	\$ 706,814,941	\$ 4,462,620,000	2008-2016			





## **Exhibit H - Pension Benefits Detailed Procedures Performed**

## **Exhibit H - Pension Benefits, Detailed Procedures Performed**

In order to achieve the objectives of the Pension Benefits Analysis, we performed the following procedures:

1. Obtained Purdue's Pension Plan document and other relevant information from Purdue for the purposes of quantifying the amount of Pension Benefits paid or owed to the Sackler Family members.
2. Identified the Sackler Family members referenced in these documents who received Pension Benefits or will become eligible to receive Pension Benefits.
3. Confirmed with Purdue's Director of Benefits and HRIS that no other Sackler Family members were or are eligible for Pension Benefits under Purdue's Pension Plan.
4. Reviewed and analyzed Deloitte's Pension Benefit calculation worksheets.
5. Reviewed Purdue's Pension Plan document in order to determine if the Sackler Family members who have been paid out under Purdue's Pension Plan as well as those who will receive future benefits appear eligible as defined in Purdue's Pension Plan document.



# **Exhibit I - Travel and Expense Reimbursements Detailed Procedures Performed**

## Exhibit I – T&E Reimbursements, Detailed Procedures Performed

In order to achieve the objectives of the T&E Spend Analysis, we performed the following procedures:

1. Requested T&E report-level data for all Purdue T&E reimbursements paid on or after January 1, 2008 from Purdue's Controller and Assistant Manager of Corporate Travel.
  - Purdue was the only Purdue entity that paid T&E reimbursements to or on behalf of the Sackler Family members.
  - Purdue had records available for T&E reimbursements submitted through the current T&E system, Databasics, starting in April 2011. T&E reimbursement information prior to April 2011 has been archived and was not available.
2. Identified the Sackler Family members who submitted expense reports in Purdue's T&E system, Databasics, which went live in April 2011. No T&E reimbursements had been submitted by or paid to the Sackler Family members through the T&E reporting system after December 31, 2018.
3. Requested individual line-item detail within expense reports for the Sackler Family members from Purdue's Assistant Manager of Corporate Travel. Reviewed transactions and summarized expenses by year, expense category (as defined by Purdue), Sackler Family member name, and reimbursement type (paid American Express company credit card vs. reimbursed a Sackler Family member directly).<sup>1</sup>
  - Expense categories were taken directly from Purdue's T&E reporting system and relied on.
  - Reviewed receipts/supporting documentation submitted through Databasic with T&E reports for approximately 73% of the total dollar amount of reimbursements made to or for the benefit of the Sackler Family members. Criteria used for selections can be found on the following page.
    - o Selected 343 items included in the T&E reports totaling approximately \$849,000 to determine if the expense reports contained documentation supporting the T&E reimbursements.
    - o Of the 343 expenses selected, 341 (or 99.4%) items included underlying receipts/supporting documentation. This represented 99.97% of the total dollar amount of T&E reimbursements selected for review.
  - No assessment of the business reasonableness of the expenses was made.
  - No assessment of whether expenses were in compliance with Purdue's T&E policies was made.

<sup>1</sup> Sackler Family members were issued American Express Corporate Credit Cards in their own names, which Purdue paid directly to American Express upon submission of expense reports. Purdue also issued Procurement Cards to various employees, however, none were issued to Sackler Family members.

## Exhibit I – T&E Reimbursements, Detailed Procedures Performed

4. Criteria for selecting the receipts/supporting documentation from Purdue's T&E reporting system for review was as follows:

Category		Selection Criteria
<b>Airline</b>		Amounts over \$5,000
<b>HCP (Health Care Professional)</b>		Amounts over \$500
<b>Hotel</b>		
	Due to Employee	Amounts over \$500
	Due to Card	Amounts over \$1,000
<b>Meals (Self)</b>		
	Due to Employee	Amounts over \$100
	Due to Card	Amounts over \$100
<b>Meals and Entertainment</b>		
	Due to Employee	Amounts over \$500
	Due to Card	Amounts over \$500
<b>Taxi/Car/Ground Transportation</b>		
	Due to Employee	Amounts over \$400
	Due to Card	Amounts over \$400
<b>Miscellaneous</b>		
	Due to Employee	Amounts over \$300
	Due to Card	Amounts over \$300

5. Identified payments made directly to the Sackler Family members recorded as T&E reimbursements in Purdue's SAP accounts payable ledger on or after January 1, 2008. No T&E reimbursements had been submitted by or paid to the Sackler Family members through accounts payable after March 31, 2019.

## **Exhibit I – T&E Reimbursements, Detailed Procedures Performed**

6. Reviewed documentation in SAP supporting T&E reimbursements paid through accounts payable, and assigned an expense category to each T&E reimbursement to the extent sufficient detail was available in Purdue's SAP accounting system.
  - Purdue's SAP accounting system included invoices, other supporting documentation and/or descriptions for approximately 87% of the total dollar amount of T&E reimbursements paid to the Sackler Family members through accounts payable.
7. Obtained and reviewed Purdue's Travel Policy and Procedures in effect during the years 2008 through 2018.
8. Held meetings and/or communicated with Purdue employees regarding the T&E policy and reimbursement process and to gain an understanding of the accounting for and quantification of T&E reimbursements paid by Purdue.
  - A list of the Purdue employees we met with and/or communicated with about T&E reimbursements is included in Appendix A.

**AlixPartners**

## **XI . Appendix**

# Index of Appendices

<b>Appendix A</b>	<b>Detailed List of Sources Relied Upon</b>	<b>317</b>
<b>Appendix B</b>	<b>List of the Sackler Family Members</b>	<b>323</b>
<b>Appendix C</b>	<b>Purdue Organizational Charts and Ownership Structure</b>	<b>325</b>
<b>Appendix D</b>	<b>Purdue Company Names and SAP Account Information</b>	<b>340</b>
<b>Appendix E</b>	<b>Rhodes Organizational Charts and Ownership Structure</b>	<b>345</b>
<b>Appendix F</b>	<b>Rhodes Company Names and SAP Account Information</b>	<b>349</b>





## **Appendix A – Detailed List of Sources Relied Upon**

## **Appendix A – Detailed List of Sources Relied Upon**

In order to achieve the objectives of the Cash Transfers of Value Analysis, we accessed and reviewed various types of sources of information from Purdue, TXP and One Stamford Realty that we used and relied on when performing our procedures.

### **1. Entity Organizational Charts**

- Organizational charts for the Purdue and Rhodes entities and certain Affiliated Entities.

### **2. SAP Accounting System Information**

- SAP company numbers and names, and chart of accounts: Financial Tables.xlsx.
- SAP general ledger detail.
- SAP master vendor table.
- SAP accounts payable ledger.
- SAP accounts receivable ledger.
- SAP cost center detail and list of customer codes.

## Appendix A – Detailed List of Sources Relied Upon

### 3. Purdue Internally Prepared Distribution Reports

- The October 19, 2018 MDL Presentation.
- Purdue’s Internal Distribution Analysis (see Excel file named: Distributions 1995 to 2017 Actuals v7.xlsx).
- Purdue’s Notes Receivable schedule of historical activity (see Excel file named: PRALP-PPLP Notes Receivable Historical Activity through 7.31.2019v2.xlsx).
- Rhodes’s Internal Distribution Analysis (see Excel files below):
  - o Coventry History – Cash Flow Statement\_since inception 2018 Revised\_05202019.xlsx.
  - o Coventry Tax Distributions LTD 2008 – 2018.xlsx.

### 4. Financial Statements

- Purdue’s audited financial statements for the years ended December 31, 2008 through December 31, 2017, and unaudited financial statements for the year ended December 31, 2018.<sup>1</sup>
- Purdue and Rhodes’s combined audited financial statements for the years ended December 31, 2014 through 2015.
- Rhode’s audited financial statements for the year ended December 31, 2016.
- Internal financial statements, reports and/or SAP accounting records for PPLP, Rhodes, PPI, PLP Associates Holdings Inc. and other Affiliated Entities whose books and records are maintained in the same SAP accounting system as Purdue’s.

<sup>1</sup> For the year ended December 31, 2018, audit fieldwork has largely been completed, but the audited financial statements have not been finalized due to the pending court appointment of Ernst & Young LLP as Purdue’s auditors.

## Appendix A – Detailed List of Sources Relied Upon

### 5. Purdue's Accounting and Approval Documentation

- Treasury department's records with transaction information and other accounting records.
- Wire instructions, bank statements, weekly bank transaction reports and bank account check clearing reconciliations.
- Written Consents and other documents from the general partners authorizing distributions.
- Other accounting records and approval documentation available in the SAP accounting system.
- Tax calculations by Purdue's Tax Department (now TXP).
- Information obtained from discussions and communications with Purdue and TXP employees.

### 6. State Complaints

- Complaints filed by various states against Purdue and/or the Sackler Family members:

State	Original/Amended	Date of Complaint
Connecticut	Amended	May 6, 2019
Indiana	Original	May 21, 2019
Iowa	Original	May 16, 2019
Kansas	Original	May 16, 2019
Maryland	Original	May 16, 2019
Massachusetts	Amended	January 31, 2019
New Jersey	Original	May 30, 2019
New York	Amended	March 28, 2019
Oklahoma	Original	June 30, 2017
Oregon	Original	September 18, 2018
Pennsylvania	Original	May 15, 2019
West Virginia	Original	May 16, 2019
Wisconsin	Original	May 16, 2019

## **Appendix A – Detailed List of Sources Relied Upon**

### **7. Payroll Records**

- Purdue payroll report detail.

### **8. Legal Expense Reports Prepared by Purdue’s Legal Operations Department**

- File provided by Legal Operations containing expenses paid to law firms that represent Sackler Family members under the Corporate Indemnity Policy. These reports listed the name of each law firm paid and the amounts invoiced to Purdue and did not include any detail as to the work performed.
- File describing all of Purdue’s corporate policies and requirements related to legal invoice processing.
- Copy of the Directors and Officers liability insurance policy.
- Minutes from the November 19, 2004 Board of Directors meeting of PPI, at which time the Corporate Indemnity Policy was adopted. The full text of the Corporate Indemnity Policy is incorporated into the minutes from that meeting.

### **9. Pension Records**

- Pension Benefit Calculation Worksheets prepared by Deloitte.
- Purdue’s Pension Plan Document.

## Appendix A – Detailed List of Sources Relied Upon

### 10. Purdue Expense Reports

- Purdue’s T&E reports from Databasics from April 2011 through December 31, 2018, including individual line-items from expense reports and available supporting documentation.
- Purdue’s SAP account payable detail and available supporting documentation related to expense reimbursements from January 1, 2008 through December 31, 2018.
- Purdue’s Travel Policy and Procedures in effect during the years 2008 through 2018.
- Transaction detail related to Purdue’s cellular phone plan costs.
- Transaction detail related to Purdue’s fleet vehicle costs, personal service employees expenses and the reimbursements of such.

### 11. Meetings with employees of Purdue, PPI, Rhodes, TXP and One Stamford Realty

Title	Company	Category
Associate General Counsel	PPLP	Compensation, Legal, and Pension
Sr. Manager, Payroll Services	PPLP	Compensation
Controller	PPLP	Cash Distributions and Travel & Expense
Assistant Manager of Corporate Travel	PPLP	Travel & Expense
Director of Law Department Operations	PPLP	Legal
Director, Benefits and HRIS	PPLP	Pension
Associate Director, SG&A Finance	PPLP	Travel & Expense
Senior Vice President and Chief Financial Officer	PPLP and PPI	Cash Distributions, Compensation, Legal and Pension
Senior Legal Analyst	PPLP	Legal
Associate General Counsel	PPLP	Legal
Treasurer & Director Business Development Finance	PPLP	Cash Distributions
Vice President Finance	Rhodes	Cash Distributions
Associate Treasury Analyst	TXP	Fringe Benefits
Transactions and Compliance Manager	TXP	Cash Distributions
Director, Finance and Accounting	TXP	Cash Distributions, Compensation and Travel & Expense
Vice President of Finance for PRALP	TXP	Fringe Benefits
Associate Director, Tax	TXP	Cash Distributions
Accounting Services, Manager	TXP	Travel & Expense
Associate Director	One Stamford Realty	Fringe Benefits



## **Appendix B - List of the Sackler Family Members**

## Appendix B - List of Sackler Family Members

Name	Purdue Director Begin Date	Purdue Director End Date
Jonathan D. Sackler	10/2/1990	12/8/2018
Ilene Sackler Lefcourt	10/2/1990	10/9/2018
Kathe A. Sackler	10/2/1990	9/27/2018
Richard S. Sackler	10/2/1990	7/24/2018
Raymond R. Sackler	10/2/1990	7/17/2017
Mortimer D. Sackler	10/2/1990	3/24/2010
Mortimer D.A. Sackler	1/15/1993	1/16/2019
Theresa E. Sackler	1/15/1993	9/7/2018
Beverly Sackler	1/15/1993	10/17/2017
Samantha (Sackler) Hunt	1/15/1993	3/8/2003
David A. Sackler	7/19/2012	8/14/2018


Family Member	Relationship	Title at Purdue (if applicable)
Mark Sackler		Delphian Sales Manager
Karen Lefcourt-Taylor		Consultant
Jeffrey Lefcourt		Consultant
Marianna Sackler	Daughter of Richard S. Sackler	Consultant
Henry Sackler		
Miles Sackler		Summer Intern
Rebecca Sackler	Daughter of Richard S. Sackler	Consultant
Benjamin Shack-Sackler	Son of Kathe A. Sackler	Summer Intern
Julia Shack-Sackler	Daughter of Kathe A. Sackler	Summer Intern
Muriel Sackler	Wife of Mortimer D. Sackler	
Susan Sackler	Wife of Kathe A. Sackler	
Ben Taylor	Husband of Karen Lefcourt-Taylor	
Beth Sackler	Ex-wife of Richard S. Sackler	





## **Appendix C - Purdue Organizational Charts and Ownership Structure**

## Appendix C - Purdue Pharma L.P. Subsidiaries, January 1, 2008 through February 14, 2008



\* General Partner has no equity interest in L.P., rather the General Partner receives a service fee for acting as General Partner


\*\* The preferred stock has been characterized as Preferred Stock A and Preferred Stock B. Bulla S ar l holds 100% of Preferred Stock A and Lymit Holdings S ar l holds 100% of Preferred Stock B. The percentages represent the total preferred stock

\*\*\*\* Effective as of January 1, 2008, New Suffolk Holdings LLP will invest up to €50.7 million as a silent partner in Mundipharma Vertriebsgesellschaft mbH & Co. KG. This silent partnership ends on December 31, 2030.

\*\*\*\* Effective as of January 1, 2008, New Suffolk Holdings LLP will invest up to €30.7 million as a silent partner in Mundipharma Vertriebsgesellschaft mbH & Co KG. This silent partnership ends on December 31, 2030.



**Appendix C - Purdue Pharma L.P. Subsidiaries, April 9, 2013 through July 8, 2014**



\* General Partner has no equity interest in L P , rather the General Partner receives a service fee for acting as General Partner

The organizational chart illustrates the corporate structure of Purdue Pharma L.P., a Delaware limited partnership. At the top is Purdue Pharma L.P. (yellow box). It has several direct subsidiaries:

- Purdue Transdermal Technologies L.P., a Delaware limited partnership (0%\*)
- Purdue Pharmaceuticals L.P., a Delaware limited partnership (0%\*)
- Purdue Pharma Products L.P., a Delaware limited partnership (0%\*)
- DT Partners L.P., a Delaware limited partnership (100%)
- Purdue Pharma Manufacturing Inc., a New York corporation (0%\*)
- Mundipharma LLC, a Delaware limited liability company (100%)
- Mundipharma FZ-LLC (Dubai) (100%)
- Purdue Products Inc., a New York corporation (0%\*)
- Purdue Products L.P., a Delaware limited partnership (100%)
- Seven Seas Hill Corp. (British Virgin Islands) (50%)
- Ophir Green Corp. (British Virgin Islands) (50%)
- Purdue Pharma of Puerto Rico, a Delaware general partnership (100%)
- IKUWA Holdings Inc. (formerly Laureate Pharma Inc.), a New York corporation (100%)
- IKUWA Holdings L.P. (formerly Laureate Pharma L.P.), a Delaware limited partnership (0%\*)
- Purdue Pharma Technologies Inc., a Delaware corporation (99%)
- Purdue Neuroscience Company, a Delaware general partnership (1%)
- Purdue Pharmaceutical Products Inc., a New York corporation (100%)
- Purdue Pharmaceutical Products L.P., a Delaware limited partnership (0%\*)
- AB Generics L.P., a New York limited partnership (100%)

Additional entities and their ownership:

- Purdue Pharma Manufacturing L.P., a Delaware limited partnership (100% owned by Purdue Pharma Manufacturing Inc.)
- Purdue Pharma of Puerto Rico is jointly owned by Seven Seas Hill Corp. and Ophir Green Corp.

Source: Purdue's Organizational Charts

The organizational chart illustrates the corporate structure of Purdue Pharma L.P., a Delaware limited partnership. At the top is Purdue Pharma L.P. (yellow box). It has several direct subsidiaries:

- Purdue Transdermal Technologies L.P., a Delaware limited partnership (0%\*)
- Purdue Pharmaceuticals L.P., a Delaware limited partnership (0%\*)
- Purdue Pharma Products L.P., a Delaware limited partnership (0%\*)
- DT Partners L.P., a Delaware limited partnership (100%)
- Purdue Pharma Manufacturing Inc., a New York corporation (100%)
- Mundipharma LLC, a Delaware limited liability company (100%)
- Mundipharma FZ-LLC (Dubai) (100%)
- Purdue Products Inc., a New York corporation (100%)
- Purdue Products L.P., a Delaware limited partnership (0%\*)
- IKUWA Holdings Inc. (formerly Laureate Pharma Inc.), a New York corporation (100%)
- IKUWA Holdings L.P. (formerly Laureate Pharma L.P.), a Delaware limited partnership (0%\*)
- Purdue Pharma Technologies Inc., a Delaware corporation (99%)
- Purdue Neuroscience Company, a Delaware general partnership (1%)
- Purdue Pharmaceutical Products Inc., a New York corporation (100%)
- Purdue Pharmaceutical Products L.P., a Delaware limited partnership (0%\*)
- AB Generics L.P., a New York limited partnership (100%)
- PharmIT Inc., a New York corporation (100%)
- PharmIT L.P., a Delaware limited partnership (0%\*)


Further down the chart, Purdue Pharma Manufacturing Inc. owns 100% of Purdue Pharma Manufacturing L.P., a Delaware limited partnership. Mundipharma LLC owns 100% of Mundipharma FZ-LLC (Dubai). Purdue Products Inc. owns 100% of Purdue Products L.P. IKUWA Holdings Inc. owns 100% of IKUWA Holdings L.P. Purdue Pharma Technologies Inc. owns 99% of Purdue Neuroscience Company, and IKUWA Holdings L.P. owns 1%. Purdue Pharmaceutical Products Inc. owns 100% of Purdue Pharmaceutical Products L.P. PharmIT Inc. owns 100% of PharmIT L.P. Finally, Purdue Pharma L.P. owns 100% of Seven Seas Hill Corp. (British Virgin Islands) and Ophir Green Corp. (British Virgin Islands), which both own 50% of Purdue Pharma of Puerto Rico, a Delaware general partnership.

Source: Purdue's Organizational Charts





## Appendix C - Purdue Pharma L.P. Subsidiaries, November 21, 2017 through August 19, 2018




\* General Partner has no equity interest in L.P., rather the General Partner receives a service fee for acting as General Partner

\*\* Name changes effective December 28, 2017




## Appendix C - Purdue Pharma L.P. Subsidiaries, September 11, 2018 through October 29, 2018




\* General Partner has no equity interest in L.P., rather the General Partner receives a service fee for acting as General Partner

## Appendix C - Purdue Pharma L.P. Subsidiaries, October 30, 2018 through May 27, 2019



\* General Partner has no equity interest in L.P., rather the General Partner receives a service fee for acting as General Partner

## Appendix C - Purdue Pharma L.P. Ownership and Subsidiaries, May 28, 2019 to Present



\* General Partner has no equity interest in L.P., rather the General Partner receives a service fee for acting as General Partner

\*\* Partner has no equity interest in LLP, rather the Partner receives a service fee for acting as a Partner

\*\*\* BR Holdings Associates Inc. is the general partner of Pharmaceutical Research Associates L.P.; Purdue Pharma Inc., PLP Associates Holdings Inc. and PLP Associates Holdings L.P. are the limited partners of Pharmaceutical Research Associates L.P.





## **Appendix D – Purdue Company Names and SAP Account Information**



## Appendix D - Cash Distribution Testing Selections – Purdue’s SAP Company Names

Company Number	Company Name	Description
208	Purdue Pharma L.P.	
301	Purdue Pharma Inc.	General Partner of Purdue Pharma L.P.
401	PLP Associates Holdings L.P.	Limited Partner of Purdue Holdings L.P. (name changed in 2018 to PRA L.P.)
402	PLP Associates Holdings Inc.	General Partner of Purdue Holdings L.P. (name changed in 2018 to PRA L.P.)
408	RSJ Company L.P.	Limited Partner of Mudipharma KK (Japan)
413	BR Holdings Associates L.P.	Limited Partner of PLP Associates Holdings L.P.
414	BR Holdings Associates Inc.	General Partner of BR Holdings Associates L.P.
416	Purdue Holdings L.P. (name changed in 2018 to PRA L.P.)	Limited Partner of Purdue Pharma L.P.
NA	Rosebay Medical Company L.P.	Limited Partner of BR Holdings Associates L.P. (50%)
NA	Beacon Company	Limited Partner of BR Holdings Associates L.P. (50%)
NA	Mexcus Corporation	Affiliated Entity (Ex-US)
NA	Maltus Corporation	Affiliated Entity (Ex-US)
NA	Mundipharma KK	Affiliated Entity (Ex-US)
NA	Clovio Corp.	Affiliated Entity (Ex-US)
NA	Lucien Holdings S.ar.l.	Affiliated Entity (Ex-US)

**Note:** The books and records for these entities are not maintained in the same SAP accounting system as Purdue.

## Appendix D - Cash Distribution Testing Selections – Purdue's SAP Account Descriptions

SAP Number	Account Type	SAP "Short Text"
100010	Asset - Cash	Cash Concentration
102208	Due from Associated Company	Purdue Pharma L.P.
102301	Due from Associated Company	Purdue Pharma Inc.
102401	Due from Associated Company	PLP Assoc Holdings
102413	Due from Associated Company	BR Holdings Assoc L.P.
102416	Due from Associated Company	Purdue Holdings L.P.
107401	Long Term Asset	Invest. PLP Asc. Hold
107204	Long Term Asset	Invest - Purdue
107408	Long Term Asset	Invest. RSJ Com LLC
107416	Long Term Asset	Invest – PH L.P.

## Appendix D - Cash Distribution Testing Selections – Purdue's SAP Account Descriptions

SAP Number	Account Type	SAP "Short Text"	Description
302042	Equity Account	Dist #42 PP Inc	Distribution to Purdue Pharma Inc.
302045	Equity Account	Dist #45 PH L.P.	Distribution to Purdue Holdings L.P.
302044	Equity Account	Dist #44 PLPAH L.P.	Distribution to PLP Associates Holdings Inc.
302032	Equity Account	Capital #32 Dist BR	Distribution to BR Holdings Associates L.P.
1018449	Vendor	BEACON TRUST COMPANY	SAP Number = Vendor Number
1004240	Vendor	UNITED STATES TREASURY	SAP Number = Vendor Number
1032548	Vendor	CLOVIO CORP	SAP Number = Vendor Number
1019140	Vendor	LUCIEN HOLDINGS SARL	SAP Number = Vendor Number
1016497	Vendor	ROSEBAY MEDICAL COMPANY LP	SAP Number = Vendor Number
1029154	Vendor	BEACON CO	SAP Number = Vendor Number
1033027	Vendor	MALTUS CORPORATION	SAP Number = Vendor Number
1033026	Vendor	MEXCUS CORPORATION	SAP Number = Vendor Number

## Appendix D - SAP Screenshot Guide for Purdue

**Document Number:** Unique transaction identification number.

**Document Date:** Date on which the original document (such as an invoice) was issued.

**Company Code:** Identifies the entity where the transaction is entered.

**Text:** Field where a description for the transaction can be provided (not required).

Doc.Type : SA ( G/L account document ) Normal document  
Doc. Number 100050281 Company Code 208 Fiscal Year 2009  
Doc. Date 17.03.2009 Posting Date 16.03.2009 Period 03  
Calculate Tax ☐  
Doc. Currency USD  
Doc. Hdr Text CTW 03102009 to 03162009

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
176	50	100010	Cash Concentration		GEN			500.000,00-	I/C PPLP TO PURDUE PHARMA TECHNOLOGIES, INC.
177	50	100010	Cash Concentration		GEN			497.457,00-	FUNDING to PURDUE PHARMA, INC.
178	50	100010	Cash Concentration		GEN			495.264,00-	FUNDING to PLP ASC. HOLDINGS, INC.
179	50	100110	Lockbox Clearing		GEN			467.234,06-	AR LOCKBOX

**Posting Date:** Date on which the entry was created.


**Account:** Identifies the general ledger accounts that are impacted by the transaction.

**Account:** Value of the transaction.



## **Appendix E – Rhodes Organizational Charts and Ownership Structure**


## Appendix E – Rhodes Ownership and Subsidiaries Effective January 1, 2008 through August 19, 2018



\*General Partner has no equity interest in L P , rather the General Partner receives a service fee for acting as General Partner

\*\*Managing General Partner has no equity interest in G P , rather the Managing General Partner receives a service fee for acting as Managing General Partner


## Appendix E – Rhodes Ownership and Subsidiaries Effective August 20, 2018 through May 27, 2019



\*General Partner has no equity interest in L P , rather the General Partner receives a service fee for acting as General Partner

\*\*Managing General Partner has no equity interest in G P , rather the Managing General Partner receives a service fee for acting as Managing General Partner

## Appendix E – Rhodes Ownership and Subsidiaries Effective May 28, 2019 to Present



\* General Partner has no equity interest in L.P., rather the General Partner receives a service fee for acting as General Partner

\*\* Partner has no equity interest in LLP, rather the Partner receives a service fee for acting as a Partner

\*\*\* BR Holdings Associates Inc. is the general partner of Pharmaceutical Research Associates L.P.; Purdue Pharma Inc., PLP Associates Holdings Inc. and PLP Associates Holdings L.P. are the limited partners of Pharmaceutical Research Associates L.P.





## **Appendix F - Rhodes Company Names and SAP Account Information**

## Appendix F - Rhodes Cash Distribution and Capital Contribution Testing Selections – SAP Company Names

Company Number	Company Name	Description
208	Purdue Pharma L.P.	
227	Rhodes Technologies	
230	Coventry Technologies L.P.	
250	Rhodes Pharmaceuticals L.P.	
301	Purdue Pharma Inc.	General Partner of Purdue Pharma L.P.
401	PLP Associates Holdings L.P.	Limited Partner of Purdue Holdings L.P. (name changed in 2018 to PRA L.P.)
402	PLP Associates Holdings Inc.	General Partner of Purdue Holdings L.P. (name changed in 2018 to PRA L.P.)
413	BR Holdings Associates L.P.	Limited Partner of PLP Associates Holdings L.P.
414	BR Holdings Associates Inc.	General Partner of BR Holdings Associates L.P.
416	Purdue Holdings L.P. (name changed in 2018 to PRA L.P.)	Limited Partner of Purdue Pharma L.P.
NA	Rosebay Medical Company L.P.	Limited Partner of BR Holdings Associates L.P (50%)
NA	Beacon Company	Limited Partner of BR Holdings Associates L.P (50%)

**Note:** The books and records for these entities are not maintained in the same SAP accounting system as Purdue and Rhodes.

## Appendix F - Rhodes Cash Distribution and Capital Contribution Testing Selections – SAP Account Descriptions

SAP Number	Account Type	SAP "Short Text"
100010	Asset - Cash	Cash Concentration
102208	Due from Associated Company	Purdue Pharma L.P.
102227	Due from Associated Company	Rhodes Technologies
102230	Due from Associated Company	Coventry Technologies LLC
102250	Due from Associated Company	Rhodes Pharmaceuticals LP
102301	Due from Associated Company	Purdue Pharma Inc.
102401	Due from Associated Company	PLP Assoc Holdings
102413	Due from Associated Company	BR Holdings Assoc L.P.
102416	Due from Associated Company	Purdue Holdings L.P.
107401	Long Term Asset	Investment PLP Associates Holding LP

## Appendix F - Rhodes Cash Distribution and Capital Contribution Testing Selections – SAP Account Descriptions

SAP Number	Account Type	SAP "Short Text"
107204	Long Term Asset	Investment Purdue
107416	Long Term Asset	Investment in Purdue Holdings LP
301026	Equity Account	Capital #26 Contribution Reigo Company
301027	Equity Account	Capital #27 Distribution Rosebay
302026	Equity Account	Capital #26 Distribution Beacon Company
302042	Equity Account	Distribution #42 Purdue Pharma Inc.
302045	Equity Account	Distribution #45Purdue Holdings LP
302044	Equity Account	Distribution #44 PLP Assoc. Holdings LP
302032	Equity Account	Capital #32 Distribution BR
1016497	Vendor	ROSEBAY MEDICAL COMPANY LP
1029154	Vendor	BEACON CO

## Appendix F - SAP Screenshot Guide for Rhodes Technologies

**Document Number:** Unique transaction identification number.

**Document Date:** Date on which the original document (such as an invoice) was issued.

**Company Code:** Identifies the entity where the transaction is entered.

**Text:** Field where a description for the transaction can be provided (not required).

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100029607	Company Code	227	Fiscal Year	2011
Doc. Date	12/12/2011	Posting Date	12/08/2011	Period	12
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	USD				
Doc. Hdr Text	CTW 12062011 to 12082011				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	102230	Coventry Tech. LLC		GEN			25,000,000.00	FUNDING to COVENTRY TECHNOLOGIES LLC
2	40	201150	Payroll Suspense		GEN			802,328.85	PAYROLL PAYMENT
3	40	100040	Chase Control ZBA		GEN			191,806.91	CONTROL DISBURSEMENT ACCOUNT FUNDING
4	40	100040	Chase Control ZBA		GEN			106,816.54	CONTROL DISBURSEMENT ACCOUNT FUNDING
5	40	100040	Chase Control ZBA		GEN			10,894.94	CONTROL DISBURSEMENT ACCOUNT FUNDING
6	40	100010	Cash Concentration		GEN			357.09	MISCELLANEOUS BANK DEPOSIT
7	50	100010	Cash Concentration		GEN			25,000,000.00-	FUNDING to COVENTRY TECHNOLOGIES LLC

**Posting Date:** Date on which the entry was created.

**Account:** Identifies the general ledger accounts that are impacted by the transaction.

**Account:** Value of the transaction.



## **XII. Disclaimer and Statement of Limiting Conditions**

## **XII. Disclaimer and Statement of Limiting Conditions**

This Cash Transfers of Value Report and the related analysis has been prepared at the direction of the Special Committee and Counsel. THIS CASH TRANSFERS OF VALUE REPORT IS NOT INTENDED TO BE RELIED UPON BY ANY PARTY OTHER THAN PURDUE, PPI, RHODES, THE SPECIAL COMMITTEE OR COUNSEL, OR INDUCE ACTION BY ANY PARTY.

The information contained herein is based upon financial and other data provided to AlixPartners by Counsel, the management and staff of Purdue, PPI, Rhodes, TXP and One Stamford Realty, and publicly available information, which was available and reviewed as of the date of this Cash Transfers of Value Report. The depth of the analyses may be limited in some respects due to the extent and sufficiency of available information. AlixPartners further relied on the assurance of Counsel and management and staff of Purdue, PPI, Rhodes, TXP and One Stamford Realty that they were unaware of any facts that would make the information provided to AlixPartners incomplete or misleading. In preparing this Cash Transfers of Value Report, AlixPartners has assumed, without any independent verification, the accuracy and completeness of all information available from public sources, Counsel, Purdue, PPI, Rhodes, TXP and One Stamford Realty or which was otherwise provided to us.

AlixPartners has not subjected the information contained herein to an examination in accordance with generally accepted auditing or attestation standards. Had AlixPartners performed such an examination, certain matters might have come to our attention that may have caused us to report different findings and observations herein. Accordingly, AlixPartners cannot and does not express an opinion on the information and does not assume any responsibility for the accuracy or correctness of the underlying financial or other data, information and assessments upon which this Cash Transfers of Value Report is based. The analysis performed was on a "level-of-effort" basis; that is, the depth of our analyses and extent of our authentication of the information may be limited in some respects due to the extent and sufficiency of available information, time constraints dictated by the circumstances, and other factors. Additionally, AlixPartners is not licensed to provide legal advice. Accordingly, nothing in this Cash Transfers of Value Report should be construed as legal advice or opinion.

Many of the observations included in this Cash Transfers of Value Report are based upon representations, both written and verbal, made by Counsel and employees of Purdue, PPI, Rhodes, TXP and One Stamford Realty. We give no assurances as to the accuracy of these representations and are not responsible whatsoever for misrepresentations made, if any. Information in this Cash Transfers of Value Report is non-public and considered highly confidential by Counsel and Purdue. Amounts included throughout this Cash Transfers of Value Report represent approximates and may include rounding differences.

This Cash Transfers of Value Report is incomplete without AlixPartners's accompanying verbal presentation and is based on the information and documents reviewed as of the date of this Cash Transfers of Value Report, and review of any additional documents may change the information included herein. The information in this Cash Transfers of Value Report reflects conditions and the views of AlixPartners as of this date, all of which are subject to change. AlixPartners undertakes no obligation to update or provide any revisions to this Cash Transfers of Value Report to reflect events, circumstances or changes that occur after the date this Cash Transfers of Value Report was prepared. Neither this Cash Transfers of Value Report nor any of its contents may be copied, reproduced, disseminated, quoted or referred to in any presentation, agreement or document with or without attribution to AlixPartners.

# **AlixPartners**

**WHEN IT REALLY MATTERS.**



**Appendix B**

**Curriculum Vitae**

## APPENDIX B



### Richard Collura

rcollura@alixpartners.com

+1 212 561 4146

+1 646 235 6870

### Professional History and Education

Richie has 25 years of experience in providing forensic accounting, investigative, dispute consulting, expert witness and auditing services. He has worked with counsel to represent companies, boards of directors, audit committees, special committees, creditors' committees, lenders and equity holders.

Richie specializes in conducting large-scale financial investigations and providing complex forensic accounting services. He also has extensive experience providing forensic accounting, expert witness and litigation-related services in connection with bankruptcy cases and distressed company situations.

His wide-ranging industry experience includes energy, financial services, healthcare, insurance, manufacturing, media and communications, real estate, retail, and RMBS.

Starting in 2010, Richie worked at Zolfo Cooper, which was acquired by AlixPartners in 2018. Prior to that, he worked at FTI Consulting and Protiviti. Richie started his career in the audit practice of Ernst & Young. He holds a B.S. in accounting from Fordham University. He is a Certified Public Accountant, Certified Insolvency and Restructuring Advisor, Certified Fraud Examiner, and is certified in financial forensics by the AICPA.

### Relevant Experience

- Richie has extensive experience uncovering financial and accounting fraud schemes, investigating allegations related to misappropriation of assets, conducting fact finding investigations, performing flow of funds and cash tracing analyses, analyzing intercompany accounts, identifying undisclosed related party transactions, investigating allegations related to alter ego and veil piercing, and quantifying damages.
- Richie has been involved in large, complex bankruptcy cases involving insider investigations, preference and fraudulent conveyance actions, solvency issues, valuation disputes, breach of fiduciary duty claims, intercompany and inter-creditor disputes, equitable subordination and loan recharacterization.
- Forensic accountant to the special committee of the board of directors of Purdue Pharma Inc. (Ch. 11)
- Forensic accountant to the UCC of Boy Scouts of America, Century 21 Department Stores, Chesapeake Energy, Commonwealth of Puerto Rico, Exide Holdings, Fusion Connect, Haggen Holdings, Modell's Sporting Goods, Murray Energy, New Century Financial Corporation, New Stream Secured Capital and Trident Holding Company
- Forensic accountant/expert witness for independent directors of the board of directors of Mission Coal (Ch.11)
- Forensic accountant to independent director of the board of directors of Cenveo (Ch. 11)
- Financial advisor to independent directors of the board of directors of Maxus Energy (Ch. 11)
- Financial advisor to Ambac Assurance in connection with alter ego and veil piercing claims against BofA and Countrywide
- Forensic accountant/expert witness for the Unencumbered Assets Trust and VI/XII Collateral Trust (NCFE Ch. 11)

## APPENDIX B

### Expert Report and Testimony Experience

- *Expert Report (December 2019) in re: Purdue Pharma L.P., et al., pending Chapter 11 Case No. 19-23649 (RDD), United States Bankruptcy Court, Southern District of New York*
  - Retained as financial advisors and forensic accountants by counsel to the Special Committee of the Board of Directors of Purdue Pharma Inc., conducted an independent investigation, and then issued expert report identifying and quantifying cash transfers of value made by the Debtors to or for the benefit of parent entities, shareholders and/or Sackler Family members, and/or any other entity in which beneficial owners or Sackler Family members own a controlling interest, including the following types of transactions:
    - i. Cash distributions;
    - ii. Compensation;
    - iii. Legal expenses;
    - iv. Pension benefits;
    - v. Travel and expense reimbursements; and
    - vi. Fringe benefits.
- *Expert Testimony (April 2019) in re: Mission Coal Company, LLC, et al., Chapter 11 Case No. 18-04177(TOM), United States Bankruptcy Court, Northern District of Alabama*
  - Retained as financial advisors and forensic accountants by counsel to the Independent Directors of Mission Coal's Board of Directors, and then provided deposition and expert testimony at Plan Confirmation (April 2019) regarding the quantification of potential causes of action against insiders and third-party lenders, including:
    - i. Breach of fiduciary duty;
    - ii. Constructive fraudulent transfer;
    - iii. Intentional fraudulent transfer;
    - iv. Equitable subordination;
    - v. Loan recharacterization;
    - vi. Preference;
    - vii. Negligence and gross negligence; and
    - viii. Veil piercing and alter ego.

## APPENDIX B

### Expert Report and Testimony Experience (continued)

- *Expert Report (February 2015) in re: Cambridge Petroleum Holding, Inc. vs. LUKOIL Americas Corporation, Supreme Court of the State of New York, County of New York, Case No. 650081/2012*
  - Retained by counsel to LUKOIL Americas Corporation and issued an expert report relating to the:
    - i. Types of notes and disclosures that are usually included in financial statements that are prepared in accordance with GAAP; and
    - ii. Appropriate accounting treatment for a seller's sale of assets pursuant to GAAP.
- *Fact-finding Report (September 2014) in re: Lehman Brothers International (Europe) (In Administration) and in the matter of the Insolvency Act 1986, In the High Court of Justice Chancery Division Companies Court, Waterfall II Application No. 7942 of 2008*
  - Retained by counsel to Wentworth Sons Sub-Debt S.a.r.l, LB Holdings Intermediate 2 Limited, King Street Capital Management L.P. and Elliott Management Corporation and co-issued fact-finding report for the Wentworth joint venture related to analyzing default rate information pertaining to:
    - i. LBIE ISDA Master Agreement Guaranty Claims filed against Lehman Brothers Holdings Inc.; and
    - ii. ISDA Master Agreement claims filed against Lehman Brothers Special Financing, Inc.
- *Expert Report (January 2012) in re: Adversary Proceeding in the National Century Financial Enterprises, et al., Chapter 11 Case No. 02-65235, United States Bankruptcy Court, Eastern District at Columbus for the Southern District of Ohio (Adv. Pro. No. 02-02576, Amedisys, Inc., et al., v. JP Morgan Chase Bank, N.A., et al.)*
  - Retained by counsel to the Unencumbered Assets Trust and VI/XII Collateral Trust and issued an expert report relating to:
    - i. Tracing the amount of funds that flowed through and remained on deposit in certain bank accounts by applying the Lowest Intermediate Balance Test; and
    - ii. Describing normal key documents that I would expect to find memorializing an asset-based revolving line of credit as compared to the way parties typically document the sale and purchase of accounts receivables.

## APPENDIX B

### ***Publications and Presentations***

- *Tracing Trust Funds in a Commingled Bank Account: A Deep Dive into Applying the Lowest Intermediate Balance Test*, American Bankruptcy Institute's Fraud Committee newsletter (September 2016).
- Numerous presentations on forensic accounting, financial accounting and auditing concepts at Fordham University.
- Provided training sessions for publicly traded companies related to improving internal controls and employee fraud awareness.
- Provided internal training sessions for company employees on forensic accounting, bankruptcy litigation, solvency methods and engagement administration.

### ***Forensic Accounting, Investigation and Litigation Experience in Bankruptcy Cases***

- *In re: Boy Scouts of America, et al., pending Chapter 11 Case No. 20-10343 (LSS), United States Bankruptcy Court, District of Delaware*
  - Retained as financial advisors and forensic accountants to the Official Committee of Unsecured Creditors and assisted counsel:
    - i. Investigate the classification of the Debtors' "restricted" and "unrestricted" assets;
    - ii. Analyze the use of unrestricted assets and reasonableness of such uses;
    - iii. Investigate whether any pools of assets which the Debtors claim are "mission critical" and outside the reach of creditors was improper; and
    - iv. Prepare for and attend mediation sessions with the Debtors and advisors of other creditor constituencies in an attempt to ensure favorable settlements and maximize recoveries for unsecured creditors.
- *In re: Century 21 Department Stores LLC, et al., Chapter 11 Case No. 20-12097 (SCC), United States Bankruptcy Court, Southern District of New York*
  - Retained as financials advisors and forensic accountants to the Official Committee of Unsecured Creditors and assisted counsel:
    - i. Investigate claims related to pre-petition transactions, including the 2017 reorganization of the Debtors and its affiliates, director and officer compensation, related party transactions, and insider transactions;
    - ii. Object to the Debtors order authorizing the sale of insurance action interest by submitting a declaration; and
    - iii. Negotiate a global settlement with the Debtors and Gindi Family resulting in a significant recovery for unsecured creditors.

**APPENDIX B**

***Forensic Accounting, Investigation and Litigation Experience in Bankruptcy Cases (continued)***

- *In re: Exide Holdings, Inc. et al., Chapter 11 Case No. 20–11157 (CSS), United States Bankruptcy Court, District of Delaware*
  - Retained as financials advisors and forensic accountants to the Official Committee of Unsecured Creditors and assisted counsel:
    - i. Investigate potential claims related to prepetition transactions, including various Note Exchanges and corporate structure reorganizations;
    - ii. Conduct interviews of board members;
    - iii. Prepare flow of funds analyses regarding use of cash proceeds from Note Exchanges;
    - iv. Evaluate preference and fraudulent transfer claims by assessing solvency and preparing reasonably equivalent value analyses; and
    - v. Calculate estimated creditor recoveries under hypothetical scenarios.
- *In re: Modell's Sporting Goods, Inc., et al., Chapter 11 Case No. 20-14179 (VFP), United States Bankruptcy Court, District of New Jersey*
  - Retained as financials advisors and forensic accountants to the Official Committee of Unsecured Creditors and assisted counsel:
    - i. Investigate claims related to pre-petition transactions with insiders, including distributions made to the Modell Family members, director and officer fees and compensation, travel and entertainment expenses, intercompany and related party transactions, and loans;
    - ii. Evaluate potential fraudulent transfer claims and assess the financial condition of Debtors; and
    - iii. Identify potential causes of action to pursue against insiders.
- *In re: The Financial Oversight and Management Board for Puerto Rico, as representative of the Commonwealth of Puerto Rico, et al., pending Title III PROMESA Case No. 17 BK 3283-LTS, United States District Court, District of Puerto Rico*
  - Retained as financials advisors and forensic accountants to the Official Committee of Unsecured Creditors and assisted counsel
    - i. Conduct a Rule 2004 investigation into various potential avoidance actions, including identifying payments to insiders, potential preference payments and potential fraudulent conveyances.

**APPENDIX B**

***Forensic Accounting, Investigation and Litigation Experience in Bankruptcy Cases (continued)***

- *In re: Cenveo, Inc., et al., Chapter 11 Case No. 18-22178 (RDD), United States Bankruptcy Court, Southern District of New York*
  - Retained as financials advisors and forensic accountants by counsel to the Independent Director of Cenveo's Board of Directors:
    - i. Conducted an independent investigation into potential claims Cenveo may have had against senior management or third parties, including fraudulent conveyances;
    - ii. Participated in key witness interviews;
    - iii. Quantified total compensation received by senior management;
    - iv. Analyzed expense reimbursements paid to senior management and considered related business purposes; and
    - v. Analyzed payments to vendors to identify the business purpose.
- *In re: Maxus Energy Corporation, et al., Chapter 11 Case No. 16-11501 (CSS), United States Bankruptcy Court, District of Delaware*
  - Prior to Maxus's bankruptcy filing, retained by counsel to the special independent committee of the board of directors of Maxus:
    - i. Conducted an independent investigation involving potential alter ego-related claims that Maxus might have against its foreign domiciled parent company. This included identifying and analyzing cash transactions between the parent company and Maxus;
    - ii. After the investigation concluded, Maxus and its parent reached an agreement to settle Maxus's alter ego-related claims. Maxus subsequently filed voluntarily petitions for relief under Chapter 11 of the United States Bankruptcy Code;
    - iii. Our role expanded to represent Maxus as its bankruptcy consultants and special financial advisors throughout the bankruptcy;
    - iv. Assisted in preparing expert report assessing potential, estimated, reasonable range of damages that could be recovered by the Debtors on account of their potential alter ego and fraudulent conveyance claims against its non-debtor, parent company; and
    - v. Estimated the potential incremental costs associated with litigating such claims and addressed the potential difficulties that the Debtors could encounter when seeking to collect on a judgment against its foreign domiciled parent company.

**APPENDIX B**

***Forensic Accounting, Investigation and Litigation Experience in Bankruptcy Cases (continued)***

- *In re: consolidated adversary proceedings in the Residential Capital, LLC, et al., Chapter 11 Case No. 12-12020 (MG), United States Bankruptcy Court, Southern District of New York (Adv. Pro. No. 13-01277 (MG), Official Committee of Unsecured Creditors v. UMB Bank, NA, and Adv. Case No. 13-01343 (MG), Residential Capital, LLC, et al., v. UMB Bank, NA)*
  - Retained as financial advisors and forensic accountants by counsel to the Ad Hoc Group of Junior Secured Noteholders:
    - i. Analyzed the nature of the transactions that comprised the nine largest intercompany balances as of the Petition Date, which represented \$8 billion of the total \$8.4 billion of intercompany balances scheduled by the Debtors;
    - ii. Analyzed the presentation of the Debtors' intercompany balances as reflected in the Debtors' pre-petition accounting records and external reports;
    - iii. Assisted with the preparation of an expert report related to the treatment of intercompany claims in a Chapter 11 bankruptcy proceeding; and
    - iv. Prepared expert witness for deposition and trial testimony.
- *In re: Suprema Specialties, Inc., et al., Chapter 7 Case No. 02-10823 (JLG), United States Bankruptcy Court, Southern District of New York*
  - Retained as financial advisors and forensic accountants to the Chapter 7 Trustee and assisted counsel:
    - i. Conduct a fraud investigation into various pre-petition transactions;
    - ii. By performing procedures to detect improper revenue recognition, round-tripping cash transactions with customers and vendors, and transactions with undisclosed related parties;
    - iii. By reviewing and analyzing information included in borrowing base certificates;
    - iv. By evaluating the company's solvency over a five-year period in connection with fraudulent conveyance claims;
    - v. Identify potential causes of action against the independent auditors and Board of Directors; and
    - vi. Prepare presentations and provide financial analyses and related findings to the U.S. Attorneys' Office, FBI and SEC.



## APPENDIX B

### ***Forensic Accounting, Investigation and Litigation Experience in Bankruptcy Cases (continued)***

- *Adversary proceeding in re: HH Liquidation, LLC, et al., (f/k/a Haggen Holdings LLC.), Chapter 11 Case No. 15-11874 (KG), United States Bankruptcy Court, District of Delaware (Adv. Pro. No. 16-51204 (KG))*
  - Retained as financial advisors to the Official Committee of Unsecured Creditors and assisted counsel:
    - i. Investigate various pre-petition transactions and identify potential fraudulent transfer claims;
    - ii. Evaluate the solvency of OpCo; and
    - iii. Investigate whether or not the PropCo Loan had more characteristics of an equity contribution as compared to a loan and consider whether a disinterested third-party would have made a loan on similar terms after taking into account the facts and circumstances that existed at the time the loan was made.
- *In re: New Stream Secured Capital, Inc., et al., Chapter 11 Case No. 11-10753 (MFW), United States Bankruptcy Court, District of Delaware*
  - Retained as financial advisors and forensic accountants to the Official Committee of Unsecured Creditors and assisted counsel:
    - i. By performing complex flow of funds analyses, calculating investor contributions and redemptions, and analyzing payments to insiders and related entities; and
    - ii. Calculate potential recovery outcomes based on settlement negotiations.
- *Adversary proceeding in re: Getty Petroleum Marketing Inc., et al., Chapter 11 Case No. 11-15606 (SCC), United States Bankruptcy Court, Southern District of New York (Adv. Pro. No. 11-02941-SCC, Getty Petroleum Marketing Inc., et al. v. LUKOIL Americas Corporation, LUKOIL North America, et al.)*
  - Retained as financial, accounting and restructuring experts by counsel to LUKOIL Americas Corporation and LUKOIL North America, LLC and OAO LUKOIL:
    - i. Assisted with the preparation of an expert report related to evaluating the estimated recoveries of creditors pursuant to a hypothetical Chapter 11 liquidation plan;
    - ii. Assisted with the preparation of a rebuttal expert report that addressed issues related to the calculation of the fair market value of an ethanol contract, including the treatment and estimated value of a contingent liability, in connection with evaluating the solvency of a company and fraudulent conveyance claims; and
    - iii. Assisted the expert witness in preparing for deposition testimony.

**APPENDIX B**

***Forensic Accounting, Investigation and Litigation Experience in Bankruptcy Cases (continued)***

- *Adversary proceeding in re: Colonial Bancgroup, Inc., Chapter 11* Case No. 09-32303 (DHW), United States District Court, Middle District of Alabama (Adv. Pro. No. 2:10-CV-198-MHT, *The Colonial Bancgroup, Inc. v. Federal Deposit Insurance Corporation, as Receiver for Colonial Bank*):
  - Retained as forensic accounting and bankruptcy experts by counsel to Colonial Bancgroup:
    - i. Traced the flow of funds through the Debtor and its subsidiaries' bank accounts; and
    - ii. Reviewed accounting records and assisted with preparing an expert report and rebuttal expert report related to the treatment of intercompany transactions pursuant to a corporate tax sharing agreement.
- *Adversary proceeding in re: DVI Inc., et al., Chapter 11* Case Nos. 03-12656 through 03-12658, United States Bankruptcy Court, For the District of Delaware, (Adv. Pro. No. 03-57446-MFW, Dennis J. Buckley, the Liquidating Trustee, as legal representative of the DVI Liquidating Trust v. DVI Business Credit Receivables Corp. III, et al.)
  - Retained as forensic accounting and bankruptcy experts by counsel to numerous global financial institutions in connection with defending a fraudulent conveyance action brought by the Liquidating Trustee:
    - i. Performed complex flow of funds analyses and analyzed intercompany transactions related to the Debtor and its subsidiaries;
    - ii. Reviewed and analyzed information included in borrowing base reports, servicer reports, general ledger reports and other accounting and financial information;
    - iii. Evaluated the solvency of the Debtor and its subsidiaries;
    - iv. Assisted counsel in evaluating and preparing defenses against allegations involving preferences and fraudulent conveyance actions; and
    - v. Assisted in preparing an expert report and rebuttal expert report.

## APPENDIX B

### ***Additional Litigation Experience***

- *In re: Ambac Assurance Corporation et al., v. Countrywide Home Loans, Inc., Countrywide Securities Corp., Countrywide Financial Corp., and Bank of America Corp., pending Case No. 651612/2010, Supreme Court of the State of New York, County of New York*
  - Retained as financial advisors, litigation consultants and bankruptcy experts by counsel to Ambac:
    - i. Assisted with the preparation of an expert report related to examining facts and circumstances attendant to Bank of America Corp.'s acquisition of, and integration with, Countrywide Financial Corp. and its subsidiaries;
    - ii. Evaluated, in the context of that acquisition and integration, the presence or absence of certain facts and circumstances understood to be commonly considered by New York courts as relevant factual indicia when evaluating whether the legal theories and principles of De Facto Merger and Alter Ego/Veil Piercing are applicable;
    - iii. Assisted counsel by providing analyses in support of Summary Judgment arguments; and
    - iv. Assisting counsel with trial preparation.
- *In re: Residential Funding Company, LLC and ResCap Liquidating Trust Litigation against Impac Funding Corporation, United States District Court, District of Minnesota, Court File No. 13-cv-3451 (SRN/JJK/HB)) arising from the Residential Capital, LLC, et al., Chapter 11 Case No. 12-12020 (MG), United States Bankruptcy Court, Southern District of New York*
  - Retained as litigation consultants by counsel to ResCap Liquidating Trust and Residential Funding Co., LLC:
    - i. Assisted with preparation of the expert report related to examining facts and circumstances attendant to the defendant's acquisition and integration of substantially all of the assets of another firm; and
    - ii. Evaluated, in the context of that acquisition and integration, the presence or absence of certain factual indicia commonly considered by courts when evaluating the legal theories and principles of De Facto Merger and Mere Continuation.

## APPENDIX B

### ***Additional Forensic Accounting and Investigation Experience***

#### ➤ *US Financial Services Company*

- Retained as forensic accounting experts by counsel to the company:
  - i. Investigated allegations of fraud and misappropriation of assets related to the financial institution's loans made to a private equity fund with purported interests in multiple portfolio companies spanning various industries;
  - ii. Conducted due diligence and asset searches and assisted counsel with identifying significant assets, including real estate and luxury automobiles, owned by other entities associated with and/or controlled by the fund manager; and
  - iii. Assisted counsel in preparing a complaint and successful motion to appoint a receiver.

#### ➤ *Global Advertising and Communications Company*

- Retained as forensic accounting experts by the Office of General Counsel of the company:
  - i. Investigated allegations of fraudulent financial reporting, misappropriation of company assets and non-compliance with corporate expense reimbursement policies;
  - ii. Performed complex flow of funds analyses that uncovered the use of company funds for payment of personal expenses;
  - iii. Calculated insurance loss and helped prepare information and forensic accounting analyses that were submitted by the company to the U.S. Attorneys' Office and the U.S. Postal Inspection Service; and
  - iv. Former employee was charged criminally and served prison time.

#### ➤ *Global Insurance and Financial Services Company*

- Retained as forensic accounting experts by counsel to the company:
  - i. Reviewed and analyzed information related to a complex fidelity bond claim; and
  - ii. Assisted the client and their counsel with evaluating the insured's proof of loss, which included allegations of a highly sophisticated computer crime scheme.

**APPENDIX B**

***Additional Forensic Accounting and Investigation Experience (continued)***

➤ *Global Payments Provider*

- Retained as forensic accounting experts by counsel to the Audit Committee of the company's Board of Directors to assist with conducting an accounting investigation:
  - i. Investigated allegations of improper revenue recognition and accounting for sign-on bonuses;
  - ii. Interacted with company's independent auditors and shared investigative findings; and
  - iii. Ultimately, the investigative analyses assisted counsel in presenting findings to the Audit Committee and developing a comprehensive remediation plan.

➤ *Global Financial Services Company*

- Retained as forensic accounting expert by counsel to the company:
  - i. Conducted a forensic accounting investigation in connection with a DOJ and IRS inquiry involving the structuring of various municipal bond offerings on behalf of a global financial institution;
  - ii. Assisted counsel investigate allegations of bid-rigging guaranteed investment contracts and interest rate arbitrage; and
  - iii. Prepared alternative damage scenario calculations in connection with various settlement negotiations.

➤ *Global Financial Services Company*

- Retained as forensic accounting experts by counsel to the company:
  - i. Conducted a forensic accounting investigation that involved tracing the movements of cash and corresponding collateral through complex tri-party repo accounts held at the financial institution; and
  - ii. Assisted counsel prepare presentation materials for meetings with various regulatory agencies.

➤ *Hotel and Restaurant Publicly Traded REIT*

- Retained as forensic accounting experts by counsel to the Audit Committee of the company's Board of Directors:
  - i. Provided forensic accounting services in response to an SEC inquiry; and
  - ii. Developed presentations for meetings with the SEC and prepared supplemental analyses in response to follow up inquiries.

**Appendix C**

**Sources Relied Upon**

**APPENDIX C**

**Cash Transfers Report**

**Sources Relied Upon**

---

**Entity Organizational Charts**

- Organizational charts for the Purdue and Rhodes entities and certain Affiliated Entities

**SAP Accounting System Information**

- SAP company numbers and names, and chart of accounts
  - Financial Tables - Company Listing -- (PPLPCNC500706226)
  - Financial Tables - SAP Account Codes -- (PPLPCNC500706227)
  - Financial Tables - SAP Company Codes -- (PPLPCNC500706249)
- SAP general ledger detail
- SAP master vendor table
- SAP accounts payable ledger
- SAP accounts receivable ledger
- SAP cost center detail and list of customer codes

**Purdue Internally Prepared Distribution Reports**

- 3.1.1 Final Deck Issued to MDL - (10.19.18.Purdue Materials) -- (PPLPCNC500059052)
- 3.3.1.1 Distributions 1995 - 2017 Actuals v7 -- (PPLPCNC500051645)
- 3.7.1 PRALP-PPLP Notes Receivable Historical Activity through 8.31.19 -- (PPLPCNC500051792)
- 3.3.2.1 Coventry Non Tax Distributions Support 2011 - 2012 -- (PPLPCNC500020854)
- 3.3.2.2 Coventry Tax Distributions LTD 2008 - 2018 -- (PPLPCNC500051775)
- 3.3.2.3 Coventry History - Cash Flow Statement\_since inception\_v1\_03072019 -- (PPLPCNC500051787)
- Coventry History - Cash Flow Statement\_since inception 2018 Revised\_05202019 -- (PPLPCNC501276967)
- Rhodes Reconciliation -- (PPLPCNC501277863)

**APPENDIX C**

**Cash Transfers Report**

**Sources Relied Upon**

---

**Financial Statements**

- 3.2.1 1709-2403904\_Coventry Technologies L.P. and Subsidiaries\_2016\_FINAL (EY 2016) -- (PPLPCNC500059068)
- 3.2.10 2015 Audited Financial Statements - PPLP\_FINAL -- (PPLPCNC500059096)
- 3.2.11 2015 Audited Financial Statements - Purdue\_Coventry -- (PPLPCNC500059146)
- 3.2.12 2016 Purdue Pharma Financials -- (PPLPCNC500059201)
- 3.2.13 Purdue Pharma Audited Financial Statements (2016) -- (PPLPCNC500059256)
- 3.2.14 Purdue Pharma Audited Financial Statements (2017) -- (PPLPCNC500059311)
- 3.2.2 2008 Audited Combined Financial Statements -- (PPLPCNC500059370)
- 3.2.3 2009 Purdue Pharma LP and Assoc'd Cos AFS FINAL -- (PPLPCNC500059409)
- 3.2.4 2010 Purdue Pharma LP and Assoc'd Cos audited FS Issued sent -- (PPLPCNC500059448)
- 3.2.5 2011 Final PPLP financial statements -- (PPLPCNC500059489)
- 3.2.6 2012 Purdue Pharma L. P. Final FS -- (PPLPCNC500059536)
- 3.2.7 2013--PPLP Final Audited Financial Statements -- (PPLPCNC500059581)
- 3.2.8 2014 Purdue AFS -- (PPLPCNC500059620)
- 3.2.9 2014 Purdue&Rhodes AFS -- (PPLPCNC500059670)
- Internal financial statements, reports and/or SAP accounting records for PPLP, PPI, Rhodes, PLP Associates Holdings Inc. and other Affiliated Entities whose books and records are maintained in the same SAP accounting system as Purdue's

**Purdue's Accounting and Approval Documentation**

- Treasury department's records with transaction information and other accounting records
- Wire instructions, bank statements, weekly bank transaction reports and bank account check clearing reconciliations



**APPENDIX C**

**Cash Transfers Report**

**Sources Relied Upon**

- Written Consents and other documents from the general partners authorizing distributions
- Other accounting records and approval documentation available in the SAP accounting system
- Tax calculations by Purdue's Tax Department (now TXP)
- Information obtained from discussions and communications with Purdue and TXP employees

**State Complaints**

Complaints filed by various states against Purdue and/or the Sackler Family members

State	Original/Amended	Date of Complaint
Connecticut	Amended	May 6, 2019
Indiana	Original	May 21, 2019
Iowa	Original	May 16, 2019
Kansas	Original	May 16, 2019
Maryland	Original	May 16, 2019
Massachusetts	Amended	January 31, 2019
New Jersey	Original	May 30, 2019
New York	Amended	March 28, 2019
Oklahoma	Original	June 30, 2017
Oregon	Original	September 18, 2018
Pennsylvania	Original	May 15, 2019
West Virginia	Original	May 16, 2019
Wisconsin	Original	May 16, 2019

**Payroll and Compensation Information**

- 3.4.1 2008-15 Part 1 -- (PPLPCNC500059722)
- 3.4.2 2008-15 Part 2 -- (PPLPCNC500059761)
- 3.4.3 2008-15 Part 3 -- (PPLPCNC500059788)
- 3.4.4 2016 YTD Earnings -- (PPLPCNC500060887)
- 3.4.5 2017 YTD Earnings -- (PPLPCNC500060888)

**APPENDIX C**

**Cash Transfers Report**

**Sources Relied Upon**

---

- 3.4.6 2018 YTD Earnings for PPLP transfers -- (PPLPCNC500060889)
- 3.4.7 2018 YTD Earnings -- (PPLPCNC500060890)
- Sackler Family Compensation Summary v4.16.2020 -- (PPLPCNC500587210)
- 2008-15 SDB -- (PPLPCNC501065339)
- 2016 YTD Earnings -- (PPLPCNC501065347)
- 2017 YTD Earnings -- (PPLPCNC501065563)
- 2018 YTD Earnings -- (PPLPCNC501065775)
- 2018 YTD Earnings for Add'l transfers -- (PPLPCNC501065770)
- 2018 YTD Earnings for PPLP transfers -- (PPLPCNC501065771)

**Legal Expense Information**

- 3.5.1 Dr. Richard Sackler - Additional Counsel Spend - 2016 - 2019 -- (PPLPCNC500144032)
- 3.5.2 Sackler Family Indemnification Costs - Through February 2019 Services -- (PPLPCNC500144033)
- File describing all of Purdue's corporate policies and requirements related to legal invoice processing
- Copy of the Directors and Officers liability insurance policy
- Minutes from the November 19, 2004 Board of Directors meeting of PPI, at which time the Corporate Indemnity Policy was adopted. The full text of the Corporate Indemnity Policy is incorporated into the minutes from that meeting

**Pension Benefits Information**

- 3.6.1 Ilene Sackler Lump Sum 11 1 2011 -- (PPLPCNC500059790)
- 3.6.2 PPLP Pension Plan\_Working Copy to Include all Amendments Adopted through September 10, 2009 -- (PPLPCNC500059792)

**APPENDIX C**

**Cash Transfers Report**

**Sources Relied Upon**

---

- 3.6.3 Richard Sackler Lump Sum 5 1 2013 -- (PPLPCNC500059844)
- 3.6.4 Sackler, Jonathan-05232019 -- (PPLPCNC500059847)
- 3.6.5 Sackler, Kathe A LS Update 04152013 -- (PPLPCNC500059851)
- 3.6.6 Sackler, Mortimer\_05232019 -- (PPLPCNC500059854)
- 3.6.7 Summary of the PPLP Pension Plan\_January 1, 2013 -- (PPLPCNC500059857)

**T&E Reimbursement Information**

- 3.8.2 Net T&E Reimbursements -- (PPLPCNC500060891)
- Purdue's T&E reports from Databasics from April 2011 through December 31, 2018, including individual line-items from expense reports and available supporting documentation
- Purdue's SAP account payable detail and available supporting documentation related to expense reimbursements from January 1, 2008 through December 31, 2018
- 3.8.1.1 2016 Travel Policies and Procedures v2 2016 -- (PPLPCNC500020870)
- 3.8.1.10 Travel Policies and Procedures - January 2011 -- (PPLPCNC500020885)
- 3.8.1.11 Travel Policies and Procedures - January 2014 -- (PPLPCNC500020905)
- 3.8.1.2 2016 Travel Policies and Procedures -- (PPLPCNC500020921)
- 3.8.1.3 2017 Travel Policies and Procedures v1 2017 -- (PPLPCNC500020937)
- 3.8.1.4 2017-2018 Travel Policies and Procedures v11.21.2017 -- (PPLPCNC500020953)
- 3.8.1.5 2018 Travel Policies and Procedures (Non-Sales Field) (Revised September 2018) -- (PPLPCNC500020970)
- 3.8.1.6 2019 Travel Policies and Procedures (Non-Sales Field) (2.6.19 - Final) -- (PPLPCNC500020987)
- 3.8.1.7 Travel Policies and Procedures - 2015 -- (PPLPCNC500021004)
- 3.8.1.8 Travel Policies and Procedures - August 2011 -- (PPLPCNC500021020)

**APPENDIX C**

**Cash Transfers Report**

**Sources Relied Upon**

- 3.8.1.9 Travel Policies and Procedures - February 2013 -- (PPLPCNC500021040)
- Purdue's Travel Policy and Procedures in effect during the years 2008 through 2018
- Transaction detail related to Purdue's cellular phone plan costs
- Transaction detail related to Purdue's fleet vehicle costs, personal service employees expenses and the reimbursements of such

**Meetings and Interviews with employees of Purdue, PPI, Rhodes, TXP and One Stamford Realty**

Title	Company	Category
Associate General Counsel	PPLP	Compensation, Legal, and Pension
Sr. Manager, Payroll Services	PPLP	Compensation
Controller	PPLP	Cash Distributions and Travel & Expense
Assistant Manager of Corporate Travel	PPLP	Travel & Expense
Director of Law Department Operations	PPLP	Legal
Director, Benefits and HRIS	PPLP	Pension
Associate Director, SG&A Finance	PPLP	Travel & Expense
Senior Vice President and Chief Financial Officer	PPLP and PPI	Cash Distributions, Compensation, Legal and Pension
Senior Legal Analyst	PPLP	Legal
Associate General Counsel	PPLP	Legal
Treasurer & Director Business Development Finance	PPLP	Cash Distributions
Vice President Finance	Rhodes	Cash Distributions
Associate Treasury Analyst	TXP	Fringe Benefits
Transactions and Compliance Manager	TXP	Cash Distributions
Director, Finance and Accounting	TXP	Cash Distributions, Compensation and Travel & Expense
Vice President of Finance for PRALP	TXP	Fringe Benefits
Associate Director, Tax	TXP	Cash Distributions
Accounting Services, Manager	TXP	Travel & Expense
Associate Director	One Stamford Realty	Fringe Benefits